Evaluation of patient adherence to artemether-lumefantrine obtained from

public and private drug outlets in Tanzania by Bruxvoort, K
Bruxvoort, K (2015) Evaluation of patient adherence to artemether-
lumefantrine obtained from public and private drug outlets in Tan-
zania. PhD thesis, London School of Hygiene & Tropical Medicine.
DOI: 10.17037/PUBS.02173661
Downloaded from: http://researchonline.lshtm.ac.uk/2173661/
DOI: 10.17037/PUBS.02173661
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
  
 
 
Evaluation of patient adherence to artemether-lumefantrine obtained from 
public and private drug outlets in Tanzania 
 
KATIA JOY BRUXVOORT 
 
 
Thesis submitted in accordance with the requirements for the degree of  
Doctor of Philosophy 
 
University of London  
DECEMBER 2014 
 
Department of Disease Control 
 
Faculty of Infectious and Tropical Diseases 
 
LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE 
 
 
 
Funded by the Bill and Melinda Gates Foundation, through a grant to the ACT Consortium 
 
Research group affiliation(s):  IMPACT2 
 
 
 
Declaration
l, Katia Joy Bruxvoo$ eonfinn that the work presented in this thesis is my own. Where information
has been derived from sther sources, I eonfirm that this has been indieated in the thesis"
signed: ft-t'-fu#
Date: 14December2A74
2
Abstract 
Adherence to artemisinin-based combination therapies (ACTs) for malaria is important for 
effective treatment. This thesis compares adherence to ACTs obtained in the public and private retail 
sectors, describes an intervention to improve dispenser knowledge and patient adherence, and 
addresses challenges of measuring patient adherence to ACTs.  
A cluster randomised trial of a text message intervention targeted at dispensers in Accredited 
Drug Dispensing Outlets (ADDOs) was conducted in Tanzania to improve provision of advice on 
artemether-lumefantrine (AL) and as a result patient adherence. An observational study was also 
conducted among patients obtaining AL from public health facilities. In a third study, smart blister packs 
that recorded when pills were removed were used to assess the validity of self-report. Adherence was 
measured as completion of all doses (“completed treatment”) and completion of each dose at the 
correct time (“timely completion”). 
The intervention improved dispenser knowledge, but had no effect on patient completion of 
treatment (intervention 68.3%, control 69.8%, p [adjusted] = 0.6), or timely completion (intervention 
33.1%, control 32.6%, p [adjusted] = 0.9). ADDO patients were wealthier, more educated, older, sought 
care later in the day, and were less likely to test positive for malaria than health facility patients. The 
adjusted odds of completed treatment and of timely completion for ADDO patients were 0.65 (95% CI: 
0.43, 1.00) and 0.69 (95% CI: 0.47, 1.01) times that of health facility patients. Timely completion, but not 
completed treatment, was lower by smart blister packs than by self-report (37% vs. 24%, p<0.0001).  
Adherence to AL in both sectors was suboptimal. As the private sector continues to be 
important for malaria treatment, better understanding is needed of which aspects of patient care are 
most important to maximise adherence and how methods of assessing adherence can be improved.  
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1  Introduction 
1.1  Overview of malaria 
Malaria is a parasitic, febrile disease that continues to pose a major global health challenge, 
despite declining morbidity and mortality in recent years. Malaria is preventable and treatable, but in 
2011-2012 caused an estimated 207 million cases and 627,000 deaths, with the vast majority of deaths 
occurring among children under five years in sub-Saharan Africa [1]. Of the estimated 3.4 billion people 
at risk of malaria, 1.2 billion are at high risk, mostly in sub-Saharan Africa. The poorest are 
disproportionately affected by malaria and most vulnerable to devastating socioeconomic consequences 
from their illness [2].  
Malaria in humans is caused by five species of the parasite Plasmodium (P. falciparum, P. vivax, 
P. ovale, P. malariae, and the zoonotic species P.knowlesi). The most virulent is P. falciparum, which is 
responsible for the vast majority of severe malaria cases and malaria deaths. The parasites are 
transmitted by female Anopheles mosquitoes prevalent in Africa, Asia, and Latin America. Effective 
preventative measures include the use of insecticide-treated bed nets, indoor residual spraying, and 
prophylactic treatment of vulnerable populations [3].  
Symptoms of uncomplicated malaria, such as fever and vomiting, are non-specific, resembling 
symptoms of many other bacterial and viral infections. As a result, patients who are treated 
presumptively for malaria may not be parasitaemic. To target treatment to patients who actually have 
malaria, the World Health Organization (WHO) now recommends the use of a diagnostic test for all 
suspected cases of malaria prior to treatment [4]. Access to prompt diagnosis and treatment is 
important, as uncomplicated malaria can rapidly progress to severe malaria, which is nearly always fatal 
if left untreated and has a case-fatality rate of up to 20% when treated [4]. Central to obtaining 
appropriate treatment is the choice and use of an effective antimalarial drug.  
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1.2  Antimalarial drugs and the challenge of resistance 
   Treatment for malaria has been characterised by the identification and widespread use of an 
antimalarial drug, followed by reducing efficacy as the malaria parasite responds to drug pressure and 
develops resistant genotypes that can survive treatment [5]. For many decades, chloroquine was the 
designated antimalarial drug of choice. Although resistance was first identified in the 1950s [6], the drug 
continued to be widely used, with sulfadoxine-pyrimethamine (SP) recommended where chloroquine 
failed. Like chloroquine, SP was also inexpensive ($0.10-0.20), well-tolerated and readily available, but 
resistance rapidly developed and spread across continents [7]. More expensive antimalarials such as 
mefloquine, halofantrine, and quinine were also used in Southeast Asia, though these drugs too became 
less effective over time [8].  
The levels and spread of resistance from the 1980s to the 1990s corresponded to an increase in 
malaria-related deaths among children under five at a time when overall childhood mortality was 
decreasing [9]. This resulted in increased demand for and consensus around the adoption of 
combination therapies for malaria at the beginning of the 21st century. The rationale is that parasites 
exposed to two drugs would be less likely to become resistant to both of them and hence resistance 
would develop at a slower rate than when monotherapies are used [8]. Artemisinin-based combination 
therapies (ACTs) are preferred, as artemisinins have very high parasite killing rates, few known adverse 
effects, and are rapidly eliminated, ensuring that residual drug concentrations exert a low selection 
pressure on parasites [5]. Artemisinins also prevent production of gametocytes, reducing transmission 
potential [10, 11].  
 Among the first ACTs implemented were artesunate + mefloquine in 1994 on the Thai-Myanmar 
border [12] and artesunate + pyrimethamine-sulfadoxine in The Gambia in 1998 [13]. In early trials, 
ACTs were shown to be highly efficacious [13-15] and to reduce the spread of resistance in low 
transmission settings [12, 16]. Barnes et al. report on the impact of the first large-scale deployment of 
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ACTs on the malaria disease burden in three countries in Africa [17]. In KwaZulu-Natal province of South 
Africa, treatment with co-formulated artemether-lumefantrine (AL) against a malaria epidemic began in 
January 2001, and vector control was scaled up. By the end of the year, malaria outpatient cases were 
reduced by 85%, and by 2003, outpatient cases and malaria admissions had each fallen by 99%, and 
malaria-related deaths by 97%. The improvements were sustained over seven years. Zambia was the 
first African country to adopt AL as first-line drug for uncomplicated malaria in 2002. By 2008 compared 
to 2001-2002, inpatient malaria cases and deaths were reduced by 61% and 66%, respectively, though 
this was partly attributed to improved vector control at the same time of AL implementation. Lastly, in 
Tigray, Ethiopia, AL was deployed through community health workers in 2005, and over a two-year 
period, the risk of malaria related mortality was lowered by 37%. In both Zambia and Tigray, AL was 
thought to be a major contributor to decreased prevalence of parasitaemia during the study periods.  
ACTs are now recommended by WHO as first-line treatment of uncomplicated P. falciparum 
malaria [4] and have been rolled out in most malaria endemic countries [1]. While several different 
partner drug combinations exist, AL is the most common in Africa, followed by artesunate-amodiaquine 
[18]. ACTs continue to be effective in most parts of the world, including Africa. However, artemisinin 
resistance, characterised by slow parasite clearance [19], has emerged or spread in many parts of 
Southeast Asia and is now a major concern in western Cambodia and the Thailand-Myanmar border 
[20]. As there are no alternative drugs that will be available and affordable in endemic countries in the 
next several years, the spread of artemisinin resistance would be a public health crisis, especially if it 
became widespread in sub-Saharan Africa where the malaria burden is most severe. To contain the 
spread of resistance and to ensure that ACTs remain effective in other malaria-endemic regions, the 
Global Plan for Artemisinin Resistance Containment (GPARC) calls for malaria control and elimination 
measures in areas with observed resistance, such the Greater Mekong subregion [21].  
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1.3  The role of patient adherence in ensuring effectiveness 
Achieving ACT effectiveness is a multi-step process dependent on a number of health systems 
and individual factors (Figure 1). The ACTs must be efficacious; patients must have access to an ACT 
provider with good quality ACTs in stock; the correct diagnosis must be made; providers must 
recommend ACT to patients with malaria; patients must obtain or purchase the ACT; and patients must 
be adherent to treatment [22-24]. The factors affecting each of these steps and their interactions are 
important for understanding the impact of interventions on ACT effectiveness and the overall public 
health impact of ACT treatment policies. 
 
Figure 1: Pathway to Effectiveness (Source: The malERA Consultative Group on Health Systems and 
Operational Research [24], as appearing in Banek et al. 2014 [25]) 
 
 
Efficacy
Access
Targeting Accuracy
Provider Compliance
Patient Adherence
Effectiveness
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This thesis focuses on patient adherence, the final step in the pathway from treatment efficacy 
to effectiveness. Patient adherence refers to correctly taking the full course of treatment (although as 
described in Chapter 2 of this thesis, there is considerable variation in the details of adherence 
definitions). Antimalarial regimens for uncomplicated malaria generally involve oral therapies and vary 
from one to 14 days, though most ACTs involve a 3-day regimen. The use of antimalarial drugs was 
previously reviewed by Yeung and White in 2004 [8], who found numerous examples of highly 
suboptimal adherence, including in some cases to ACTs. For example, in a study in Zambia, only 39% of 
patients took all doses of AL at the correct times [26]. Suboptimal adherence to ACTs is a concern for 
two key reasons, first for the effect on the likelihood of recovery for patients taking ACTs, and secondly 
for the potential implications on hastening the development of drug resistance. 
 Implications for treatment failure. While clearly patients must take the medication to realise 
therapeutic benefits, there is surprising little data on how adherent to ACTs patients must be in order to 
prevent treatment failure. Early trials showed that six-dose regimens of AL had higher cure rates (> 96%) 
compared to a four-dose regimen (83%), suggesting that six doses are needed to optimise effectiveness 
[27, 28]. Cure rates for ACTs have been very high for both supervised and unsupervised treatment 
groups. One study reported slightly higher treatment failure rates to artesunate-mefloquine in an 
unsupervised group compared to a supervised group (3.9% vs. 0.0%, p=0.015) [29], while another study 
comparing treatment with AL and quinine in Uganda reported in a multivariate analysis of AL and 
quinine groups combined that taking more than 80% of pills was associated with reduced treatment 
failure [30]. There have also been accounts of patients who did not receive correct doses for their 
weight or received poor quality drugs and experienced treatment failure [31, 32].  
Implications for drug resistance. In addition to causing treatment failure, sub-therapeutic drug 
concentrations resulting in recrudescence can select for resistant parasites [33, 34]. This occurs when 
drug concentrations are sufficient to suppress sensitive parasites, but newly arisen mutant parasites 
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survive and produce sufficient gametocytes for transmission [34]. There is some evidence that current 
dosing recommendations are inadequate for hyperparasitaemic patients and vulnerable groups such as 
young children and pregnant women, and these under-dosed patients may contribute most to drug 
pressure [31]. Patient adherence is thus one important factor in ensuring sufficient drug concentrations 
to avoid resistance.  
 
1.4  The role of the private for-profit sector  
Antimalarial drugs are available at public health facilities, private not-for-profit health facilities, 
private for-profit outlets, and community health workers. In some countries (e.g. Zambia), public health 
facilities are the most common source of antimalarials, but in some countries (e.g. Nigeria and 
Democratic Republic of Congo) treatment is more frequently sought at private for-profit outlets [35], 
and in many settings such outlets are an important source of care [36-39]. Data synthesised across 
household surveys in sub-Saharan Africa indicate that in 2013, of children under five years with fever 
who reported receiving drugs, 35% visited the private for-profit sector [40]. Where data are available for 
all age groups it appears that the private sector is an even more important source of medicines in older 
children and adults [40-42]. 
Types of private for-profit outlets include private facilities, pharmacies, drug stores, general 
retailers, and itinerant vendors [43], with the dominant type varying between countries. For example, in 
Ghana, Nigeria, Tanzania and Uganda drug stores are the most common type of private for-profit outlet 
stocking antimalarials, while in Madagascar and Niger general retailers are most common [43, 44].  
  Preference for private for-profit outlets may be motivated by factors such as their longer 
opening hours, proximity, speed of service, approachability of providers, availability of drugs, lower 
costs or availability of credit, and dissatisfaction with health facilities [39, 45-47]. However, substandard 
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practices have also been noted in drug stores, including dispensing of inappropriate or ineffective drugs, 
dispensing of incorrect doses, and inadequate knowledge of medication instructions [39, 48].    
Since their introduction, the expense of ACTs has limited their availability in the private sector 
[49, 50]. The proportion of private sector clients obtaining ACTs has increased over time as ACTs have 
become more widely known, and their price has fallen, particularly in some settings where they have 
been subsidised by programs such as the Affordable Medicines Facility- malaria (AMFm) [51]. For 
example, in 2011 the percentage of private for-profit outlets stocking antimalarials that stocked quality-
assured ACTs was over 60% in five of the AMFm settings (Ghana, Kenya, Tanzania-mainland, Uganda and 
Zanzibar), though less than 15% in two other AMFm countries (Madagascar and Niger), and just above 
20% in two non-AMFm countries (Benin and Zambia) [44, 52, 53].  
As ACTs become more available in the private sector, monitoring how they are used becomes 
important to maximise their benefits. One might expect lower adherence from some private for-profit 
providers such as drug shops if dispensers are less likely than their public sector counterparts to provide 
appropriate doses or advice. While a number of interventions have been targeted at improving the 
practices of such drug retailers [54-57] few have focused on strategies to increase patient adherence to 
the antimalarials they provide [58-62]. There is thus a need for further study of the nature of 
antimalarial adherence among patients treated by private retailers, and of interventions to enhance this. 
 
1.5  Thesis aims and overview 
This thesis adds to the limited literature on patient adherence to ACTs obtained in the private 
for-profit sector by comparing adherence to ACTs obtained in public health facilities and private drug 
stores and describing an evaluation of an intervention to improve retail staff knowledge and patient 
adherence. In addition, the thesis addresses the methodological challenges of measuring patient 
adherence to ACTs. 
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Chapter 2 highlights key gaps in understanding and measurement of adherence in an updated 
literature review on adherence to antimalarial drugs, including recent studies on adherence to ACTs. An 
overview of the setting and context of the research is presented in Chapter 3, and objectives and 
methods are outlined in Chapter 4. Chapter 5 presents a text message intervention targeted at 
dispensers in private drug shops to improve their knowledge of advice to provide when dispensing AL 
and to assess the effects on patient adherence. Chapter 6 compares patient adherence to AL obtained in 
the private and public sectors and factors associated with adherence in each setting. Methods of 
assessing patient adherence are explored in Chapter 7, which also reports on the use of smart blister 
packs that recorded the date and time each pill was removed from packaging. Finally, Chapter 8 reviews 
the main findings of the thesis and discusses methodological strengths and limitations, as well as 
implications for future research and policy. 
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2  Literature review 
2.1  Introduction 
This chapter contains a systematic literature review entitled “How patients take malaria 
treatment: A systematic review of the literature on adherence to antimalarial drugs” that was published 
in PLOS ONE in January 2014. Following the literature review in Section 2.2, updates to the review and 
concluding thoughts are described in Section 2.3. 
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Abstract
Background: High levels of patient adherence to antimalarial treatment are important in ensuring drug effectiveness. To
achieve this goal, it is important to understand levels of patient adherence, and the range of study designs and
methodological challenges involved in measuring adherence and interpreting results. Since antimalarial adherence was
reviewed in 2004, there has been a major expansion in the use of artemisinin-based combination therapies (ACTs) in the
public sector, as well as initiatives to make them more widely accessible through community health workers and private
retailers. These changes and the large number of recent adherence studies raise the need for an updated review on this
topic.
Objective:We conducted a systematic review of studies reporting quantitative results on patient adherence to antimalarials
obtained for treatment.
Results: The 55 studies identified reported extensive variation in patient adherence to antimalarials, with many studies
reporting very high adherence (90–100%) and others finding adherence of less than 50%. We identified five overarching
approaches to assessing adherence based on the definition of adherence and the methods used to measure it. Overall,
there was no clear pattern in adherence results by approach. However, adherence tended to be higher among studies
where informed consent was collected at the time of obtaining the drug, where patient consultations were directly
observed by research staff, and where a diagnostic test was obtained.
Conclusion: Variations in reported adherence may reflect factors related to patient characteristics and the nature of their
consultation with the provider, as well as methodological variations such as interaction between the research team and
patients before and during the treatment. Future studies can benefit from an awareness of the impact of study procedures
on adherence outcomes, and the identification of improved measurement methods less dependent on self-report.
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Introduction
While considerable progress has been made in the last decade to
reduce malaria morbidity and mortality, malaria continues to
cause more than 200 million cases and more than 600,000 deaths
per year [1]. The vast majority of deaths occur among children
under five in Africa, though many other parts of the world are also
affected. Malaria is entirely preventable and treatable, but if
treatment is delayed or ineffective, the parasite burden may
rapidly increase and cause severe malaria, which has a case fatality
rate of 10–20% even among those receiving treatment [2].
Resistance of parasites to antimalarials, exacerbated by their
widespread and indiscriminate use, threatens the effectiveness of
malaria treatment.
In order for antimalarial treatment to be effective, multiple steps
must occur [3–4]. The patient must promptly seek care, the
correct diagnosis must be made; the correct drug and dose must be
recommended; the drug must be efficacious, of good quality and in
stock; the patient must receive or purchase the correct dose; and
the correct dose must be taken with correct timing until all doses
are complete. Not only can incomplete dosage result in treatment
failure, but it may arguably contribute to the spread of resistance
[5–6]. Sub-therapeutic treatment can result in recrudescence and
select for resistant parasites [7]. Patient adherence, defined as
correctly taking the full therapeutic course of treatment, is thus a
critical step in ensuring antimalarial effectiveness and reducing
malaria mortality.
To achieve this goal, it is important for policymakers to
understand levels of patient adherence to antimalarials, how they
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e8455527
vary by context, and how adherence can be improved. However,
studies measuring patient adherence encounter substantial meth-
odological challenges, such as selection of appropriate definitions
of adherence and appropriate measurement methods. This results
in a broad diversity of study designs which, along with the wide
range of study contexts and different antimalarial drugs, can
challenge interpretation of adherence results.
The use of antimalarial drugs was last reviewed by Yeung and
White in 2004 [8]. Of the 22 studies they identified in Africa, Asia
and South America that reported quantitative data on patient
adherence, only five assessed adherence to artemisinin-based
combination therapies (ACTs), and only eight studies, mostly
household surveys, measured adherence to antimalarials obtained
through community health workers or drug retailers. Since
publication of this review, there has been a major expansion of
the availability of ACTs, which have been shown to be efficacious
and may reduce the spread of resistance in low transmission
settings [9–12]. Due to the development of resistance to older
antimalarials, such as chloroquine and sulfadoxine pyrimethamine
(SP), ACTs have become the first-line treatment for Plasmodium
falciparum malaria in the public sector in most malaria-endemic
countries. In addition, a growing number of initiatives to increase
ACT use through community health workers and private sector
providers have been implemented [13]. Furthermore, a large
number of new studies assessing adherence to antimalarials,
particularly to ACTs, have been conducted in the last nine years,
raising the need for an update on this topic.
Here, previously reviewed and recent studies providing quan-
titative results on adherence to antimalarials obtained for
treatment are analysed. We examine how results vary by definition
of adherence and key methodological characteristics, and we
present the studies’ own findings on factors associated with
adherence. We emphasize challenges in measuring adherence,
avoiding bias, and implications for future research.
Methods
Studies included in this review were identified by three methods.
First, a systematic literature search was conducted on PubMed
using MeSH and free text terms as follows: (Medication
Adherence (MeSH) or Patient Compliance (MeSH) or compliance
or adhere*) and (Antimalarials (MeSH) or antimalarial*). Second-
ly, reference lists from studies and reviews identified were searched
manually for relevant studies. Finally, researchers known to be
currently active in the field were contacted.
Studies that were clearly irrelevant were immediately discarded,
and abstracts and manuscripts of the remaining studies were
examined in detail to determine relevance. Published studies that
provided quantitative data on patient adherence to antimalarials
obtained for treatment of malaria were included in this review.
Where papers employed both quantitative and qualitative
methods, only the quantitative results are reported here. Studies
were included from all parts of the world in any language utilizing
various study designs, including household surveys and clinical
trials examining the effectiveness of supervised versus unsupervised
treatment that specifically reported data on adherence in the
unsupervised arm. Studies assessing adherence to antimalarials
obtained for prophylaxis, and effectiveness studies that did not
report data on adherence were excluded. Manuscripts of studies
meeting inclusion criteria were read in detail and data on study
settings, objectives, study design, definitions of adherence, methods
of assessing adherence and results were systematically reviewed
and abstracted into a database.
Results
The initial literature search using PubMed identified 1340
studies (Figure 1). In total, 49 studies were retained from the initial
search. Many of the excluded studies referred to antimalarials
obtained for prophylaxis or treatment of conditions other than
malaria. Manual examination of reference lists and personal
communication with other researchers in the field identified six
additional studies, making a total of 55 studies.
Characteristics of studies included
Three main types of studies were identified: descriptive studies,
interventions to improve adherence, and studies with clinical
outcomes as a primary endpoint (Tables 1–3). While there is
clearly some overlap between types, studies were categorised as
descriptive except for those that described an intervention to
improve adherence or simultaneously measured clinical outcomes
and patient adherence. Distinguishing studies with clinical
outcomes is helpful, as they were often conducted under relatively
controlled conditions, or with relatively intensive follow-up, which
may have influenced adherence results.
More than half of the 55 studies were descriptive (30 studies)
[4,14–42]. The majority of these (21 studies) were observational
follow-up studies [14–34], where patients obtaining a drug were
visited at their home or returned to the drug outlet after a specified
number of days, at which time adherence data were collected.
While most follow-up studies were prospective, two studies
retrospectively identified patients to follow-up for adherence
assessments [21,25]. Several of these studies were part of larger
studies that included an intervention (e.g. use of community health
workers [15,24] or subsidization of ACTs in private retail outlets
[16]), but did not provide information on the impact on adherence
through pre and post or control group comparisons, so the studies
were categorised as ‘‘descriptive’’ in terms of their assessment of
adherence. Eight studies used household surveys to collect
descriptive data [35–42], and one study used both household
survey and follow-up methods [4]. In these household surveys,
households in selected areas were visited without prior knowledge
of who had obtained antimalarial drugs, and interviews were
conducted about episodes of illness occurring in the weeks prior to
the survey, treatment obtained, and adherence.
Figure 1. Literature search results.
doi:10.1371/journal.pone.0084555.g001
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Thirteen studies evaluated interventions to improve adherence
[43–55]. Of these, seven were randomized controlled trials (RCTs)
[44,46–47,50–51,54–55], two were controlled pre- and post-
intervention studies [43,45], two were uncontrolled pre- and post-
intervention studies [48–49], and two were post-intervention only
adherence assessments [52–53]. Follow-up methods were used by
eight of the thirteen intervention studies, while the remaining four
used household surveys. The interventions included new packag-
ing with and without training, including pre-packaging of two
component drugs together and pictorial inserts to packaging
[47,50–53,55], as well as dispenser training of shopkeepers [48–
49] or community health workers [54]. Ansah et al. (2001) [44]
conducted an RCT of chloroquine tablets for children compared
to chloroquine syrup, while Denis et al. (1998) [45] evaluated
videos and posters as community health education strategies to
improve adherence to a 7-day regimen of quinine + tetracycline.
The third type of studies, those assessing clinical outcomes as a
primary endpoint in addition to reporting patient adherence,
included seven RCTs comparing effectiveness and adherence of
different drug regimens [56–60] or supervised versus non-
supervised treatment [61–62], and four uncontrolled studies also
assessing effectiveness and adherence [63–66], all of which
employed follow-up methods. In addition, a prospective open
cohort study examined the association of previous compliance with
antimalarials for malaria caused by P. falciparum or P. vivax and
occurrence of malaria during follow-up [67].
Of the 55 studies, 40 took place in Africa, 11 in Asia, and four in
Latin America. Subjects included all age groups in 25 studies, only
children under five in 19 studies, both children under five and
older children in an additional seven studies, and only adults in
four studies. Most studies assessed adherence to antimalarials
taken to treat infection with P. falciparum, with five studies focusing
on treatment for P. vivax [21,25,31,51,62], and three studies on
treatment for both species [32,66–67]. Most studies assessed
adherence to treatment obtained in health facilities or malaria
clinics. Four follow-up studies evaluated adherence to drugs
obtained from community agents [15,24,28,54] three took place in
the context of complex humanitarian emergencies [17–18,26], and
three were conducted from private drug shops [16,30,45]. Most
household surveys reported adherence to antimalarials obtained
from both public and private sectors, except for four that focused
on interventions to improve adherence to antimalarials obtained
from drug shops [48–49] or community health workers [36,53].
Patient adherence to more than one drug regimen was assessed
in 12 studies, while 43 studies reported adherence to a single drug
(Tables 1–3). Adherence to ACTs was assessed in 26 studies.
Artemether-lumefantrine (AL) was the ACT in 18 of these studies,
with two of these 18 also reporting adherence to artesunate-
amodiaquine [36,60]. Other ACTs evaluated included two
additional studies of artesunate-amodiaquine [14,20], as well as
SP + artesunate [17,23] and artesunate + mefloquine [52,63–64].
Non-artemisinin-based combinations featured in 13 studies
(chloroproguanil-dapsone (CPD) [57–58], quinine + doxycycline
or tetracycline [45,59,67], chloroquine + SP [26,40,47], SP +
amodiaquine [65] and, for treatment of P. vivax malaria,
chloroquine + primaquine [25,31–32,51,62,66–67]). Adherence
to chloroquine and other monotherapies was assessed in 20
studies.
Definitions of adherence and measurement methods
The 55 studies reviewed here employed a wide range of
definitions and methodologies. Adherence was measured by
questionnaires containing varying detail about how and when
drugs were taken (self-report); physical counts of tablets remaining
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in packaging or dispensing envelopes (pill counts) and volumetric
measurement of syrups; pill containers with electronic caps that
record the date and time of each opening (electronic pill boxes);
assays for drug levels in biological samples; and composites of these
methods.
At least one approach used in 52 of the 55 studies could be
classified under one of five overarching approaches defined for the
purpose of this review, based on both the nature of adherence
required and the method used to measure adherence (Table 4).
‘‘Completed treatment’’ identifies individuals who said they
completed treatment. ‘‘Verified completed treatment’’ refers to
reported completed treatment that is corroborated by a pill count.
‘‘Timely completion’’ refers to patients reporting that they
completed each dose at an appropriate time. ‘‘Verified timely
completion’’ identifies those reporting timely completion with a
pill count to confirm that no tablets were left. Lastly, ‘‘biological
assay’’ refers to detection of sufficient levels of drugs in biological
samples.
Correct timing of doses, involving the correct dose, frequency,
and duration, was required in 22 studies (‘‘timely completion’’ and
‘‘verified timely completion’’), 11 of which were studies of ACTs.
However, there was considerable variation in which intervals were
considered ‘‘correct’’, ‘‘recommended’’ or ‘‘prescribed’’. Several
studies calculated the expected time of each dose per the
manufacturer’s instructions and allowed an interval of several
hours on either side [22–23,28], while other studies required the
correct dose to be taken on each day specified, or for AL twice per
day for three days [15,18,33,61], and other studies did not report
exactly what was considered correct. This is in contrast to
assessments of ‘‘completed treatment’’ and ‘‘verified completed
treatment’’, which did not require correct timing of doses.
Furthermore, many studies reported in their methods that drug
packaging was inspected, but only 21 studies specifically incorpo-
rated pill counts into adherence definitions, requiring self-reported
adherence verified by empty packages or the expected number of
remaining pills (‘‘verified completed treatment’’ and ‘‘verified
timely completion’’).
Adherence results
The studies reported a very wide range of results for the
percentage of patients adherent, ranging from 1.5% to 100%
across different studies and settings. Below we explore how the
results varied firstly by the approach to assessing adherence and
data collection, secondly by antimalarial and outlet type, and
thirdly by the nature of the interaction between patients and
dispensers or researchers during the study. Scatter plots are used to
facilitate the identification of general patterns in these results.
Finally we present the studies’ own findings on factors found to be
associated with adherence in multivariate models.
(i) Variation by approach and data collection method
Figure 2 shows a comparison of adherence results by the five
approaches. The plot includes multiple points from studies which
used more than one approach to report adherence. Studies that
did not use any of the five approaches were not plotted [4,37,56].
In addition, when results of adherence to the same drug were
reported from more than one study site within the same country,
the weighted average of these sites was plotted [35,45]. For
intervention studies, only baseline results were plotted in order to
represent standard practice; thus, two studies were not plotted
since they provided adherence results post-intervention only [52–
53]. When multiple non-overlapping degrees of adherence were
used (such as definitely non-adherent, probably non-adherent, probably
adherent), the most adherent level was considered the proportion
adherent for the purpose of Figure 2.
Overall, it does not appear that using stricter approaches
involving correct dose timing (‘‘timely completion’’ and ‘‘verified
timely completion’’) or requiring pill counts in addition to self-
reported histories (‘‘verified completed treatment’’ and ‘‘verified
timely completion’’) are associated with lower adherence, but this
does not account for differences in contexts and methodologies.
However, among studies of AL, adherence by ‘‘verified timely
completion’’ (38.7%–65%) [18,28–29] was lower compared to
Figure 2. Percentage of patients classified as adherent, by
Approach to assessing adherence.
doi:10.1371/journal.pone.0084555.g002
Table 4. Approaches to assessing patient adherence across studies.
Approach Definition Method Number of studies1
Completed treatment Patient completed treatment Self-report 28
Verified completed
treatment
Patient completed treatment Self-report and pill count 10
Timely completion Patient exactly followed instructions in terms of dose, frequency and duration Self-report 12
Verified timely
completion
Patient exactly followed instructions in terms of dose, frequency and duration Self-report and pill count 11
Biological assays Sufficient levels of drug(s) in biological samples Biological assays 4
Unique approaches Various Various 11
1All studies are included if adherence is reported by at least one of these five approaches (n = 52 studies) and are included more than once if multiple approaches were
used.
doi:10.1371/journal.pone.0084555.t004
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‘‘timely completion’’ (88.3%–100%) [15,22,33], except in studies
where the research team enrolled patients at the time the drug was
obtained and likely had a more significant research presence than
in other studies (90% and 93%) [19,61]. Similarly, adherence to
AL by ‘‘verified completed treatment’’ (64.1%–83%) [16,24,27,
29,60] tended to be lower than for ‘‘completed treatment’’ (67%–
100%) [22,28,36,38,57–58], with the exception of two household
surveys without pill counts with adherence of 47% [41,46].
Household surveys, which all used the ‘‘completed treatment’’
approach and assessed adherence from both public and private
community sources, tended to have lower adherence results than
studies with other designs, particularly studies with primary clinical
outcomes (Tables 1–3). In addition, studies plotted before
implementation of an intervention had lower adherence for all
approaches, as is particularly evident in the community-based
interventions by Marsh et al. (1999, 2004) and Winch et al. (2003)
and the private-sector follow-up study by Denis et al. (2008); this
may be because most of the interventions included in the review
are older studies and the interventions (e.g. pre-packaging of
drugs) have become a standard part of antimalarial treatment used
in the newer studies.
Among studies using unique approaches, two studies used
electronic pill boxes (Medication Events Monitoring Systems –
MEMSTM) to measure adherence [34,57]. In the study by Bell et
al. (2009) adherence by self-report (‘‘completed treatment’’) was
100% for AL and 99.2% for CPD, but by the electronic pill boxes,
adherence was 92% for AL and 91% for CPD. Similarly, in the
study by Twagirumukiza et al. (2010), adherence to quinine tablets
was 100% by both self-report (‘‘verified timely completion’’) and
pill count (no pill boxes had pills remaining), but only 78% of
patients took at least 80% of the doses based on the electronic pill
box data [34].
Results using biological assays to assess adherence were high
(above 90%), but this accounted for only a few studies [15,51,64].
Qingjun et al. (1998) evaluated a packaging intervention to
improve adherence to chloroquine + primaquine marked with
phenobarbital to detect concentrations in plasma, while Na-
Bangchang et al. (1997) measured adherence to artesunate +
mefloquine by whole blood mefloquine concentrations based on a
reference interval [64]. Similarly, Congpuong et al. (2010) used
both whole blood mefloquine concentrations and plasma concen-
trations of primaquine [63] to detect adherence to artemether +
mefloquine + primaquine. One additional study (Shwe et al., 1998)
also found high adherence of 99.5%, but was not included in the
plots because adherence to artesunate + mefloquine was only
reported after implementation of a co-packaging and training
intervention; in this study, tablets of quinine and chloroquine were
added to the regimen as markers for detection by urine assays. Five
other studies measured plasma levels of lumefantrine using HPLC
with mass spectrometry or UV detection [19,33,57,60–61], but
adherence was not reported on the basis of these assays. Median
lumefantrine concentrations were not significantly different
between patients who were or were not considered adherent by
self-report (‘‘completed treatment’’ and ‘‘timely completion’’) or
self-report with pill count (’’verified timely completion’’).
(ii) Variation by antimalarial type and outlet type
The pattern of adherence results between antimalarials was not
clear. Across all approaches and by ‘‘completed treatment’’
adherence to AL (47%–100%) [22,28,36,38,41,46,57–58] was
higher than both adherence to monotherapies estimated from
Figure 3. Percentage of patients classified as adherent, by patient interaction with research staff and dispensers.
doi:10.1371/journal.pone.0084555.g003
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household surveys (3.7%–34%) [35,39–40,42,48–49] and adher-
ence to longer primaquine regimens for the treatment of vivax
malaria (25%–85%) [21,25,31–32,51,62,66–67]. Adherence to AL
by ‘‘verified completed treatment’’ (64.1%–83%) [16,24,27,29,60]
was lower than adherence to artesunate-amodiaquine (77%–91%)
[14,60] and chloroquine+SP (96%) [26]. However, adherence to
AL by ‘‘timely completion’’ was high in three studies (88.3%–
100%) [15,22,33] in contrast with studies of SP + amodiaquine
(37.7%) [65] and SP + artesunate (76.6%) [23]. By ‘‘verified timely
completion’’ adherence to AL was similar in three studies (38.7%–
Table 5. Factors associated with adherence in multivariate models (p,0.05 or 95% confidence interval crosses the null).
Factors Studies
Demographics
Education
- Caretaker education at least 7 years Beer et al. 2009 [14]
- Attending some secondary school or beyond Cohen et al. 2012 [16]
- Higher education Onyango et al. 2012 [41]
Residence in one of two areas in study location Duarte et al. 2003 [67]
Age
- Respondent age 25-50 years versus less than 25 years Lawford et al. 2011 [27]
- Patient age 15 years or more versus less than 15 years Lawford et al. 2011 [27]
- Patient age less than 13 years Onyango et al. 2012 [41]
Ownership of radio Lemma et al. 2011 [28]
Higher household income Onyango et al. 2012 [41]
Simba et al. 2012 [33]
Treatment-seeking behaviour
Not having sought treatment at a public health facility Cohen et al. 2012 [16]
Respondent sought treatment within 24 hrs of symptom onset versus waiting longer Lawford et al. 2011 [27]
Delay of more than 1 day in seeking treatment after the onset of fever Lemma et al. 2011 [28]
Previous care sought Souares et al. 2008 [65]
Factors related to the consultation
Having received exact number of pills to complete treatment Beer et al. 2009 [14]
Reporting having been given instructions at the shop Cohen et al. 2012 [16]
Reporting that instructions given were clear Cohen et al. 2012 [16]
Attended Migowi HC (one of three study outlets) Mace et al. 2011 [29]
Package used as visual aid by dispenser to explain how to take the drug Mace et al. 2011 [29]
Received written instructions Pereira et al. 2011 [31]
Quality of history taking (i.e. nurses at the consultation asked questions about history, symptoms,
and previous care)
Souares et al. 2008 [65]
Behaviour
Took first AL dose at HC Mace et al. 2011 [29]
Taking AL with food or oil Simba et al. 2012 [33]
Knowledge and perceptions
Knowledge that only mosquitoes cause malaria Gerstl et al. 2010 [20]
Knowledge of malaria aetiology Khantikul et al. 2009 [25]
Respondent had seen the drug before Lawford et al. 2011 [27]
Being able to cite at least one correct instruction on how to take AL Lawford et al. 2011 [27]
Belief that malaria cannot be treated traditionally Lemma et al. 2011 [28]
Access to information about antimalarials Khantikul et al. 2009 [25]
Knowledge of the seriousness of the infection/knowing the species in mixed transmission areas Yepez et al. 2000 [66]
Satisfaction
Having an improved condition at follow-up Cohen et al. 2012 [16]
Lower expectation of getting malaria in the next 30 days Cohen et al. 2012 [16]
Did not report dislikes/side-effects to medication Lawford et al. 2011 [27]
Preference for AL Mace et al. 2011 [29]
Satisfaction with received information Souares et al. 2008 [65]
doi:10.1371/journal.pone.0084555.t005
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65%) [18,28–29] to adherence to other ACTs (39.4%–75%)
[17,20,23] and higher in two other studies (90%–93%) [19,61].
Although most studies evaluated adherence to antimalarials
obtained in the public sector, the two descriptive private sector
follow-up studies had low adherence, with Nshakira et al. (2002)
reporting adherence of 37.8% to chloroquine by ‘‘completed
treatment’’, and Cohen et al. (2012) describing adherence of 65.8%
to AL. Three household surveys [46,48–49] and one follow-up
study [45] assessing interventions in private drug stores and
surrounding communities also all reported adherence of less than
50%. Adherence where antimalarials were obtained from CHWs
in four studies using follow-up methods ranged widely from 1.5%–
100% [15,24,28,54], with a study of AL by Lemma et al.(2011) in
Ethiopia finding adherence of 38.7% by ‘‘verified timely
completion’’ and 73.5% by ‘‘completed treatment’’. In addition,
a study evaluating adherence to ACTs dispensed by CHWs
reported high adherence of 83%–97% by ‘‘completed treatment’’
in household surveys in three countries [36].
(iii) Variation by nature of interaction of patients with dispensers
and research personnel
We explored how adherence results varied depending on the
nature of the interaction reported between patients and their
dispensers, and between patients and research personnel.
Figure 3a–d shows how patient adherence (as assessed by any of
the five approaches) varied with four aspects of patient interaction
that we hypothesised might influence adherence results. As shown
in the first plot, patients in some studies were asked for informed
consent to participate in the study at the outlet upon obtaining the
drug, while patients in other studies were not asked for informed
consent until a later follow-up visit, having had several days to take
the drug (Figure 3a). Secondly, research staff in some studies
observed the consultation of the patient with the dispenser or
conducted the consultation themselves, while other studies did not
(Figure 3b). Studies where most patients obtained a malaria
diagnostic test prior to treatment were plotted in comparison to
studies where patients were not tested (Figure 3c). The fourth plot
compares studies where dispensers did and did not observe the
patient swallowing the first dose of the drug (Figure 3d). Results of
all studies that used one of the five approaches are plotted, as
described previously for Figure 2, except that for studies using
multiple approaches to assess adherence, only the most inclusive
approach reported was plotted (i.e. ‘‘completed treatment’’).
Studies could not be plotted if the nature of the patient interaction
for each of the four plots was not reported.
Figure 3a suggests that collecting informed consent from
patients at the outlet visit when the drug is dispensed can result
in higher adherence compared to requesting informed consent at
the time of the follow-up visit. Similarly there is an indication that
observation by the study team of patients’ consultations with
dispensers may influence patients to be more adherent (Figure 3b),
and that where patients were confirmed to have malaria with a
Table 6. Factors associated with non-adherence in multivariate models (p,0.05 or 95% confidence interval crosses the null).
Factors Studies
Demographics
Being male Achan et al. 2009 [56]
Pereira et al. 2011 [31]
Caretaker having different mother tongue to pharmacist Depoortere et al. 2004 [17]
Education
- Caretaker education (none versus some) Depoortere et al. 2004 [17]
- Lack of formal education Fogg et al.2004 [19]
Age
- Being a child under 5 Mace et al. 2011 [29]
- Being a child age 8–10 years versus 2–4 years Souares et al. 2008 [65]
Head of household profession (retailer/employee vs. farmer) Souares et al. 2008 [65]
Treatment-seeking behaviour
No fever reported Kalyango et al. 20131 [24]
Seeking care after 2 or more days Kalyango et al. 20131 [24]
Takeuchi et al. 20092 [62]
Factors related to the consultation
Treatment with oral quinine versus AL Achan et al. 2009 [56]
Being counselled about what to do in case of vomiting Kachur et al. 2004 [23]
Not understanding instructions Kalyango et al. 20131 [24]
Knowledge and perceptions
Caregiver’s perception that illness is not severe Kalyango et al. 20131 [24]
Satisfaction
Vomiting Achan et al. 2009 [56]
Kalyango et al. 20131 [24]
1Includes patients receiving Al only and AL plus antibiotics (treatment group not significant in multivariate analysis);
2Associated with non-adherence in the second week of primaquine treatment for P. vivax infection.
doi:10.1371/journal.pone.0084555.t006
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rapid diagnostic test (RDT) or blood smear prior to being
dispensed antimalarials, adherence was higher than among those
not tested (Figure 3c). There is also some indication that studies
where dispensers observed patients’ first dose had higher
adherence than those where the first dose was not observed,
although the pattern is less clear (Figure 3d).
(iv) Factors associated with adherence in multivariate models
Understanding the characteristics and behaviours associated
with patient adherence to antimalarials is vital to designing
interventions to improve appropriate use of ACTs. Twenty-four
studies used multivariate analysis to examine factors associated
with adherence: of these, 13 studies reported 30 factors
significantly associated with adherence in multivariate models,
nine studies found 12 factors associated with non-adherence, and
five studies reported not finding any factors significantly associated
with adherence or non-adherence [32,44,50,55,61]. While many
of the twenty-four studies tested similar factors, such as demo-
graphics, instructions given and patient knowledge, there was
substantial diversity in which factors were found significant.
Tables 5–6 show factors significantly associated with adherence
(Table 5) and non-adherence (Table 6), including demographics,
treatment-seeking behaviour, factors related to the consultation,
behaviour, knowledge and perceptions, and satisfaction. Factors
significantly associated with adherence in more than one study
included higher education [14,16,41], higher household income
[33,41], provision of better information on how to take drugs
[16,29,31], and knowledge about malaria and antimalarials
[20,25,27–28,66]. Factors significantly associated with non-adher-
ence in more than one study included being male [31,56], lack of
education [17,19], and vomiting [24,56]. There were contrasting
results for the effects on adherence of patient age and the number
of days after onset of symptoms that treatment was sought. Older
age of the patient was associated with adherence in one study [27]
and non-adherence in another [65], while two other studies found
younger age associated with adherence [41] and non-adherence
[29]. Similarly, Lemma et al. (2011) found that patients who waited
more than one day to seek care after onset of fever were more
likely to be adherent, but other studies showed that seeking care
within 24 hours of symptom onset was associated with adherence
[27], and waiting two or more days was associated with non-
adherence [24,62].
Discussion
Extensive variation was observed in patient adherence to
antimalarials, with many studies reporting very high adherence
(90–100%) and others finding clearly suboptimal adherence,
sometimes of less than 50%. This may be an important problem,
both in terms of clinical outcomes and also in the context of the
development of resistance to artemisinin in South-East Asia [68].
However, it is unclear how good adherence must be for ACTs to
be efficacious, and which features of adherence (such as correct
timing of dose intervals or taking each dose with a fatty meal)
matter most.
We identified five overarching approaches to assessing adher-
ence based on recall (‘‘completed treatment’’ and ‘‘timely
completion’’), recall and pill counts (‘‘verified completed treat-
ment’’ and ‘‘verified timely completion’’) and on biological assays.
By ‘‘completed treatment’’ and ‘‘verified completed treatment’’,
adherent patients were defined as completing the full course of
treatment though not necessarily following a specific schedule.
Whether these are appropriate approaches to assess adherence
should be considered in light of the pharmacology of the specific
drug: if the safety or efficacy of the drug is critically dependent on
the timing of the doses then it will be important to assess this when
evaluating adherence. As these approaches do not include the
spacing of the doses, it is possible for patients to have taken some
doses too close together or even to have taken all doses at one time
and still be considered ‘‘adherent’’, though such practices could be
of concern for drug safety and efficacy. Furthermore, there is
potential variation within each approach in what was considered
correct treatment, with some studies taking into account national
guidelines on the correct dose-for-weight that the patient should
have consumed and other studies assuming the correct amount
was obtained.
By ‘‘timely completion’’ and ‘‘verified timely completion’’,
adherent patients were defined as exactly following instructions in
terms of dose, frequency and duration according to their responses
to interview questions. As noted above, there was considerable
variation in definitions of ‘‘correct’’ timing, which may have
affected comparability within these approaches. More information
is needed on how precise time intervals between doses must be in
order for drugs to be efficacious. For example, the packaging of
various brands of AL states that the second dose should be taken
eight hours after the first dose, which would fall in the middle of
the night if the drug is obtained in the evening. In this situation it is
unclear whether a patient should still be considered adherent if
they take the drugs first thing the next morning instead.
The majority of the adherence studies used one or more of these
approaches relying primarily on self-reported drug histories, which
may be susceptible to recall and social desirability bias. Studies in
Tanzania and Cambodia found high levels of antimalarials
circulating in the blood among patients stating they had not
taken any drugs in the previous 28 days [69–70]. Patients may not
accurately recall information about the quantity of drugs taken.
Moreover, even if the precise time of obtaining the drug from the
provider is known, asking patients when each dose was taken is
problematic as they may not have had clocks available or may not
know or remember the exact time. Recall bias is likely to be higher
in data obtained from household surveys, where interviewers
frequently ask about drugs taken in the previous 14 days,
compared to follow-up studies, where recall time is usually 4–7
days. Even with short recall periods, patients may not correctly
remember details related to each dose. Cultural and demographic
factors may also affect the reliability of self-reported data [71]. For
example, in a study of the impact of the length of recall periods for
health surveys, different recall periods gave different results, and
these differences were shown to vary by income group [72].
To avoid being seen as ignorant or negligent, patients who are
aware of the expected behaviour may say they were adherent even
if they actually were not. A study by Peeters Grietens et al. (2010)
found that while 72% of patients reported taking the full course of
primaquine, only 49% claiming to take the full course had actually
received the full course according to records [21]. Likewise, Bell
and colleagues stated that self-reported data, which resulted in
100% adherence to AL and CPD in Malawi, was unreliable
compared to MEMSTM containers [57].
In order to reduce recall and social desirability bias, some
studies incorporated manual examination of drug packaging into
their definitions of adherence (‘‘verified completed treatment’’ and
‘‘verified timely completion’’). For studies of AL, these approaches
yielded lower adherence results than the equivalent approaches
without the pill counts (‘‘completed treatment’’ and ‘‘timely
completion’’). However, even results including pill counts may
over-estimate true adherence as removing pills from blister packs
does not guarantee that the pills were consumed. Similarly,
opening electronic pill boxes does not guarantee a dose was
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consumed. Patients may have ‘‘played’’ with their pill boxes,
opening them without removing pills, or alternatively, they may
also have removed multiple doses at one opening, either to
discard, consume, or save until the appropriate time.
Despite the limitations of self-reported and pill count approach-
es, Souares et al. (2008) suggested that self-reported data may be
more reliable and feasible than assays for drug levels, which
require invasive sample collection and complicated field logistics
[68]. Drug assays were rarely used for measuring adherence, and
their utility and appropriate role remains unclear. Adherence
evaluated by the detection of drugs in biological assays was very
high (90–100%) in four studies, but these studies assessed
adherence to drugs other than AL and involved close interaction
of the research staff with patients and in some cases extended
follow-up periods. The five studies that reported measuring
lumefantrine concentrations, but did not incorporate these assays
into adherence results, did not find significant differences in
lumefantrine concentrations between patients adherent and non-
adherent by self-report. This may have been due to the metabolic
variability of the study population, including age, pregnancy,
concomitant fat intake and other factors affecting drug absorption,
limiting the value of quantitative assessments of patient adherence
[73–74]. Methods of collecting blood samples, sample preservation
under field conditions, and details of the assays themselves are also
likely to affect results.
Regardless of the approach used for assessing adherence,
Hawthorne bias may occur if a patient’s awareness of being
studied positively influences medication-taking behaviour. Simi-
larly, if researchers observe patient consultations with the
dispenser, this may positively influence the care and advice
provided by the dispenser and/or patients’ attentiveness and
adherence to the treatment. In the studies reviewed here,
adherence was higher when informed consent was collected at
the time of obtaining the drug and to some degree when patient
consultations were directly observed (Figures 3a and 3b). While it
is reasonable to assume that medication-taking behaviour of
patients who are not aware they are being studied more accurately
reflects behaviour in real life contexts, these concerns must be
balanced by practical constraints, such as fulfilling other study
objectives and the need to obtain the patient’s consent and address
for follow-up visits.
Some specific patient-dispenser interactions might also be
expected to improve adherence. For example, confirmation of
diagnosis of malaria by an RDT or blood smear might increase
adherence if patients are more aware that they are suffering from
malaria, and if patients with confirmed malaria see a better
response to treatment than those who have other conditions.
Observing the first dose of treatment is another commonly
recommended practice and was found to be significantly
associated with adherence to AL in one study [29]. We found
some indication that malaria diagnosis was associated with higher
adherence in the reviewed studies, although the effect was less
marked for observing the first dose on adherence overall.
In addition to the approach to measurement and the nature of
the patients’ consultations, other factors often hypothesised to
influence adherence include patient characteristics, antimalarial
type and outlet type. However, it was not possible to discern clear
patterns across the studies reviewed. There was some evidence
from multivariate studies that patients who had higher socio-
economic status and were better educated or informed had higher
adherence. While there is some concern that the greater number
of tablets required for treatment with ACTs (i.e. 24 for an adult)
contributes to lower adherence compared to antimalarials
requiring fewer tablets, this was not clear in the studies reviewed
here. One potential explanation for this is that ACTs often come
in co-formulated or co-packaged blister packs, with different
coloured packages for each age or weight group. This is in contrast
to loose tablets dispensed into paper envelopes, which was often
the case for older antimalarials. Not only can the dispenser give
the patient the incorrect number of tablets, but the tablets may
need to be cut in half to achieve the appropriate doses, and it may
be more difficult for the patient to remember how many to take.
Secondly, more effective antimalarials such as ACTs may
encourage higher patient adherence; if drugs are perceived to be
ineffective, patients may use a drug briefly or not at all before
looking for a more effective alternative [8]. Finally, perceptions of
side-effects may cause variation in adherence across antimalarials,
with drugs such as chloroquine and quinine known to have more
common minor adverse effects than ACTs such as AL.
It was hard to assess variation across outlet types as of the 55
studies included, only five specifically evaluated adherence to
antimalarials from private drug shops [16,30,45,48–49] and five
from community health workers [15,24,28,36,54]. However, there
were some indications that adherence was relatively low from
private sector outlets, highlighting the need for more studies to
evaluate adherence to ACTs obtained in this sector and to design
interventions to ensure drugs are used appropriately. Interventions
to improve adherence that are currently being tested in the private
sector include the introduction of RDTs [75–76], new packaging,
SMS reminders to patients [77], and SMS reminders to drug shop
dispensers to encourage them to advise patients on the importance
of adherence [78].
Conclusion
The literature reports extensive variation in patient adherence
to antimalarials. The unsatisfactory patient adherence sometimes
reported to ACTs obtained in the public sector, and the current
dearth of data from the private sector, represent significant
challenges for maximising the impact of ACTs. Variations in
adherence may reflect factors related to patient characteristics and
knowledge, their treatment seeking behaviour, and the nature of
their consultation with the provider. However, methodological
variations between studies are also likely to be an important source
of variability in results, including the methods used for collecting
data, and any interaction between the research team and patients
before and during the treatment course. Future studies could be
strengthened by a greater awareness of the impact of study
procedures on adherence outcomes, and the identification of
improved measurement methods that are less dependent on self-
report.
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2.3  Updates to the literature review paper 
 In addition to our published review, two other related reviews were also published in January 
2014. First, the review by Fuangchang et al. focused on interventions to improve adherence to 
antimalarial drugs [1]. The authors identified 16 studies, though some of the studies included under the 
categories of medication supervision and convenient regimen were trials assessing effectiveness of 
supervised versus unsupervised treatment (n=2 studies) or comparing effectiveness of drugs (n=4 
studies) and were not actually interventions to improve adherence. The authors categorised 
interventions into six types: packaging aids, visual media, combined visual media and verbal 
information, community education, medication supervision, and convenient regimen. The most effective 
approach for improving adherence was suggested to be the combination of visual media and verbal 
instructions, although this was based on limited evidence. Similar to our review, the authors noted that 
some effective interventions, such as pre-packaging, are now standard for ACTs, and that there are 
relatively few studies assessing interventions to improve adherence to ACTs, particularly in the private 
sector.  
The systematic review by Banek et al. [2] focused on ACTs, and compared levels of adherence by 
ACT regimen, noting as we do that factors such as study designs, definitions, and methods of assessing 
adherence vary substantially. In distinction, our review included studies of all antimalarial drugs, 
compared results of studies using different approaches to assessing adherence, and examined the 
effects on adherence of patient interaction with research staff and dispensers. Echoing the 2005 review 
by Yeung and White [3], both our review and the Banek et al. review emphasise the need for improved 
and standardised methods of assessing adherence.   
Through reading the Banek et al. review and personal communication with the lead author, I 
became aware of eight studies that were erroneously omitted from our review. There were several 
42
reasons for these omissions. First, I systematically searched only one database (PubMed), using fairly 
general search terms ((Medication Adherence (MeSH) or Patient Compliance (MeSH) or compliance or 
adhere*) and (Antimalarials (MeSH) or antimalarial*)). In contrast, Banek et al. searched three 
databases (Medline, Embase, and Global Health) with comprehensive search terms that included many 
of the common names used for each available antimalarial drug. Had I searched the Global Health 
database or possibly used different search terms, I would have identified additional studies [4-8]. 
Secondly, I conducted the search alone, reading a large number of abstracts and manuscripts. In doing 
so, I overlooked several studies that were in my search results [9-11]. Having a second reviewer to 
compare findings with might have prevented these studies from being inappropriately excluded.   
 Table 2.3.1 contains the details of the studies that were missed in our published review, as well 
as four new studies that were published after January 2013, when our search was completed and 
through September 2014, when the table was updated [12-15]. These studies have been added to the 
plots of the percentages of patients classified as adherent, by patient interaction with research staff and 
dispensers (Figure 2.3.1). As in our published review, studies that did not use one of the five approaches 
to assess adherence were not plotted. For studies using multiple approaches, only the most inclusive 
approach was plotted (e.g. “completed treatment”). In addition, when results of adherence to the same 
drug were reported from more than one study site within the same country, the weighted average of 
these sites was plotted. For intervention studies, only baseline or control results were plotted in order 
to represent standard practice. Thus, five of the eight missed studies and two of the four new studies 
were added to the plots. 
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Table 2.3.1  Characteristics of additional studies meeting criteria for inclusion in review (through September 2014) 
Study 
Country 
Type of study 
Source(s) of drugs 
 
 
Drug regimen(s)
1,2 
 
Method(s) of 
assessing 
adherence 
Approach(es) to 
assessing adherence
3 
Day of follow-
up visit  (Day 1 
= drug 
dispensed) 
Level of adherence 
(N=denominator) 
Other notes 
Alba et al. 2010 [7] 
Tanzania 
Descriptive 
Multiple sources 
AL, SP 
 
Household 
survey 
questionnaire 
Completed treatment n/a SP (2004): 76% (N=72) 
SP (2008): 84% (N=49) 
AL (2008): 69% (N=32) 
Plotted, weighted 
average for SP  
Almeida et al. 2014 [12] 
Brazil 
Descriptive 
Health facility 
Chloroquine + 
primaquine (7 days) 
Self-report 
(compared 
dichotomous 
scale (DS) to six-
point Likert 
scale (LS)), pill 
count 
Unique approach (1) = 
based on scores to DS 
and LS, with values 
below the median used 
to determine adherence  
Unique approach (2) = 
pill count only with 70% 
of pills taken used as 
adherence cut-off 
Day 8 Unique approach (1): 
68.9% (N=135) 
Unique approach (2): 
71.1% (N=135) 
Not plotted (unique 
approach) 
Asante et al. 2009 [8] 
Ghana 
Clinical 
Health facilities 
Artesunate + 
amodiaquine (3 days) 
 
Pill-count Unique approach = 
correct number of pills 
remaining  
Day 3 92.6% (N=211) Not plotted (unique 
approach) 
Meankaew et al. 2010 
[6] 
Thailand 
Intervention 
Health facilities 
Artesunate + 
mefloquine (AS + MQ) 
(3 days) 
Chloroquine + 
primaquine (CQ + PQ) 
(14 days)  
 
Self-report Completed treatment Day 7 (ASMQ) 
Or 
Day 14 (CQ + 
PQ) 
No intervention: n/a 
With intervention: 
AS + MQ: 94% (N=285) 
CQ + PQ: 42.6% (N=249) 
 
Mobile technology 
module for malaria 
disease and treatment 
monitoring 
 
Not plotted (with 
intervention only) 
Minzi et al. 2014 [13] 
Tanzania 
Descriptive 
Health facility 
AL (3 days) Self-report, pill 
count, 
laboratory 
assays
4
 
Completed treatment, 
Verified timely 
completion 
Day 4 Completed treatment: 
79.7% (N=143) 
Verified timely 
completion: 7% (N=143) 
Plotted most lenient 
approach only 
(completed treatment) 
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Study 
Country 
Type of study 
Source(s) of drugs 
 
 
Drug regimen(s)
1,2 
 
Method(s) of 
assessing 
adherence 
Approach(es) to 
assessing adherence
3 
Day of follow-
up visit  (Day 1 
= drug 
dispensed) 
Level of adherence 
(N=denominator) 
Other notes 
Mubi et al. 2011 [10] 
Tanzania 
Descriptive 
Community health 
workers 
AL (3 days) Self-report Timely completion Day 4 AL (clinical diagnosis 
group): 99.3% (N=1399) 
AL (RDT group): 97.4% 
(N=760) 
RCT comparing clinical 
diagnosis with rapid 
diagnostic tests 
 
Plotted, weighted 
average except for 
diagnosis plot 
Ogolla et al. 2013 [15] 
Kenya 
Descriptive 
Health facility 
AL (3 days)  Self-report, pill 
count 
Verified timely 
completion  
Day 4 (?) 75.8% (N=62) Minimal information 
given in text, plotted 
when data available 
Ogutu et al. 2014 [14] 
Kenya 
Clinical 
Health facility 
AL (3 days), 
dihydroartemisinin-
piperaquine (DHAPQ)  
(3 days) 
Unclear Unclear  n/a AL: 93.6% (N=126) 
DHAPQ: 85.6% (N=124) 
All patients admitted 
until clinically stable 
with a negative blood 
slide. Interviewed on 
discharge and at 
subsequent follow up 
visits. Unclear how 
adherence was 
measured, or if this 
study meets inclusion 
criteria, therefore not 
plotted. 
Ratsimbasoa et al. 2012 
[11] 
Madagascar 
Clinical 
Community health 
workers 
 
Artesunate-
amodiaquine (3 days) 
Self-report, pill 
count 
Verified timely 
completion 
Day 4 90% (N=543) Plotted  
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Study 
Country 
Type of study 
Source(s) of drugs 
 
 
Drug regimen(s)
1,2 
 
Method(s) of 
assessing 
adherence 
Approach(es) to 
assessing adherence
3 
Day of follow-
up visit  (Day 1 
= drug 
dispensed) 
Level of adherence 
(N=denominator) 
Other notes 
Watsierah et al. 2011 
[9] 
Kenya 
Descriptive 
Multiple sources 
AL, SP, quinine (QN), 
chloroquine (CQ) 
Household 
survey 
questionnaire 
Unique approach (1) = 
correct dose 
Unique approach (2) = 
correct duration 
n/a Unique approach (1): 
AL: 29.4% (N=127) 
AP: 85% (N=147) 
QN: n/a 
CQ: 51.7% (N=29) 
Unique approach (2): 
AL: 33% (N=127) 
SP: 82% (147) 
QN: 96.4% (28) 
CQ: 34.5% (29) 
Not plotted (unique 
approaches) 
Yeung et al. 2008 [5] 
Cambodia 
Descriptive 
Multiple sources 
Artesunate + 
mefloquine (AS + MQ), 
other ACT, artesunate 
monotherapy (AS), 
quinine + tetracycline 
(QN + tet), quinine (QN), 
choloroquine (CQ) 
Household 
survey 
questionnaire 
Completed treatment n/a AS + MQ: 77% (N=44) 
Other ACT: 13% (N=31) 
AS: 28% (N=29) 
QN + tet: 0% (N=13) 
QN: 13% (N=24) 
CQ: 35% (N=63) 
Plotted (all of results as 
different drugs) 
Zaw Win et al. 2012 [4] 
Myanmar 
Descriptive 
Health facilities 
AL (3 days) Self-report, pill 
count 
Verified completed 
treatment 
Day 4 89.5% (N=248) Plotted 
1 
Duration of drug regimen in days not given for household surveys. 
2 
Co-formulated combination therapies are written with a “+”, as opposed to a “-” (not co-formulated). 
3 
See Table 4 in published review for definitions. 
4
Not incorporated into adherence definition. 
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Figure 2.3.1  Percentage of patients classified as adherent, by patient interaction with research staff and dispensers (updated) 
 
N= Number of adherence results reported from studies with this characteristic 
Number of studies not reporting data: 2 (A), 7 (B), 11 (C), 21 (D) 
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In both the studies in the published review and those in Table 2.3.1, the diversity of study drugs, 
settings, and factors related to study design made it difficult to identify any differences in adherence 
among approaches involving exact timing of doses compared to completion of treatment, or compared 
to studies where these approaches were verified by pill counts. Among studies of AL, however, some 
trends were apparent, and incorporating the studies in Table 2.3.1 had an effect on the ranges of results 
for approaches with and without pill count. Our published review suggested that “verified completed 
treatment” (64.1%-83%), was lower compared to “completed treatment” (67%-100%) and “verified 
timely completion” (38.7%-65%) was lower compared to “timely completion” (88.3%-100%). 
Incorporating the studies in Table 2.3.1 changed the range of “verified completed treatment” from 
64.1%-83% to 64.1%-89% [4, 16-20] , but did not change the range for “completed treatment” ((67%-
100%) [13, 21-26], (47%-100% if household surveys are included  [7, 27, 28]). The range for “verified 
timely completion” changed to 7%-75.8% [13, 15, 18, 26, 29] (7%-93% if including three studies where 
the research team enrolled patients at the time the drug was obtained and likely had a more significant 
research presence than in other studies  [11, 30, 31]), but the range for “timely completion” did not 
change  (88.3%-100%) [10, 25, 32, 33]. Consequently, there is now less suggestion in the literature that 
studies using pill count in addition to self-report to assess completion of AL treatment had lower results 
than if self-report alone was used, but there is some indication that in studies of AL with minimal 
involvement from the research team, timely completion was lower when pill counts were used along 
with self-report. However, other factors related to study context and methodologies may also affect 
these results. 
 Consistent with our published review, Figure 2.3.1 demonstrates that patient interaction with 
research staff and dispensers may influence adherence. Higher adherence was observed in studies (A) 
where informed consent from patients was collected at the consultation (when the drug was dispensed) 
compared to at the time of the follow-up visit, (B) where the study team observed patients’ 
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consultations with dispensers, (C) where patients were confirmed with a diagnostic test to have malaria, 
and (D) where dispensers observed patients taking the first dose of treatment. While the number and 
characteristics of studies with information available may affect the trends observed in these plots, and 
the plotted interactions may also be interrelated (e.g. studies with higher research staff involvement 
might have also required confirmation of malaria and observation of the first dose), these results 
suggest that future adherence studies should minimise patient interaction with research staff in order to 
avoid bias. In terms of policy, testing for malaria and observation of the first dose of treatment are good 
practices that might encourage patient adherence. 
 Our published literature review explored factors associated with adherence or non-adherence in 
multivariate analyses, finding that these associations varied considerably between studies. There was 
some evidence that patients who had higher socioeconomic status and were better educated or 
informed had higher adherence, although as Banek et al. note, these associations were not consistent 
across studies. Among the studies in Table 2.3.1, only three report examining factors associated with 
adherence or non-adherence in multivariate analyses. Minzi et al. did not find age, sex, or education 
associated with adherence, but found that the odds of adherence were much higher among patients 
taking the first dose at the health facility compared to those who took the first dose at home [13]. In the 
household survey by Yeung et al. adherence was similarly not affected by age, sex, education, 
socioeconomic status, or distance from closest public health facility [5]. Finally, Watsierah et al. reported 
that knowledge of antimalarial drugs was associated with taking the correct dose and taking the drug for 
the correct duration [9]. 
 In summary, this section updates our literature review publication with additional studies from 
two other reviews and several new studies. Overall, the main conclusions of our published review are 
upheld and supported by the additional studies, though the evidence that using pill counts in addition to 
self-report leads to lower estimates of adherence was slightly weakened.  
49
References 
 
1. Fuangchan A, Dhippayom T, Kongkaew C: Intervention to promote patients' adherence to 
antimalarial medication: a systematic review. Am J Trop Med Hyg 2014, 90:11-19. 
2. Banek K, Lalani M, Staedke SG, Chandramohan D: Adherence to artemisinin-based combination 
therapy for the treatment of malaria: a systematic review of the evidence. Malar J 2014, 13:7. 
3. Yeung S, White NJ: How do patients use antimalarial drugs? A review of the evidence. Trop 
Med Int Health 2005, 10:121-138. 
4. Zaw Win T, Zaw L, Khin W, Myitzu Tin O, Thar Tun K, Kyaw Zin T: Adherence to the 
recommended regimen of artemether-lumefantrine for treatment of uncomplicated 
falciparum malaria in Myanmar. Myanmar Health Sci Res J 2012, 24:48-53. 
5. Yeung S, Van Damme W, Socheat D, White NJ, Mills A: Access to artemisinin combination 
therapy for malaria in remote areas of Cambodia. Malar J 2008, 7:96. 
6. Meankaew P, Kaewkungwal J, Khamsiriwatchara A, Khunthong P, Singhasivanon P, Satimai W: 
Application of mobile-technology for disease and treatment monitoring of malaria in the 
"Better Border Healthcare Programme". Malar J 2010, 9:237. 
7. Alba S, Dillip A, Hetzel MW, Mayumana I, Mshana C, Makemba A, Alexander M, Obrist B, Schulze 
A, Kessy F, et al: Improvements in access to malaria treatment in Tanzania following 
community, retail sector and health facility interventions -- a user perspective. Malar J 2010, 
9:163. 
8. Asante KP, Owusu R, Dosoo D, Awini E, Adjei G, Amenga Etego S, Chandramohan D, Owusu-
Agyei S: Adherence to Artesunate-Amodiaquine Therapy for Uncomplicated Malaria in Rural 
Ghana: A Randomised Trial of Supervised versus Unsupervised Drug Administration. J Trop 
Med 2009, 2009:529583. 
9. Watsierah CA, Jura WG, Raballah E, Kaseje D, Abong'o B, Ouma C: Knowledge and behaviour as 
determinants of anti-malarial drug use in a peri-urban population from malaria holoendemic 
region of western Kenya. Malar J 2011, 10:99. 
10. Mubi M, Janson A, Warsame M, Martensson A, Kallander K, Petzold MG, Ngasala B, Maganga G, 
Gustafsson LL, Massele A, et al: Malaria rapid testing by community health workers is effective 
and safe for targeting malaria treatment: randomised cross-over trial in Tanzania. PLoS One 
2011, 6:e19753. 
11. Ratsimbasoa A, Ravony H, Vonimpaisomihanta JA, Raherinjafy R, Jahevitra M, Rapelanoro R, 
Rakotomanga Jde D, Malvy D, Millet P, Menard D: Compliance, safety, and effectiveness of 
fixed-dose artesunate-amodiaquine for presumptive treatment of non-severe malaria in the 
context of home management of malaria in Madagascar. Am J Trop Med Hyg 2012, 86:203-
210. 
12. Almeida ED, Rodrigues LC, Vieira JL: Estimates of adherence to treatment of vivax malaria. 
Malar J 2014, 13:321. 
13. Minzi O, Maige S, Sasi P, Ngasala B: Adherence to artemether-lumefantrine drug combination: 
a rural community experience six years after change of malaria treatment policy in Tanzania. 
Malar J 2014, 13:267. 
14. Ogutu BR, Onyango KO, Koskei N, Omondi EK, Ongecha JM, Otieno GA, Obonyo C, Otieno L, 
Eyase F, Johnson JD, et al: Efficacy and safety of artemether-lumefantrine and 
dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum 
malaria in Kenyan children aged less than five years: results of an open-label, randomized, 
single-centre study. Malar J 2014, 13:33. 
50
15. Ogolla J, Ayaya O, Otieno C: Levels of adherence to Coartem© in the routine treatment of un-
complicated malaria in children aged below five years, in Kenya. Iran J Public Health 2013, 
42:129-133. 
16. Kalyango JN, Rutebemberwa E, Karamagi C, Mworozi E, Ssali S, Alfven T, Peterson S: High 
adherence to antimalarials and antibiotics under integrated community case management of 
illness in children less than five years in eastern Uganda. PLoS One 2013, 8:e60481. 
17. Lawford H, Zurovac D, O'Reilly L, Hoibak S, Cowley A, Munga S, Vulule J, Juma E, Snow RW, Allan 
R: Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala 
districts, Kenya. Malar J 2011, 10:281. 
18. Mace KE, Mwandama D, Jafali J, Luka M, Filler SJ, Sande J, Ali D, Kachur SP, Mathanga DP, 
Skarbinski J: Adherence to treatment with artemether-lumefantrine for uncomplicated malaria 
in rural Malawi. Clin Infect Dis 2011, 53:772-779. 
19. Cohen JL, Yavuz E, Morris A, Arkedis J, Sabot O: Do patients adhere to over-the-counter 
artemisinin combination therapy for malaria? Evidence from an intervention study in Uganda. 
Malar J 2012, 11:83. 
20. Faucher JF, Aubouy A, Adeothy A, Cottrell G, Doritchamou J, Gourmel B, Houze P, Kossou H, 
Amedome H, Massougbodji A, et al: Comparison of sulfadoxine-pyrimethamine, unsupervised 
artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation 
for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness 
noninferiority trial. J Infect Dis 2009, 200:57-65. 
21. Ajayi IO, Browne EN, Bateganya F, Yar D, Happi C, Falade CO, Gbotosho GO, Yusuf B, Boateng S, 
Mugittu K, et al: Effectiveness of artemisinin-based combination therapy used in the context of 
home management of malaria: a report from three study sites in sub-Saharan Africa. Malar J 
2008, 7:190. 
22. Barnes KI, Durrheim DN, Little F, Jackson A, Mehta U, Allen E, Dlamini SS, Tsoka J, Bredenkamp 
B, Mthembu DJ, et al: Effect of artemether-lumefantrine policy and improved vector control on 
malaria burden in KwaZulu-Natal, South Africa. PLoS Med 2005, 2:e330. 
23. Bell DJ, Wootton D, Mukaka M, Montgomery J, Kayange N, Chimpeni P, Hughes DA, Molyneux 
ME, Ward SA, Winstanley PA, Lalloo DG: Measurement of adherence, drug concentrations and 
the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-
pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar J 2009, 8:204. 
24. Dunyo S, Sirugo G, Sesay S, Bisseye C, Njie F, Adiamoh M, Nwakanma D, Diatta M, Janha R, Sisay 
Joof F, et al: Randomized trial of safety and effectiveness of chlorproguanil-dapsone and 
lumefantrine-artemether for uncomplicated malaria in children in the Gambia. PLoS One 2011, 
6:e17371. 
25. Kabanywanyi AM, Lengeler C, Kasim P, King'eng'ena S, Schlienger R, Mulure N, Genton B: 
Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial 
treatment: evidence from a rural community in Tanzania. Malar J 2010, 9:48. 
26. Lemma H, Lofgren C, San Sebastian M: Adherence to a six-dose regimen of artemether-
lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region, 
Ethiopia. Malar J 2011, 10:349. 
27. Kangwana BP, Kedenge SV, Noor AM, Alegana VA, Nyandigisi AJ, Pandit J, Fegan GW, Todd JE, 
Brooker S, Snow RW, Goodman CA: The impact of retail-sector delivery of artemether-
lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized 
controlled trial. PLoS Med 2011, 8:e1000437. 
28. Onyango EO, Ayodo G, Watsierah CA, Were T, Okumu W, Anyona SB, Raballah E, Okoth JM, 
Gumo S, Orinda GO, Ouma C: Factors associated with non-adherence to Artemisinin-based 
51
combination therapy (ACT) to malaria in a rural population from holoendemic region of 
western Kenya. BMC Infect Dis 2012, 12:143. 
29. Depoortere E, Salvador ET, Stivanello E, Bisoffi Z, Guthmann JP: Adherence to a combination of 
artemether and lumefantrine (Coartem) in Kajo Keji, southern Sudan. Ann Trop Med Parasitol 
2004, 98:635-637. 
30. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, Namiiro P, Musabe J, Kyomugisha A, 
Guthmann JP: Adherence to a six-dose regimen of artemether-lumefantrine for treatment of 
uncomplicated Plasmodium falciparum malaria in Uganda. Am J Trop Med Hyg 2004, 71:525-
530. 
31. Rahman MM, Dondorp AM, Day NP, Lindegardh N, Imwong M, Faiz MA, Bangali AM, Kamal AT, 
Karim J, Kaewkungwal J, Singhasivanon P: Adherence and efficacy of supervised versus non-
supervised treatment with artemether/lumefantrine for the treatment of uncomplicated 
Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. Trans R Soc Trop 
Med Hyg 2008, 102:861-867. 
32. Simba DO, Kakoko D, Tomson G, Premji Z, Petzold M, Mahindi M, Gustafsson LL: Adherence to 
artemether/lumefantrine treatment in children under real-life situations in rural Tanzania. 
Trans R Soc Trop Med Hyg 2012, 106:3-9. 
33. Chinbuah AM, Gyapong JO, Pagnoni F, Wellington EK, Gyapong M: Feasibility and acceptability 
of the use of artemether-lumefantrine in the home management of uncomplicated malaria in 
children 6-59 months old in Ghana. Trop Med Int Health 2006, 11:1003-1016. 
 
52
3  Research Context  
This chapter describes the context of the research presented in this thesis. Section 3.1 begins by 
describing the geography and sociodemographics of Tanzania, trends in mortality rates, and malaria 
epidemiology. Options for malaria treatment in the public and private retail sector are explained. 
Section 3.2 focuses on Mtwara, the region where the studies took place. Finally, Section 3.3 outlines the 
IMPACT2 project, the umbrella project under which this thesis was developed. 
 
3.1  Tanzania 
Tanzania is a large country in East Africa, sharing borders with Kenya, Uganda, the Democratic 
Republic of Congo, Rwanda, Burundi, Zambia, and Mozambique (Figure 1). The country is divided into 30 
administrative regions, with a population in 2012 of 44,928,923 [1], including mainland Tanzania and the 
islands of Zanzibar. Seventy percent of Tanzanians live in rural areas, and over half of the population is 
under 18 years of age. Tanzania is among the least developed countries in the world, ranking 159th 
among 187 countries in the 2013 Human Development Index [2]. Gross national income per capita is 
$630, 43.5% live on less than $1.25 per day, and 28% are below the national poverty line [3]. Net 
enrolment in primary school for children aged 7-13 years is approximately 77%, with little difference 
between males and females, and the adult literacy rate is 78% (2012) [1]. Secondary school enrolment 
for children aged 14-19 years is much lower (25.3% in 2010, data not available for 2012) [4].  
Tanzania has made progress in recent years at reducing mortality rates. Between 2006-2010, 
mortality among children under five years was 81 deaths per 1,000 live births, compared to 106 and 143 
deaths per 1,000 live births from 2001-2005 and from 1996-2000, respectively [4]. Similarly, in the last 
decade infant mortality has declined by 50%, but improvements in neonatal mortality are not as 
substantial, decreasing from 33 deaths per 1,000 live births from 1996-2000 to 26 deaths per 1,000 live 
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births from 2006-2010. Maternal mortality has also remained a challenge, with 432 deaths per 100,000 
live births in 2012 [1, 4].  
 
Figure 1: Map of Tanzania showing zonal and regional boundaries. (Source: Tanzania HIV / AIDS and 
Malaria Indicator Survey, 2011-2012 [5]) 
 
 
Malaria continues to be a leading cause of morbidity and mortality in mainland Tanzania, where 
100% of the population is considered at risk. In 2012, there were approximately 40 confirmed cases per 
1000 population and 15 inpatient deaths per 100,000 [6]. The major species is P. falciparum, with very 
few infections caused by P. malariae and P. ovale, and the principal vectors are the Anopheles gambiae 
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complex (An. gambiae s.s and An. arabiensis). Seasonal malaria corresponds with the main rainy season, 
typically from March-May, with some parts of the country also experiencing rain November-January. In 
the largely arid central plateau, malaria is unstable and seasonal, while higher year-round transmission 
with some seasonal variations occurs in regions along the coast, Lake Victoria, and the southern 
lowlands. The remainder of the country has stable, seasonal transmission. Prevalence of malaria has 
been declining in much of the country, with 18% of children age 6-59 months positive by RDT in the 
2007-2008 Tanzania HIV and Malaria Indicator Survey (THMIS) [7], compared with 9.5% in the 2011-
2012 THMIS [5]. Prevalence is highest around Lake Victoria and in the southern lowlands.  
 In Tanzania, treatment for malaria is sought from public health facilities, private not-for-profit 
facilities, and private for-profit outlets. Public health facilities include hospitals, health centres, and 
smaller dispensaries. According to national guidelines, treatment for malaria is provided free of charge 
for children under five years, pregnant women, the elderly, and those who cannot afford to pay [8], but 
these exemptions are not always implemented [9, 10]. Tanzania adopted AL as the first-line antimalarial 
drug in 2004, although it was not available in public health facilities until 2006. The recommended 
treatment regimen is six doses over 3 days, with 1-4 tablets (20 mg artemether / 120 mg lumefantrine) 
per dose depending on the patient's weight / age band (Figure 2). Dispersible tablets are used for 
children. National guidelines state that the second dose should be taken eight hours after the first dose, 
followed by the remaining doses each morning and evening of the second and third days [11]. To 
maintain stocks of AL, drugs are ordered through an Integrated Logistics System (ILS), in which individual 
health facilities submit requests to the District Medical Officer (DMO), who then authorises drugs to be 
delivered from zonal stores. Health workers also receive text message prompts to report on current 
stocks from the SMS for Life system, which records data on drug stocks in each health facility and sends 
summary reports to the DMO [12].  
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Figure 2: Example of AL treatment regimen (Source: Tanzania National Guidelines for Diagnosis and 
Treatment of Malaria, 2011 [11])  
  
 
Diagnosis of malaria was mostly presumptive in health facilities until RDTs were rolled out in 
2010-2012. However, an evaluation in three regions (Mwanza, Mbeya, and Mtwara) in 2012 showed 
that only about half of febrile patients attending public health facilities were tested, and facility stock-
outs of both RDTs and AL were major challenges [13]. Stock-outs in the public sector were suggested to 
be one reason for a shift in care-seeking behaviour from public health facilities to the private retail 
sector observed in rural areas in a household survey in these regions from 2010-2012 [14]. Across all 
health facilities in Tanzania during a 15-month period from October 2011-December 2012, complete 
stock-outs of all four packs of AL were recorded from an average of 29% of health facilities each week 
[15].  
 In the private for-profit sector, treatment for malaria in Tanzania is frequently obtained from 
private facilities and the private retail sector (pharmacies, drugs stores, and general shops). As 
pharmacies are typically not located outside of urban centres, the 9,000-plus drug stores account for the 
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majority of private retail sector sales in peri-urban and rural areas. Prior to 2003, the primary drug 
stores were duka la dawa baridi (DLDB). These shops were typically small buildings with cement or brick 
walls and a tin roof [16]. Most shops had 1-2 sellers with a low-level medical qualification (e.g. nurse 
assistant) and less medical training than the required four years. They were allowed to stock over-the-
counter medicines, such as antipyretics / pain killers and oral antimalarials (e.g. chloroquine, 
amodiaquine, and SP), but not prescription-only antimalarials (e.g. injectables) and oral antibiotics. 
However, many DLDB illicitly stocked unregistered or prescription-only drugs [16-18]. Drugs were mostly 
obtained from wholesalers or pharmacies in Dar es Salaam, although many shops were located several 
hundred kilometres away. DLDB were required to be registered with the Tanzania Food and Drug 
Administration (TFDA), but knowledge of regulations was poor and many shops failed to obtain the 
appropriate permits. Furthermore, TFDA funding for inspections was very limited, and DLDB were 
essentially able to operate outside of the regulatory framework [18].   
In 2001, the Strategies for Enhancing Access to Medicines (SEAM) Program run by Management 
Sciences for Health (MSH) through a grant from the Bill and Melinda Gates Foundation conducted an 
assessment that identified many of these issues. The Accredited Drug Dispensing Outlets (ADDO) 
initiative was launched by TFDA and SEAM in order to improve availability, quality, and affordability of 
pharmaceutical services in rural and peri-urban areas without pharmacies [19]. ADDOs (also known as 
duka la dawa muhimu (DLDM), or essential drug shops) were first piloted in Ruvuma region in 2003, 
with a wide range of stakeholders participating in the design and implementation of the program [18].  
Upgrading and accreditation of DLDBs to ADDOs involved multiple components. Dispensers 
were required to have a health qualification of a nurse assistant or higher. A mandatory six-week 
training included topics such as laws, regulations, record-keeping, and dispenser ethics, as well as 
ADDO-approved medicines, common indications and contraindications, common dosages, side 
effects, patient information, and effective communication skills. The intent was for ADDO dispensers 
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to fill prescriptions, or when prescriptions were not available, to ask about the patients’ symptoms, 
recommend appropriate treatment, provide advice on how to take medicines at home, and when 
necessary refer patients to health facilities for further care. In addition to training, the ADDO program 
involved dispenser incentives, including permission to sell an approved list of prescription-only 
medicines (e.g. certain oral antibiotics and oral quinine), a marketing campaign to raise awareness of 
ADDOs, and the establishment of regional pharmaceutical wholesalers. To improve regulation, 
government officials were trained to conduct ADDO inspections several times per year.  
By August 2005, more than 150 shops had been accredited, and an evaluation of the ADDO 
program showed some improvements in access to quality medicines and services [18, 19]. The Ministry 
of Health and Social Welfare then decided to expand the program nationwide and phase-out DLDBs. 
Although ACTs were the first-line treatment for uncomplicated malaria and available in public health 
facilities since 2006, the expense of ACTs ($8-10 in pharmacies) limited their availability in ADDOs [20]. 
In 2007-2008, a pilot program to make subsidised ACTs available in ADDOs was conducted in five 
districts each in Ruvuma and Morogoro regions, led by TFDA, the NMCP, and SEAM, with funding from 
the President’s Malaria Initiative (PMI). ACTs were added to the list of prescription-only medicines that 
ADDOs were allowed to sell, and the pilot program established a supply of subsidised ACTs, set a 
recommended retail price, and ran a two-day training for dispensers on treatment of malaria with ACTs, 
as this had not been covered in previous training. After one year of the program, 70% of ADDOs stocked 
ACTs, and the percentage of antimalarial sales that were ACTs had increased modestly from 3% in July 
2007 to 28% in June 2008, with substantial variation by district [21].  
Another study run by the Clinton Health Access Initiative (CHAI) also piloted the introduction of 
subsidised ACTs in regions where ADDOs had not yet been introduced [22]. Dispensers at DLDB in an 
intervention district in each of Shinyanga and Dodoma regions were trained for one day on malaria 
symptoms and ACT dispensing and were given permission to sell ACTs. A designated wholesaler in Dar es 
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Salaam purchased the ACTs at a subsidised price ($0.11) and sold them to DLDB in the intervention 
districts. Compared to the TFDA pilot in Morogoro and Ruvuma ADDOs, a similar proportion of DLDB 
stocked ACTs after one year (70%). However, a more marked increase from 1% in August 2007 to 44% in 
August 2008 was observed in the percentage of antimalarial sales that were ACTs. In addition, the CHAI 
pilot found that DLDBs that had not stocked ACT during the study were located farther from roads, the 
district town, other DLDB and public facilities, and had lower total antimalarial sales [23].  
Both the TFDA and CHAI studies piloted the provision of subsidised ACTs in drug shops. This 
approach was subsequently expanded nationwide as Tanzania was one of seven pilot countries (eight 
considering Zanzibar separately) to receive AMFm-subsidised drugs. The first co-paid drugs for the 
private for-profit sector arrived in Tanzania in October 2010, and by the end of 2012, nearly 24.6 million 
doses had been delivered [14]. The Medical Stores Department was the first-line buyer for the public 
sector, while in the private for-profit sector ten first-line buyers were registered, five of which placed 
orders with manufacturers. The recommended retail price for an adult dose was 1,000 Tanzanian 
Shillings ($0.64). Interventions to increase community awareness of subsidised ACTs included mass 
media campaigns (e.g. TV and radio spots). Community-level communications, such as shows and school 
activities led by community change agents and community based organisations, took place in two 
districts per region. The Independent Evaluation showed that AMFm led to significant reductions in the 
price of ACTs and a corresponding increase in their availability and market share [24]. Availability of 
quality-assured ACTs increased from 11% to 66% in the private for-profit sector between 2010 and 2011, 
with their market share increasing from 2% to 32% [14]. 
Although ACTs were officially only allowed to be sold in ADDOs, AMFm-subsidised ACTs flowed 
through the normal distribution channels, reaching drug stores in regions with and without ADDOs 
(Thomson et al., in draft). When AMFm was launched, ADDOs operated in eight regions (Ruvuma, 
Rukwa, Mtwara, Morogoro, Mbeya, Singida, Pwani, and Lindi), but only dispensers in the TFDA pilot 
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districts in Ruvuma and Morogoro had previously received training on ACTs (in 2007). In Mtwara and 
Lindi regions only, a one-day refresher training that included treatment of malaria with ACTs (as well as 
the use of oral rehydration solutions and family planning) was offered for dispensers with previous 
nursing training in August 2011. Roll out of ADDOs to additional regions incorporated ACTs into the 
general training. In September 2012, when the studies presented in this thesis were conducted, ADDO 
roll out had taken place in six more regions, with an additional six in progress. At this time, RDTs were 
not permitted in ADDOs. Nationwide ADDO roll out was completed in 2013, with approximately 60% of 
the 9,000-plus drug shops having completed the training and accreditation process [25]. 
 
3.2 Mtwara region 
The research presented in this thesis was conducted in Mtwara region in southeastern Tanzania. 
Mtwara is a primarily rural region located on the southeastern coast with Mozambique on its southern 
border. The distance from Dar es Salaam to the main urban centre in Mtwara is 558 km [26] on mostly 
paved road, though in 2012 some unpaved sections proved difficult during the rainy seasons. There is 
also an airport in Mtwara, with a daily direct flight from Dar es Salaam. Mtwara is composed of six 
districts (Mtwara Urban, Mtwara Rural, Masasi, Nanyumbu, Newala, and Tandahimba). The main town is 
in Mtwara Urban, and peri-urban centres are located in Masasi, Newala, and Tandahimba. The road 
from Mtwara town to Masasi (200 km) is paved, but the majority of roads in the region are not. 
The population of Mtwara is 1,270,854, with a density of approximately 76 persons per square 
kilometre [26].  More than 80% of the population are small-scale farmers [1], and over one third of the 
population is in the lowest national wealth quintile [4]. The population is mostly Muslim, and adult 
literacy is 71%, slightly lower than the national average (78%). Mobile phone ownership in the Southern 
zone (Mtwara and Lindi) is 34% among women and 47% among men. The most common source of mass 
media is the radio, with 62% of women and 80% of men listening to the radio at least once per week, 
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and less than 25% of men and 15% of women exposed to TV or newspapers [5]. Coverage with national 
or community-based health insurance is very low (less than 5%), and approximately 60% are able to 
access a public health facility within an hour or less [27]. 
Monthly rainfall in Mtwara in 2012 was highest January – May (180 mm in January, reducing to 
55 mm in May), with little rainfall from June to November (range 6 – 15 mm), and increasing again to 44 
mm in December [26]. Prevalence of malaria was 15% by reference blood smears among patients 
seeking care for fever at ADDOs in March 2012 [28], 32% by reference blood smears among patients 
seeking care for fever in health facilities in July 2012 [13], and 17% by RDT in a household survey in 
August – September 2012 [27].   
There are approximately 150 public health facilities in Mtwara, the majority of which are small 
dispensaries. There are also approximately 150 ADDOs (subject to turnover) and four pharmaceutical 
wholesalers located in the region, two each in Mtwara and Masasi towns. By 2011, all drug shops in 
Mtwara were officially required to have upgraded to ADDO status, but in practice some shops had not 
yet paid fees or received training but were tolerated as “prospective ADDOs.” 
 
Figure 3: Mtwara ADDOs 
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Prior to AMFm, ACTs were rarely sold in ADDOs in Mtwara. From February 2011 to January 
2012, a study in Mtwara and Rukwa regions reported that the availability of AMFm-subsidised ACTs in 
ADDOs increased from 25% to 88% in Mtwara and from 3% to 62% in Rukwa [29]. The mean retail price 
of an adult ACT treatment decreased during this time from $1.03 to $0.81, with a median in 2012 of the 
recommended retail price ($0.64). AL was the primary ACT available, with only a few shops stocking 
artesunate-amodiaquine. Unlike the previous CHAI pilot in Shinyanga and Dodoma regions [22, 23], 
degree of remoteness within Mtwara did not have a significant effect on availability of ACTs, although 
availability in Mtwara remained higher than in the more remote Rukwa region. Shops with a higher 
number of ADDOs within three kilometres, a higher number of customers, and a higher fraction of 
customers seeking care for malaria were more likely to stock ACTs [30]. In a related household survey in 
Mtwara and Rukwa, ACT use among suspected malaria cases increased from 51% in March 2011 to 62% 
in March 2012, with the largest increase among retail sector patients (31% go 61%) [31].  
 
3.3  The IMPACT2 Project 
This research was conducted within the framework of the IMPACT2 project in Tanzania.  
IMPACT2 is a collaboration of the London School of Hygiene and Tropical Medicine (LSHTM), the U.S. 
Centers for Disease Control and Prevention (CDC), and Ifakara Health Institute (IHI), with funding from 
the Bill and Melinda Gates Foundation through the ACT Consortium. The project, which began in 2009, 
focused on monitoring interventions to improve ACT access and targeting, with the aim of evaluating 
the national roll out of RDTs and the introduction of AMFm-subsidised drugs in terms of the impact on 
coverage, equity and quality of malaria treatment. IMPACT2 activities included household surveys, 
health facility surveys, and qualitative data collection in three regions of Tanzania (Mwanza, Mbeya, and 
Mtwara) in 2010 and 2012, as well as a 2012 survey of parasitaemia and ACT purchasing among ADDO 
patients in Mtwara and Mwanza [13, 14, 28]. The project also conducted national drug outlet surveys in 
62
2010 and 2011 as part of the Independent Evaluation of AMFm [32-34]. All other IMPACT2 field work 
had been completed when data collection for this thesis began. 
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4  Research objectives and methods 
 This chapter outlines the main objective of each of the three research papers presented in this 
thesis and explains how the research papers in Chapters 5-7 fit together. While most of the methods 
used are presented in detail in each paper, an overview of the methods is provided, with additional 
details available in appendices.  
 
4.1  Research objectives 
 The specific objectives of the research presented in this thesis are: 
1. To determine differences in patient characteristics and levels of adherence between patients 
obtaining AL in public health facilities and ADDOs, and to examine factors associated with adherence in 
both of these settings (Chapter 6). 
2.  To evaluate the effect on dispenser knowledge and patient adherence of text message reminders 
targeted at ADDO dispensers concerning advice to provide when dispensing AL (Chapter 5). 
3. To compare the validity of assessing patient adherence with self-reported data compared to smart 
blister packs (Chapter 7). 
In this thesis, the second research objective is addressed first (Chapter 5), with Chapter 6 
addressing the first research objective. This order was necessary, as the research paper on the text 
message intervention in ADDOs was published first, and the subsequent research papers reference its 
description of methods. 
 
4.2  Overview of study design 
 The research was composed of three related studies, a cluster-randomised trial (CRT) of a text 
message intervention, an observational study in public health facilities, and a comparison of methods to 
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assess adherence. The first two studies relied on adherence measured by self-report and pill count, but 
in order to assess the validity of this approach, a third study using smart blister packs—a customised 
electronic monitoring device—was nested within the other two studies.  
A CRT was chosen to evaluate the text message intervention. In CRTs, as in other randomised 
controlled trials, the random allocation of the intervention ensures (theoretically) that known and 
unknown factors that might affect the outcome are evenly distributed, allowing differences in outcome 
between control and intervention arms to be attributed to the intervention. In order to minimise 
contamination between dispensers working in the same or nearby shops, the intervention was delivered 
at the cluster (ADDO) level. The observational study in public health facilities was conducted in order to 
address whether or not adherence to AL obtained in ADDOs was lower than in public health facilities. 
These studies were conducted in parallel, with teams simultaneously working at ADDOs and public 
health facilities in each district of Mtwara.  
Mtwara region was selected as the research site, as this was one of three focus regions for the 
IMPACT2 umbrella project, along with Mwanza and Mbeya. Mtwara was selected for this adherence 
study for several reasons. Both Mtwara and Mbeya had established ADDOs, but Mwanza did not, and 
DLDB could not officially supply ACTs. In Mbeya, the low prevalence of malaria might have resulted in 
slow patient enrolment compared to Mtwara region, where transmission is moderately high. Finally, an 
IHI office is located in Mtwara and could help with field logistics. 
ADDO census. Preliminary data collection for the CRT began in May 2012 with a census and brief 
survey of all ADDOs in Mtwara. The primary purpose of the census was to build a sampling frame for the 
CRT and collect data to guide the sampling process in order to minimise contamination between control 
and intervention ADDOs. Selection and randomisation of ADDOs, as well as selection of public health 
facilities for the observational study, are described further in Chapters 5 and 6. 
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Text message intervention. The text message intervention is described in Chapter 5. Briefly, 
dispensers at selected ADDOs were visited prior to beginning the intervention to invite participation. 
Messages were scheduled in advance and sent automatically Monday – Friday of the first four weeks, 
and Monday, Wednesday, Friday of the next 10 weeks. Content of text messages was based on ACT 
dispensing instructions.  Each of the seven content messages was paired with a unique quote to 
encourage reading or a question based on the content of a previous message. Respondents that replied 
correctly (at their own expense) were compensated with extra airtime.  
Enrolment of outlets. From September – November 2012, both control and intervention ADDOs 
and selected public health facilities were visited and asked to participate in the research. Dispensers 
were provided with smart blister packs of AL (discussed in Chapter 7) and asked to register all patients 
that obtained any drug for fever or malaria at the outlet on a study form (Appendix 1a-b). The intention 
was to register 12 patients obtaining ACTs in one week per outlet, but it took 2-3 weeks to recruit this 
number in some outlets.  
Patient and dispenser interviews. Registered patients obtaining AL were visited at home on day 
4 for a structured interview covering when and how each dose of AL was taken (Appendix 1c) and 
collection of blood samples and blister packs. Determination of patient adherence is described in 
Chapters 5-7. Interviews of ADDO dispensers were conducted from mid-October – November 2012, 
following completion of patient interviews in a given district. Dispensers were asked about their 
knowledge of advice to provide patients when dispensing AL using open-ended questions. Responses 
were recorded verbatim and evaluated against a pre-specified description of correct responses.  
Key informant interviews (KIIs). Key informant interviews were conducted in each district with 
the DMO and, when available, the District Pharmacist, the District Nursing Officer, and / or the Malaria 
Focal Person. Data were collected on ADDO roll out, training, supervision, inspection, and community 
sensitization, as well as availability of ACTs and RDTs in health facilities, and other malaria control  and 
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research activities. The data are not presented separately in this thesis but inform the interpretation of 
the studies described in the research papers. 
 Socioeconomic indices. To determine socioeconomic status, data were collected from patients 
on ownership of household possessions, housing characteristics, and access to utilities, based on 
standard Demographic and Health Survey variables (http://www.measuredhs.com). Socioeconomic 
indices were calculated using principal component analysis, with the factor scores from the first 
principal component used as weights [1]. Scores were divided into quintiles, and the proportions of 
patients in each quintile were presented in tables.  
Registration of CRT and ethical approvals. The CRT was registered with Current Controlled Trials, 
ISRCTN83765567. Both the CRT and the observational study were submitted together for ethical 
approval to LSHTM and IHI. An amendment was also submitted to LSHTM when it was decided to test 
patients with RDTs at the interview, in addition to collecting blood smears and filter papers (this 
amendment was included in the original protocol submitted to IHI). Approval letters are included in 
Appendix 2.  
When enrolling outlets to participate in the study, a consent form with a standard introduction 
to the research was read and signed by a dispenser at each outlet (Appendix 1a). Informed consent was 
also collected from patients and dispensers prior to interview.    
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5  Text message intervention in ADDOs 
5.1  Introduction 
This chapter covers the first of three research papers presenting results of the studies 
conducted for this thesis. Published online in the American Journal of Hygiene and Tropical Medicine in 
July 2014, this paper addresses the second research objective, evaluating the effect on dispenser 
knowledge and patient adherence of text message reminders targeted at ADDO dispensers concerning 
advice to provide when dispensing AL. This chapter is placed before the chapter addressing the first 
research objective (Chapter 6), as this research paper was published first, and the second and third 
papers (Chapters 6-7) refer to methods presented in this paper. 
 Details of the ADDO census, selection, and randomisation, as well as the full schedule of text 
messages are included in Appendix 3. 
 
5.2  Research paper (cover sheet on next page) 
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Abstract. Artemisinin combination therapies are available in private outlets, but patient adherence might be
compromised by poor advice from dispensers. In this cluster randomized trial in drug shops in Tanzania, 42 of 82
selected shops were randomized to receive text message reminders about what advice to provide when dispensing
artemether-lumefantrine (AL). Eligible patients purchasing AL at shops in both arms were followed up at home and
questioned about each dose taken. Dispensers were interviewed regarding knowledge of AL dispensing practices and
receipt of the malaria-related text messages. We interviewed 904 patients and 110 dispensers from 77 shops. Although
there was some improvement in dispenser knowledge, there was no difference between arms in adherence measured as
completion of all doses (intervention 68.3%, control 69.8%, p [adjusted] = 0.6), or as completion of each dose at the
correct time (intervention 33.1%, control 32.6%, p [adjusted] = 0.9). Further studies on the potential of text messages
to improve adherence are needed.
INTRODUCTION
Patient adherence to treatment is an important step in
ensuring the effectiveness of artemisinin-based combination
therapies (ACTs) for malaria.1 Incomplete adherence to recom-
mended treatment can result in poor clinical outcomes, under-
mine the effectiveness of case management as a tool for malaria
control, and may contribute to the selection of drug-resistant
malaria parasites.2,3 ACTs are first-line treatment of Plasmo-
dium falciparum malaria in the public sector of most malaria-
endemic countries, with patient adherence reported to range
widely from39% to 100%.4,5Many patients seek care formalaria
in the private retail sector.6–9 The proportion of private sector
clients obtaining ACTs has increased over time as ACTs have
become more widely known, and their price has fallen, particu-
larly in settings where they have been subsidized by programs
such as the AffordableMedicines Facility-malaria (AMFm).10
Althoughaccess toeffective antimalarials in theprivate sector
may have increased, drug sellers may not always provide
patients with appropriate doses or advice, raising concerns
about patient adherence, though evidence is very limited. Only
five studies have specifically assessed patient adherence to anti-
malarials obtained in the private retail sector.11–15 Of these,
ACTs were used only in one study by Cohen and others
(2012)11 in Uganda, which reported 66% of patients seeking
care from drug shops were adherent. As ACTs become more
available in the private sector, it becomes increasingly important
to understand patient adherence and the effects of interven-
tions intended to improve adherence. Supporting interven-
tions, such as shopkeeper training, have previously succeeded
in increasing the proportion of patients who receive and com-
plete the recommended dose of non-ACT antimalarials,13,16
but such interventions have yet to be tested on a national scale
or applied to ACTs.
Mobile phones are a promising tool for the delivery of
healthcare interventions as coverage of mobile networks and
handset ownership increases.17–19 Text messaging, the least
expensive mobile phone function, has been used in malaria
control settings for commodity monitoring, disease surveil-
lance, and pharmacovigilance.20 In addition, a trial in public
health facilities in Kenya21 showed that 6 months of text mes-
sage reminders improved public health workers’ management
of pediatric malaria by 24% points immediately after the
intervention, and the improvements were sustained for at
least 6 months after the intervention was withdrawn. The text
message reminders were well accepted by health workers,22
inexpensive, and cost-effective.23
Given the concerns over inadequate patient adherence to
ACTs delivered through the private retail sector, and the
potential benefit of text-message interventions to enhance
adherence, we designed and completed a cluster randomized
trial in southern Tanzania to assess the effect of text message
reminders to drug shop workers on patient adherence to
artemether-lumefantrine (AL). We also evaluated the effect
of text messages on dispenser knowledge and advice.
The private retail sector in Tanzania is an important source
of treatment of malaria,24,25 and ACT availability in such
outlets increased after the implementation of AMFm in 2010.
Another key intervention in Tanzania’s private sector has
been the creation of accredited drug dispensing outlets
(ADDOs) by the Tanzania Food and Drug Administration
(TFDA) to improve regulation of drug shops and quality of
medicines. ADDOs are drug shops that have been upgraded
through a process of training and certification and are allowed
to sell a limited number of prescription-only drugs, including
some antibiotics and ACTs.26,27
METHODS
Study setting. The study was conducted in Mtwara, a rural
region in southeastern Tanzania with 35.5% of the population
in the lowest national wealth quintile.28 Prevalence of malaria
*Address correspondence to Katia Bruxvoort, 15-17 Tavistock Place,
London, WC1H 9SH. E-mail: katia.bruxvoort@lshtm.ac.uk
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among children 6–59 months of age in Mtwara was 17.4%
in the 2011–2012 HIV/AIDS and Malaria Indicator Survey29
and 23% in a survey of patients seeking treatment at private
drug shops.30 AL has been recommended as the first-line
treatment of malaria since 2004, although it was not available
in public health facilities until 2006. The recommended treat-
ment regimen is six doses of AL over 3 days, with 1–4 tablets
(20 mg artemether/120 mg lumefantrine) per dose depending
on the weight/age band. National guidelines state that the
second dose should be taken 8 hours after the first dose,
followed by the remaining doses morning and evening of the
second and third days.31
In Mtwara, ADDO accreditation commenced in 2006, and
officially only accredited drug stores are allowed to function. In
reality, a large number of non-accredited shops exist because of
a lack of training, unpaid fees, or administrative delays. These
shops are tolerated by regulating authorities and considered
“prospective ADDOs.” Before AMFm, ACTs were not com-
monly available in ADDOs in Mtwara, and dispenser training
on ACTs was limited, but ACT availability significantly
increased after AMFm implementation, with 88% of ADDOs
stocking ACTs in Mtwara in August 2011.32 To support
AMFm roll out, TFDA offered a 1 day refresher training that
included treatment of malaria with ACTs to dispensers with
previous nursing training in Mtwara in August 2011.
Sample size calculations. We based the sample size for this
two arm cluster randomized trial on data from the public
sector in Tanzania, where patient adherence to AL was 65–
98%(Khatib R, unpublished data).33–35 We assumed lower
adherence to AL obtained at ADDOs in Mtwara (60%) and
powered the study to detect a 15% point increase in the inter-
vention arm. We wanted to recruit a small number of patients
per cluster to reduce the potential bias caused by increasing
community awareness of the study’s objectives. Assuming a
coefficient of variation of 0.25, 80% power, 5% significance,
and 20% loss to follow-up, 13 patients from 36 outlets in each
arm were required, a total of 468 patients per arm.
Selection of study ADDOs. In May 2012, we conducted a
census of all drug shops in Mtwara (ADDOs or prospective
ADDOs). Data were collected on the characteristics of owners
and dispensers, ACT stocks and sales, and global positioning
system (GPS) coordinates. ADDOs were excluded from the
sampling frame if they had sold fewer than five antimalarial
treatments in the previous week, no dispensers used a mobile
phone, the shop was located on the border with Mozambique
or was not accessible, or the owner refused to participate
(Figure 1). The final sampling frame consisted of 131 ADDOs.
The 82 ADDOs were selected sequentially at random, with any
ADDOs within 400 m of a selected ADDO, or any ADDOs
where staff from a selected ADDO also worked, removed from
the sampling frame. The selected ADDOs were then stratified
by location in urban or rural wards, and the intervention
was randomly allocated to 29 of 57 urban ADDOs and 13 of
25 rural ADDOs.
Intervention design. We designed seven content messages
about advice that dispensers should provide when dispensing
AL (Figure 2). The messages were derived from the govern-
ment refresher training booklet and reflected the recom-
mended practices for dispensing AL. Messages were pilot
tested in ~20 ADDOs in a semi-urban district outside of
Dar es Salaam. Dispensers at these ADDOs were sent each
potential message in turn and asked to explain their understand-
ing of the meaning and relevance of each message. Dispensers
were also asked if they would find receipt of the messages
helpful, how often they would like to read the messages, and
whether complementary components such as quotes or ques-
tions would encourage reading. Phrasing and frequency of the
messages were adjusted based on feedback received during
the pilot.
Before sending the first message, the 42 ADDOs in Mtwara
randomized to the intervention arm were visited to invite
participation and collect an updated list of mobile numbers
for all dispensers. Messages began in July 2012 and were sent
in random order once per day Monday–Friday for the first
4 weeks, followed by once per day Monday, Wednesday, and
Friday for the next 10 weeks. Messages were written in
Swahili and scheduled in advance on an automated platform,
with each message paired with a different complementary
component each time to promote interest. Complementary
components consisted of inspirational quotes or proverbs or,
once per week, a quiz question on message content that
earned correct respondents free air time (500 TSH or $.30).
Over the 14-week period, 49 messages were sent to each of
60 dispensers, and detailed delivery reports were kept for
each message.
Data collection. From September through November 2012,
dispensers at ADDOs in the intervention and control arms
were visited by study supervisors and given a standard intro-
duction about study objectives. To limit patients’ awareness
of our primary interest in adherence, which could have led to
a biased assessment, dispensers were told we were studying
how patients chose to treat fever and would visit some, but
not all, patients at their homes. They were asked to fill out a
registration form for all patients purchasing any treatment of
fever, including the day and time of their ADDO visits, the
patients’ names, the drugs purchased, and a description of
where the patients lived. Dispensers were provided with blis-
ter packs of AL that they could then sell to patients needing
treatment of malaria. Study staff visited ADDOs every day to
check and collect registration forms for 1–3 weeks, or until
12–15 patients purchasing AL were registered if quicker.
Eligible patients who obtained AL were identified from the
registration forms and assigned patient identification numbers
(recorded on follow-up forms). Patients were followed up
~68–72 hours after their ADDO visit, according to a pre-
defined schedule, and all attempts to locate and interview
patients were recorded. Where written informed consent was
given, patients or their caregivers were asked about demo-
graphic and socioeconomic characteristics, treatment-seeking
history, illness symptoms, detailed information about each
dose of AL taken and the advice provided by the ADDO
dispenser. Blister packs were requested for a pill count, and
blood samples were collected for a blood smear and a malaria
rapid diagnostic test (mRDT) (Pf-specific from ICT Diagnos-
tics, Cape Town, South Africa). Blood smears were stained
in the field and transported to the Ifakara Health Institute,
where they were double-read by two microscopists blinded
to results from each other and the mRDT, with discrepant
results read by a third microscopist.
Adherence was defined in two ways.5 Patients were consid-
ered to have “verified completed treatment” if they reported
taking all doses by the time of the follow-up visit and a pill
count verified that no pills remained in the blister pack,
if available. The second, more stringent definition included
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a time component, based on patient reports of the time
each dose was taken using the Swahili times of day: “alfajiri”
(early morning), “asubuhi” (morning), “mchana” (afternoon),
“jioni” (evening), “usiku” (night), and “usiku sana” (late
night). Patients were considered to have “verified timely com-
pletion” if they took the second dose at the Swahili time of
day corresponding with 8 hours after the first dose, and then
took each of the remaining doses at the Swahili time of day
Figure 1. Consort-like style flow diagram of trial.
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corresponding with 12 hours after the previous dose, verified
by the absence of pills in the blister pack. For ease of reading,
we hereafter refer to these definitions as “completed treat-
ment” and “timely completion.”
After completion of patient interviews, dispensers working
at the study ADDOs were interviewed on ADDO character-
istics, demographics, receipt of study text messages, and
advice they would give to patients when dispensing AL. To
assess knowledge corresponding with message content, we
used an open-ended question, e.g., “I would like to ask about
which advice you think you should provide to a person of
any age taking treatment for malaria. For the following topics
(e.g., “when to take the second dose” or “what to do with the
pills if the patient feels better,” etc.) tell me if advice on this
topic is important or not, and if so, what advice you would
provide.” Responses were recorded verbatim and evaluated
by the study leader using predetermined criteria based on
message content.
Data entry and analysis.All patient and dispenser interview
data were collected using personal digital assistants, and data
extracted from study forms (census, registration, and follow-
up forms) were double entered into Microsoft Access data-
bases (Microsoft Corp., Redmond, WA). Data were analyzed
in Stata 11.0 (Stata Corporation, College Station, TX). Pri-
mary outcomes were analyzed by intention-to-treat. Compar-
ison of adherence was based on a t test of the proportion
adherent in each cluster. A list of potentially important con-
founders was identified a priori consisting of ADDO accredi-
tation certificate, number of customers purchasing ACTs in
the previous week, dispenser medical qualification, dispenser
training on ACTs, patient age, and patient education. Adjust-
ment for variables on this list found to be unbalanced between
arms was performed by fitting a logistic regression model to
the individual data and performing analysis on the aggregated
residuals, as described by Bennett and colleagues.37
Ethics. All questionnaires, consent forms, and other study
documents were translated into Swahili and piloted before
use. Written informed consent was collected from dispensers
before census, patient registration and interview, and from
patients or their caregivers prior to interview. The study pro-
tocol was approved by the ethical review boards of Ifakara
Health Institute and London School of Hygiene and Tropical
Medicine. The Centers for Disease Control and Prevention
(CDC) investigators provided technical assistance in design
and analysis but were not engaged in data collection. The trial
is registered with Current Controlled Trials, ISRCTN83765567.
RESULTS
Figure 1 shows the trial profile. Of the 82 randomized
ADDOs, 37 from the control arm and 40 from the interven-
tion arm participated in the study. The number of registered
patients eligible for follow-up was 537 in the control arm and
518 in the intervention arm, with ~15% of patients in each
arm lost to follow-up. Most outlets were in urban wards (70%
in both arms), had a single dispenser, and had at least some
ACTs in stock on the day of interview (Table 1). Of 51 dis-
pensers in the control arm and 59 in the intervention arm,
~80% in both arms were female and had a low-level medical
qualification, mostly nurse assistants (Table 2). Though low in
both arms, more ADDOs in the control arm compared with
the intervention arm were able to show an accreditation cer-
tificate (43% versus 20%, respectively). However, the differ-
ence in the percentages of dispensers that had received
training on ACTs was not as pronounced (69% in the control
Table 1
Characteristics of accredited drug dispensing outlets (ADDOs)
Control Intervention
Number (N) 37 40
Number urban (%) 26 (70%) 28 (70%)
Median number of dispensers per
ADDO (range)
1 (1–3) 1 (1–4)
Number with one or more trained
medical staff (%)*
36 (97%) 37 (92%)
Number with any ACTs in stock
on day of interview (%)
35 (95%) 40 (100%)
Number with all four weight-based
packs in stock on day
of interview (%)
11 (30%) 14 (35%)
Median number of customers
purchasing ACTs in last 7 days
(range)
13 (0–82) 19 (0–147)
Number with ADDO accreditation
certificate (%)
16 (43%) 8 (20%)
Number with drinking water
available in ADDO (%)
30 (81%) 37 (93%)
*Medical staff is defined as pharmacists, pharmacist assistants, medical doctors, assistant
medical doctors, clinical officers, assistant clinical officers, midwives, nurses, nurse assistants,
and laboratory technologists. Most were nurse assistants or nurses.
ACTs = artemisinin-based combination therapies.
Figure 2. Content of text messages sent to dispensers in the intervention arm.
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arm versus 60% in the intervention arm), though the median
year of training was more recent in the control arm (2011
versus 2009).
Characteristics of patients were well balanced between arms
(Table 3). A high percentage of patients (36% in the control
arm and 38% in the intervention arm) had sought care before
attending the study ADDO, with most patients going to a kiosk
or general shop and only 7% of patients in the control arm and
4% in the intervention arm going to a public health facility.
Approximately 90% reported symptoms of fever or headache,
and approximately half had upset stomachs or nausea. Based
on anmRDT taken at the time of follow-up, 28% in the control
arm and 25% in the intervention arm tested positive, with only
1.4% and 1.6%, respectively, testing positive by study blood
smear. (Some degree of discrepancy is expected because of the
persistence of HRP2 detected by the mRDT.)
Seventy percent of dispensers received at least 75% of the
text messages. The median percentage of messages received
was 86%, with 20% of dispensers receiving no messages
(Figure 3). Table 4 presents results of the dispenser interviews
on knowledge of advice to provide patients when dispensing
AL. Dispensers in the intervention arm reported slightly
better knowledge of the correct AL regimen for adults in the
intervention arm compared with the control arm (90% versus
78%; adjusted prevalence ratio [aPR] = 1.2 (95% confidence
interval [CI]: 0.95, 1.5); p [adjusted] = 0.0748), though knowl-
edge of the correct regimen for a child aged four weighing
20 kg was lower than for adults in both arms (75% versus
64%; aPR = 1.2 [0.85, 1.7]; p [adjusted] = 0.2). Dispenser
knowledge was considerably higher in the intervention arm than
the control arm on advice to take AL with fatty food (60%
versus 20%; aPR = 3.4 [95% CI: 1.6, 7.1]; p [adjusted] < 0.0001)
and to continue to take AL if minor side effects occur (68%
versus 43%; aPR = 1.6 [95% CI: 1.0, 2.4]; p [adjusted] = 0.0188).
However, surprisingly high dispenser knowledge (87–99%) was
recorded in both arms on advice to complete treatment even if
feeling better, advice to return to the ADDO or go to a health
facility if the condition worsens, and advice to take the second
dose after 8 hours (Table 4). Knowledge on advising patients
to take a replacement dose in case of vomiting within half an
hour of taking a dose was lower (55% versus 50%), with no
difference observed between arms.
Table 5 shows that ~60% of patients in both arms reported
being told how to take AL correctly, with similar percentages
reporting being told to take the second dose after 8 hours and
to complete treatment even if feeling better, indicating that
dispensers were providing some advice even in the absence of
the intervention. However, no differences were found between
control and intervention arms for any piece of advice. Less
than 5% of patients in both arms reported being told about
vomiting, side effects, or taking AL with fatty food, and < 10%
in both arms took the first dose of AL at the ADDO.
There was no difference in patient adherence between
arms (Table 6). Completed treatment was 70% in the control
arm and 68% in the intervention arm (adjusted risk ratio
Table 2
Characteristics of dispensers (post-intervention)
Control Intervention
Total number of dispensers 53 59
Number interviewed (N) 51 59
Male (%)* 10 (20%) 13 (22%)
Age (%)*
Under 35 years of age 18 (35%) 23 (39%)
35–49 years of age 23 (45%) 17 (29%)
50 years and above 10 (20%) 19 (32%)
Number with a medical
qualification (%)*†
44 (86%) 47 (81%)
Socioeconomic status (%)‡§
1st quintile (most poor) 9 (18%) 13 (22%)
2nd quintile 12 (24%) 10 (17%)
3rd quintile 9 (18%) 13 (22%)
4th quintile 8 (16%) 14 (24%)
5th quintile (least poor) 12 (24%) 9 (15%)
Number that had attended
training on ACTs (%)*
35 (69%) 35 (60%)
Median year of training
(range)
2011 (2005–2012) 2009 (2001–2012)
*Data missing for one dispenser in intervention arm.
†Medical staff is defined as pharmacists, pharmacist assistants, medical doctors, assistant
medical doctors, clinical officers, assistant clinical officers, midwives, nurses, nurse assistants,
and laboratory technologists. Most were nurse assistants or nurses.
‡Data missing for one dispenser in control arm.
§Wealth quintiles determined using a principal component analysis of sampled dispensers
based on standard Demographic and Health Survey variables.
Table 3
Characteristics of patients
Control Intervention
Number (N) 451 453
Male 240 (53%) 211 (47%)
Age*
Under 3 years 81 (18%) 78 (17%)
3 years to under 8 years 104 (23%) 91 (20%)
8 years to under 12 years 41 (9%) 42 (9%)
12 years and above 225 (50%) 242 (53%)
Blister pack obtained
1 + 6 (6 tablets) 109 (24%) 107 (23%)
2 + 6 (12 tablets) 95 (21%) 88 (19%)
3 + 6 (18 tablets) 50 (11%) 43 (10%)
4 + 6 (24 tablets) 197 (44%) 215 (48%)
Patient (or caregiver if patient
below age 12) completed
primary school†
323 (72%) 343 (76%)
Socioeconomic status‡
1st quintile (most poor) 87 (19%) 94 (21%)
2nd quintile 99 (22%) 82 (18%)
3rd quintile 97 (22%) 84 (19%)
4th quintile 85 (19%) 96 (21%)
5th quintile (least poor) 83 (18%) 97 (21%)
Slept under any bed net
the night before the
follow up interview
321 (71%) 357 (79%)
Sought care before attending
study ADDO
171 (38%) 163 (36%)
Median days since illness
onset before seeking
care at ADDO§
1 1
Symptoms¶
Fever or headache 410 (91%) 416 (92%)
Respiratory 34 (8%) 34 (8%)
Stomach upset 220 (49%) 209 (46%)
Otherk 216 (48%) 211 (47%)
mRDT positive at follow up** 121 (28%) 108 (25%)
Blood smear positive
at follow up††
6 (1.4%) 7 (1.6%)
*Age categories based on recommended age breakdown for artemether-lumefantrine
(AL) blister packs in Tanzania.
†Caregiver education missing for 3 patients < 12 in intervention arm.
‡Wealth quintiles determined using a principal component analysis of sampled patients
based on standard Demographic and Health Survey variables.
§Eleven patients in control arm and 4 patients in intervention arm did not remember the
number of days after illness onset when they sought care at the study accredited drug
dispensing outlets (ADDO).
¶Percents do not add to 100% as patients experienced multiple symptoms.
kIncludes fatigue, body aches, dizziness, shaking, convulsions, unusually-colored urine,
yellow mouth/eyes/body, etc.
**Malaria rapid diagnostic test (mRDT) data missing for 12 patients in control arm and 12
patients in intervention arm.
††Blood smear data missing for 18 patients in control arm and 13 patients in intervention arm.
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[aRR] = 0.96 [95% CI: 0.82, 1.1]; p [adjusted] = 0.6), with a
similar percentage of patients adherent to each of the four
age-appropriate blister packs and no important differences
between arms. The mean number of doses taken by non-
adherent patients was four in both arms, and the most common
reported reasons for non-adherence included planning to take
the medication later, forgetting to take the tablets, feeling
better, and other reasons (Figure 4). Timely completion was
much lower, with 33% of patients in both arms taking all doses
at appropriate times. A per protocol analysis, excluding patients
attending ADDOs where at least one dispenser did not receive
any messages, had no impact on results.
DISCUSSION
We have reported results from a cluster randomized trial of
a text message intervention directed at drug shop dispensers
to improve patient adherence to ACTs in Tanzania. The
intervention increased dispenser knowledge of some compo-
nents of advice to provide patients when dispensing AL, but
knowledge of other components was already very high in the
absence of the intervention. The improvements in knowledge
did not translate into an increase in information patients
reported receiving, even though patients commonly reported
receiving some advice. There was no difference in adherence
of patients to the ACT regimen between the arms.
Adherence by completed treatment was < 70% to ACTs
obtained from ADDOs, comparable to the 66% adherent by
the same definition in the study by Cohen and others (2012)11
in the private retail sector in Uganda. However, timely com-
pletion was only 33% in our study, indicating that even
patients who complete treatment may do so with poor adher-
ence to the recommended schedule. Both of these results are
comparable to reported adherence to ACTs obtained from
public health facilities, where studies under real life condi-
tions have found adherence of 64–77% for completed treat-
ment verified by pill count and 39–75% for timely completion
verified by pill count,5 including one study from Tanzania.35
Two other studies from public health facilities in mainland
Tanzania using different definitions and methods have reported
higher adherence (88.3% and 90%).33,34
Although the text message intervention targeting dispensers
was not effective at improving patient adherence, there was a
marked increase in dispenser knowledge of advising patients to
take AL with fatty foods or milk and to continue AL even if
minor side effects occurred. However, knowledge in both arms
was surprisingly high, particularly on advising patients to take
the second dose after 8 hours, to complete treatment even if
feeling better, and to seek further care if the condition worsens.
This could reflect the recent ADDO trainings in Mtwara, rais-
ing the possibility that the intervention’s impact could have
been different in the absence of recent training.
Knowledge did not necessarily result in the provision of
advice, even though some advice was provided. For example,
98% of dispensers in both arms knew it was important to
advise patients to complete treatment even if feeling better,
but only 60% of patients reported receiving this advice. Other
advice was much less commonly provided, with < 5% of
patients in both arms reporting being advised on what to do
in case of minor side-effects or vomiting, even though dis-
penser knowledge of this advice was much higher. This may
be because the dispensers did not deem the advice helpful to
their business or to the patients, as it could heighten a nega-
tive perception about the effects of their products. Dispensers
may have also perceived that clients were in a hurry or not
receptive to advice. Alternatively, patients or caretakers may
not have recalled the advice given to them several days
before. Exit interviews or mystery shopper surveys may have
been useful in assessing whether advice was communicated,
but these methods also have limitations, such as greater
potential for a Hawthorne effect and ethical challenges.
Figure 3. Percentage of text messages received by dispensers
in the intervention arm.
Table 4
Dispenser knowledge of correct advice (mean of cluster summaries)
Control* (N = 37)
% (SD)
Intervention* (N = 40)
% (SD)
Adjusted prevalence ratio
(95% CI)†
Adjusted
P value†
Proportion that gave correct advice on:
Correct AL regimen for adult‡ 78.4 (38.3) 90.0 (33.7) 1.19 (0.95, 1.49) 0.075
Correct AL regimen for a child (4 years and 20 kg)‡ 63.5 (46.6) 74.6 (40.4) 1.20 (0.85, 1.70) 0.2
Take with fatty food 20.3 (38.1) 60.0 (45.6) 3.41 (1.63, 7.12) 0.0001
Continue treatment if minor side effects occur 42.8 (42.8) 67.5 (45.2) 1.58 (1.03, 2.42) 0.019
Return to ADDO or go to a health facility if condition worsens 91.0 (25.3) 100.0 1.04 (0.84, 1.31) 0.7
Take second dose after 8 hours 86.9 (32.2) 97.5 (15.8) 1.11 (0.93, 1.32) 0.1
Take replacement dose in case of vomiting within half hour of taking dose 49.5 (45.7) 55.0 (46.4) 1.20 (0.77, 1.86) 0.4
Complete treatment even if feeling better 98.6 (8.2) 98.8 (7.9) 1.07 (0.88, 1.30) 0.5
*Total number of dispensers interviewed was 51 in the control arm and 59 in the intervention arm.
†Adjusted for accredited drug dispensing outlet (ADDO) accreditation, number of customers at ADDO purchasing artemisinin-based combination therapies (ACTs) (< 20 vs. 20 or more),
dispenser medical qualification, and training on ACTs
‡To be considered correct, responses had to identify artemether-lumefantrine (AL) as first-line treatment and specify that six doses should be taken, with each dose consisting of four pills
(adult) or 2 pills (child 4 years of age). Dose intervals considered correct included (A) taking a dose morning and evening for 3 days or (B) taking the second dose 8 hours after the first dose and the
remaining doses 12 hours apart (or morning and evening for the next 2 days).
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We intentionally avoided telling dispensers that the purpose
of our study was to improve patients’ adherence. Although
dispensers receiving text messages were aware that the content
focused on advising patients about the correct use of AL, we
did not mention the objective to dispensers in either arm to
avoid this information being relayed to patients, who might
then change their behavior because they expected their adher-
ence to be monitored.5 However, if this intervention were to be
scaled up outside the study context, one might include greater
emphasis on adherence and its value in communications with
dispensers, which might in turn increase the likelihood that
they would provide appropriate advice.
The evaluation of patient adherence relied on self-reported
data from patients or their caregivers, which may be subject to
recall and social desirability bias. We inspected blister packs
for the 80% of patients who could provide them and identi-
fied only 10 patients (1%) that had reported completing all
doses but had pills remaining. On the other hand, patients
may have removed pills from the packaging to consume at a
later time. Even though Swahili times of day, based on sunrise
and sunset, were used to assess timely completion, patients or
their caregivers may not have remembered when each dose
was taken or may have provided the expected responses to
avoid being seen as negligent.
A similar text message intervention targeting health
workers in public health facilities in Kenya found significant
improvements in health worker case management of pediatric
malaria.21 The primary outcome measure by Zurovac and
colleagues included completion of four treatment tasks (e.g.,
prescribing AL) and at least four of six dispensing and
counseling tasks, of which the biggest improvements were
seen in giving the first dose at the health facility and advising
patients to take the second dose after 8 hours, take each dose
after a meal, and what to do in case of vomiting. Although we
found strong evidence in the intervention arm of improved
dispenser knowledge of advice to take each dose with a fatty
meal, we recorded high dispenser knowledge in both arms of
advice to take the second dose after 8 hours and no difference
between arms in knowledge of advice on what to do in case of
vomiting. We also recorded < 10% of patients in either arm
taking the first dose of AL at the ADDO, even though drink-
ing water was available at many ADDOs. The contrasts
between our findings and those of Zurovac and colleagues
could reflect the private drug shop setting, as we found
patients’ relatives often seek care at ADDOs on behalf of
patients, in contrast to public health facilities where patients
themselves must be present for a clinical exam. Health
workers in public health facilities may also be more accus-
tomed to taking on advisory roles than dispensers in private
drug shops and less concerned with making a profit.37
Interventions involving training of dispensers in the private
retail sector, although limited in number, have improved dis-
penser knowledge across a range of diseases and settings, but
the impact of improved knowledge on dispenser and patient
behavior has been mixed.37,38 Even fewer studies have
reported effects of an intervention targeted at retail dispensers
Table 5
Patient report of advice received from dispenser (mean of cluster summaries)
Control* (N = 37)
% (SD)
Intervention* (N = 40)
% (SD)
Adjusted prevalence ratio
(95% CI)†
Adjusted
P value†
Explained correct dose regimen‡ 60.6 (21.2) 62.9 (21.5) 1.00 (0.84, 1.20) 0.9
Told to take second dose after 8 hours 64.2 (19.6) 63.0 (20.2) 1.00 (0.87, 1.15) 0.9
Told to complete treatment even if feeling better 61.3 (25.3) 59.3 (27.3) 0.94 (0.76, 1.17) 0.5
Told not to give drug to anyone else or save for future illnesses 41.3 (23.3) 35.1 (25.1) 0.88 (0.65, 1.18) 0.4
Told to return to ADDO or go to a health facility if condition worsens 34.1 (20.5) 35.0 (22.4) 1.01 (0.75, 1.35) 0.9
Told to take replacement dose in case of vomiting 3.3 (8.9) 3.2 (3.2) 1.48 (0.56, 3.90) 0.5
Told about possible side effects 2.8 (5.1) 2.0 (5.1) 0.60 (0.13, 2.77) 0.4
Told to take each dose with fatty food or milk§ 2.2 (8.4) 4.2 (9.7) 1.70 (0.40, 7.24) 0.4
First dose was observed at ADDO 5.4 (9.1) 6.9 (12.7) 1.32 (0.63, 2.76) 0.5
*Total number of patients interviewed was 451 in the control arm and 453 in the intervention arm.
†Adjusted for accredited drug dispensing outlet (ADDO) accreditation, number of customers at ADDO purchasing artemisinin-based combination therapies (ACTs) (< 20 vs. 20 or more),
dispenser medical qualification, and training on ACTs
‡To be considered correct, responses had to include the correct number of pills per dose for blister pack obtained, two doses per day, and 3 days duration (or 4 days to account for artemether-
lumefantrine [AL] obtained late on Day 1)
§If taking with any food or milk is considered correct, percentages increase to 60.2 (22.1) in the control arm and 58.8 (26.0) in the intervention arm, P = 0.8)
Table 6
Patient adherence (mean of cluster summaries)
Control* (N = 37)
% (SD)
Intervention* (N = 40)
% (SD)
Adjusted prevalence
ratio
(95% CI)†
Adjusted
P value†
Completed treatment‡ 69.8 (20.9) 68.3 (23.4) 0.96 (0.82, 1.12) 0.6
1 + 6 (6 tablets) 68.2 (33.3) 73.4 (30.9) 1.04 (0.81, 1.33) 0.7
2 + 6 (12 tablets) 62.0 (33.4) 70.7 (40.5) 1.10 (0.85, 1.43) 0.5
3 + 6 (18 tablets) 73.0 (35.7) 62.5 (39.7) 0.86 (0.66, 1.13) 0.4
4 + 6 (24 tablets) 73.8 (23.1) 67.8 (29.1) 0.89 (0.74, 1.08) 0.2
Timely completion§ 32.6 (18.4) 33.1 (21.6) 1.01 (0.76, 1.36) 0.9
1 + 6 (6 tablets) 37.2 (36.7) 26.4 (34.5) 0.67 (0.35, 1.28) 0.2
2 + 6 (12 tablets) 25.7 (24.9) 33.1 (36.6) 1.32 (0.86, 2.00) 0.4
3 + 6 (18 tablets) 35.5 (41.3) 37.9 (41.4) 1.02 (0.57, 1.81) 0.9
4 + 6 (24 tablets) 38.1 (27.6) 34.8 (29.3) 0.90 (0.57, 1.41) 0.6
*Total number of patients interviewed was 451 in the control arm and 453 in the intervention arm.
†Adjusted for accredited drug dispensing outlet (ADDO) accreditation, number of customers at ADDO purchasing artemisinin-based combination therapies (ACTs) (< 20 vs. 20 or more), and
patient education (patient or caregiver completed primary school).
‡Completed treatment unknown for three patients in the control arm and two patients in the intervention arm.
§Timely completion unknown for 10 patients in the control arm and 11 patients in the intervention arm.
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on patient adherence to antimalarial drugs. One study from
1998–2001 in Kilifi, Kenya found that trained shopkeepers
were willing to take on an advisory role, resulting in both
increases in advice and the proportion of patients taking ade-
quate doses of chloroquine and sulfadoxine pyrimethamine or
sulfadoxine-pyrimethamine.14 Although receiving instructions
has been associated with patient adherence to antimalarials in
several studies in the public and private sectors,11,39,40 other
factors might also influence patient adherence, including
patient education, higher socioeconomic status, treatment-
seeking behavior, understanding the instructions, knowledge
and perceptions of the illness or of the drug, and satisfaction
with information received or with the drug.5
The private retail sector is likely to continue to be an
important source of treatment of malaria and there is a need
to maximize patient adherence to ACTs. Given the effective-
ness of text message reminders on health worker case man-
agement in Kenya and the low cost of this intervention, there
is potential for further evaluations of text message interven-
tions targeted at dispensers in the private retail sector to
improve dispenser knowledge, advice provided, and patient
adherence, particularly in settings where dispensers have not
received recent training on malaria. Such interventions should
ensure message content addresses gaps in dispenser knowl-
edge and would benefit from additional research on dispenser
readiness to provide advice, and client receptivity to their
advice. There should also be further consideration of how best
to design the evaluation so that dispensers are motivated to
communicate the importance of adherence without biasing
study results.
The double gap between dispenser knowledge and provid-
ing advice and then patients receiving advice and being adher-
ent may also call for other interventions to enhance
adherence. Text message reminders to patients have been
shown to be a low-cost approach to improve patient adher-
ence to antiretroviral therapy for HIV41–43 and have been used
in two recent studies to increase patient adherence to malaria
test results and treatment (Goldberg J, unpublished data).44
However, scaling up a text message intervention targeted at
malaria patients in Tanzania would require an increase in per-
sonal mobile phone use among patients most at risk of
malaria,45 as only about half of the households in rural areas
own a mobile phone,29 and the phone may be shared among
household members. In contrast, nearly all dispensers censused
in Mtwara regularly used at least one mobile phone.
Other interventions that have been shown to improve
patient adherence to antimalarial drugs include packaging and
community education.46 ACTs are now mostly available in
factory packaged unit dose packs blister packs with illustrated
instructions, therefore additional room for improvement may
be limited. One possible modification could be improved
instructions in local languages. Community education through
communication campaigns could be helpful in emphasizing
the importance of taking all doses, but it may be challenging
to communicate the details of when and how to take each
dose to the general population. Finally, the introduction of
mRDTs in the private sector might have positive implica-
tions for patient adherence, especially if also combined with
dispenser advice.5
CONCLUSION
Text message reminders improved some aspects of dis-
penser knowledge of advice to provide to patients when dis-
pensing AL in the private sector. However, patients in the
intervention arm were not more likely to report receiving
improved advice and did not have higher adherence than
patients in the control arm. Adherence to AL among patients
in both arms was suboptimal, highlighting the need for studies
evaluating other interventions to improve adherence to ACTs
obtained in the private retail sector.
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6  Adherence in the public and private retail sectors 
6.1  Introduction 
This chapter addresses the first research objective, comparing differences in patient 
characteristics and levels of adherence between patients obtaining AL in public health facilities and 
ADDOs, and examining factors associated with adherence in both of these settings. This paper reports 
results from the observational study in public health facilities in comparison with the control arm of the 
CRT described in the previous chapter. 
 In addition to the paper submitted to the Malaria Journal, Section 6.3 presents and discusses 
additional data that were not included in the submitted manuscript. 
 
6.2 Research paper (cover sheet on next page) 
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Abstract 
Background 
Artemisinin combination therapy (ACT) is first-line treatment for malaria in the public sector of 
most endemic countries and increasingly available in the private sector. Most studies on ACT 
adherence have been conducted in the public sector, with minimal data from private retailers.  
Methods 
Parallel adherence studies were conducted in Mtwara, Tanzania, in which patients obtaining 
artemether-lumefantrine (AL) at 40 randomly selected public health facilities and 37 accredited 
drug dispensing outlets (ADDOs) were followed up at home and questioned about each dose 
taken. The effect of health sector on adherence, controlling for potential confounders was 
assessed using logistic regression with a random effect for outlet.  
Results 
Of 572 health facility patients and 450 ADDO patients, 74.5% (95% CI: 69.8, 78.8) and 69.8% 
(95% CI: 64.6, 74.5), respectively, completed treatment and 46.0% (95% CI: 40.9, 51.2) and 
34.8% (95% CI: 30.1, 39.8) took each dose at the correct time (‘timely completion’). ADDO 
patients were wealthier, more educated, older, sought care later in the day, and were less likely to 
test positive for malaria than health facility patients. Controlling for patient characteristics, the 
adjusted odds of completed treatment and of timely completion for ADDO patients were 0.65 
(95% CI: 0.43, 1.00) and 0.69 (95% CI: 0.47, 1.01) times that of health facility patients. Higher 
socio-economic status was associated with both adherence measures. Higher education was 
associated with completed treatment (adjusted OR=1.68, 95% CI: 1.20, 2.36); obtaining AL in 
the evening was associated with timely completion (adjusted OR=0.35, 95% CI: 0.19, 0.64). 
Factors associated with adherence in each sector were examined in separate models. In both 
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public and private sectors, recalling correct instructions was positively associated with both 
adherence measures. In health facility patients, but not ADDO patients, taking the first dose of 
AL at the outlet was associated with timely completion (adjusted OR=2.11, 95% CI: 1.46, 3.04).  
Conclusion 
When controlling for patient characteristics, there was some evidence that the adjusted odds of 
completed treatment and timely completion for ADDO patients was lower than that for public 
health facility patients. Better understanding is needed of which aspects of patient care are most 
important for adherence, including the role of effective provision of advice. 
Keywords  Malaria, ACT, adherence, public health facilities, private sector, ADDOs 
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Background 
  
As artemisinin-based combination therapy (ACT) for malaria becomes widely available, patient 
adherence to the full course of treatment is increasingly important to ensure positive clinical 
outcomes and minimize the selection of drug-resistant parasites [1-3]. ACT is the first-line 
treatment for Plasmodium falciparum malaria in most malaria-endemic countries and has 
become increasingly available in the private retail sector, where many patients seek care for 
malaria [4-9].  
 
Estimates of patient adherence to ACT range from 39 to 100%, reflecting both variation in 
patient characteristics, interaction with providers, study settings, differences in study procedures, 
and methods of assessing adherence [10, 11]. The vast majority of studies designed to measure 
adherence have been conducted in the public sector, while a few studies have used household 
survey data to assess adherence from mixed community sources [12-17]. Only one study had 
specifically addressed patient adherence to ACT obtained in the private sector. This study, 
conducted in a convenience sample of four shops in a single Ugandan district where subsidized 
ACT had been made available through a pilot programme, reported that 66% of patients seeking 
treatment completed the full course of ACT [18].  
 
As access to ACT increases, there is a need to understand levels and determinants of patient 
adherence in both public and private sectors, in order to design and target appropriate 
interventions. Patients seeking care in the private retail sector may have different characteristics 
(e.g., age, socio-economic status, illness severity, etc.) than patients who seek care in public 
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health facilities [7, 19, 20], though some patients seek care in both sectors. Similarly, provider 
characteristics (e.g., training, communication, reputation, costs, drug availability, motivation, 
etc.) may also vary and affect where patients seek care [7, 21]. It is unclear how these differences 
affect patient adherence.  
 
In Tanzania, artemether-lumefantrine (AL) for treatment of uncomplicated malaria was first 
rolled out to public health facilities in 2006. The recommended treatment regimen is six doses of 
AL over three days, with one to four tablets (20 mg artemether/120 mg lumefantrine) per dose 
depending on the patient's weight/age band. National guidelines state that the first dose should be 
taken under observation of the dispenser, the second dose eight hours after the first dose, and the 
remaining doses morning and evening of the second and third days [22]. Treatment at public 
health facilities for children under five years of age and pregnant women is intended to be free of 
charge, but this policy is not always followed [20].  
 
Treatment for malaria in the private sector in Tanzania is sought at private health facilities, 
pharmacies, drug shops, and general stores. More than two-thirds of anti-malarial drug sales 
from private for-profit providers occur in drug shops [23], many of which have been upgraded 
through the accredited drug dispensing outlet (ADDO) programme. ADDOs were first piloted in 
2003 in order to improve availability, quality, and affordability of pharmaceutical services in 
rural and peri-urban areas without pharmacies. ADDOs have now been rolled-out nationwide, 
with an estimated 9,000 ADDOs serving the 25 regions of mainland Tanzania [24]. The ADDO 
programme involves multiple components including training, accreditation, and regulatory 
oversight by trained inspectors [24-26]. Dispensers are required to have a health qualification of 
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a nurse assistant or higher and must attend a six-week training course on topics such as business 
practices, regulations, record-keeping, use of ADDO-approved medicines, dispenser ethics and 
communication skills. ADDOs are allowed to sell a limited number of prescription-only drugs, 
including an approved list of antibiotics and antimalarial drugs. Availability of ACT was limited 
in ADDOs until the implementation of the Affordable Medicines Facility- malaria (AMFm) in 
2010, which led to a significant reduction in price and a corresponding increase in availability 
[23, 27].   
 
This paper reports results of two parallel, contemporaneous studies in southern Tanzania to 
compare patient adherence to ACT obtained in public health facilities with adherence to ACT 
obtained from ADDOs in the same area and to examine factors associated with adherence in 
each sector. 
 
 
Methods 
 
Study setting 
The studies were conducted in Mtwara, a rural region in southeastern Tanzania with more than a 
third of the population in the lowest national wealth quintile [28]. In 2012, malaria prevalence in 
Mtwara in patients of all ages seeking care for febrile illness was 15% among patients attending 
ADDOs and 32% among patients attending public health facilities [29, 30]. Conversion of drug 
shops to ADDOs in Mtwara commenced in 2006, with all drug shops in Mtwara officially 
required to have upgraded to ADDO status by 2011. At the time of the study, some shops had not 
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yet paid fees, received training, or been visited by inspectors but were tolerated as ‘prospective 
ADDOs’ (in this paper the term ADDOs is used to include both accredited outlets and 
‘prospective ADDOs’). To support the increased availability of ACT in ADDOs, the government 
offered a one-day training that included treatment of malaria with ACT to dispensers with 
previous nursing training in Mtwara in August 2011. 
 
Study design 
In health facilities, a descriptive study was conducted to assess patient adherence to AL. The 
study in ADDOs was designed as part of a cluster-randomized trial to evaluate a text message 
intervention to improve dispenser knowledge of advice to provide to patients obtaining AL. 
Details of the intervention and results of the trial are presented separately [31]. Only data from 
the control arm, which did not receive any intervention, are presented here. 
 
Sample size calculations 
The target sample size for ADDO patients was based on the text message intervention trial [31], 
and a similar sample size was desired for public health facilities within the constraints of study 
resources. Based on adherence previously reported among patients obtaining ACT at public 
health facilities in Tanzania, which ranged from 75 to 98% [32-34], adherence among patients 
attending public health facilities was expected to be 75%, with lower adherence among patients 
attending ADDOs (60%). Assuming a hypothesized design effect of 2.5 and 20% loss to follow-
up, 448 registered patients from 36 outlets in each sector (approximately 12 to 13 patients per 
outlet) would have 80% power to detect this difference with 95% confidence. Given the lower 
design effect observed in the study (1.5) and more interviewed patients than anticipated, the 
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study was powered to detect a 10 percentage point difference between sectors, but was not able 
to detect if a smaller difference in completion rates between sectors was due to random error. 
 
Selection of outlets 
A list of all public dispensaries and health centres in Mtwara, excluding district hospitals, was 
compiled by visiting each district and interviewing the district medical officers. The health 
facilities were randomly ordered, and the first 40 health facilities were selected. Sampling of 
ADDOs was based on a census in Mtwara of all ADDOs, including prospective ADDOs, 
conducted prior to the text message intervention trial. From this list, ADDOs were selected 
sequentially at random, with all ADDOs within 400 m of a selected ADDO, or any ADDO where 
staff from a selected ADDO also worked, removed from the sampling frame. Forty ADDOs were 
randomized to the control arm [31].  
 
Study procedures 
From September through November 2012, dispensers at selected public health facilities and 
ADDOs were visited by study supervisors and given a standard introduction about study 
objectives. In order to limit patients’ awareness of the primary interest in adherence, which could 
have led to a biased assessment, dispensers were told the focus was how patients chose to treat 
fever and that some, but not all, patients would be visited at their homes. Dispensers were asked 
to fill out a registration form for all patients dispensed any treatment for fever, including day and 
time of the visit, the patient’s name, drugs dispensed, and a description of where the patient 
lived. Dispensers were provided with blister packs of AL to be dispensed in public health 
facilities to patients prescribed ACT, and in ADDOs to patients indicating an intention to 
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purchase treatment for malaria. Study staff visited outlets every day to check and collect 
registration forms. While the intention had been to register 12 patients obtaining ACT for one 
week per outlet, the protocol was adjusted due to low attendance at some outlets to register all 
patients obtaining ACT for two to three weeks per outlet.   
 
Eligible patients who obtained AL were identified from the registration forms and assigned 
patient identification numbers. Patients were visited at their homes three days later (day 4), and 
all attempts to locate and interview patients were recorded. Where written informed consent was 
given, patients or their caregivers were asked about demographic and socio-economic 
characteristics, treatment-seeking history, symptoms, and detailed information about each dose 
of AL taken. Patients were asked if dispensers provided each of several aspects of advice on AL 
(e.g., number of pills to take per dose, when to take second dose, etc.), and if so, what advice was 
given. Blister packs were also requested for a pill count. Since the P. falciparum histidine-rich 
protein II (HRP-2) persists in the blood following treatment, HRP-2-based malaria rapid 
diagnostic tests (mRDTs) (Pf-specific from ICT Diagnostics, Cape Town, South Africa) were 
conducted to indicate infection prior to treatment. Blood smears were collected to detect 
infection at the time of interview. Blood smears were stained in the field and transported to the 
Ifakara Health Institute, where they were double-read by two microscopists blinded to results 
from each other and the mRDT, with discrepant readings resolved by a third microscopist.  
 
Adherence was defined in two ways [10]. Patients were considered to have verified completed 
treatment if they reported taking all doses by the time of the interview and, when available, a pill 
count verified that no pills remained in the blister pack. Where blister packs were not available, 
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self-report alone determined if patients completed treatment. The second, more stringent 
definition included a time component, based on patient reports of the time each dose was taken 
using the Swahili times of day: alfajiri (early morning), asubuhi (morning), mchana (afternoon), 
jioni (evening), usiku (night), and usiku sana (late night). Patients were considered to have 
verified timely completion if they took the correct number of pills for each dose, and took the 
second dose at the Swahili time of day corresponding with eight hours after the first dose, 
followed by taking each of the remaining doses at the Swahili time of day corresponding with 12 
hours after the previous dose, verified when possible by the absence of pills in the blister pack. 
The terms completed treatment and timely completion are hereafter used to refer to these 
definitions. 
 
Data entry and analysis 
All patient and dispenser interview data were collected using personal digital assistants, and data 
extracted from study forms (census, registration and follow-up forms) were double entered into 
Microsoft Access databases. Data were analysed in Stata 11.0 (Stata Corporation, College 
Station, USA). Robust standard errors were used for percentages and 95% confidence intervals, 
with p-values reported for the Pearson design-based F test. Wealth quintiles describing socio-
economic status were assigned to patients based on standard Demographic and Health Survey 
variables, using principal components analysis of the pooled sample of public health facility and 
ADDO patients [28]. Two analyses of factors associated with adherence were conducted: (i) a 
comparison of adherence between the public and private sectors controlling for patient 
characteristics; and, (ii) an analysis within each sector exploring the association of adherence 
with factors related to the care received at the outlet and patient characteristics. 
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 Comparison of adherence between sectors 
In the analysis on the impact of sector on patient adherence, random effects logistic regression 
was used for both completed treatment and timely completion to compare the odds of adherence 
between private sector ADDO patients and public sector health facility patients, adjusting for 
patient characteristics identified a priori (age group, education and time between obtaining AL 
and interview) or those that made important changes to the odds ratio for sector in bivariate 
models. In this analysis, no adjustment was made for variables related to care received at the 
outlet (e.g., taking first dose at outlet, recalling correct instructions on how to take AL, etc.), as 
these factors might mediate the effect of sector (i.e., lie on the causal pathway between sector 
and adherence). 
 
Factors associated with adherence within sectors 
Within each sector, the association of variables related to care received at the outlet with 1) 
completed treatment, and, 2) timely completion was explored in univariate and multivariate 
models. Logistic regression with robust standard errors was used, as checks showed that the 
quadrature approximations for random effects models were not reliable. Patient characteristics 
and care-related variables that were associated with completed treatment or timely completion in 
either sector in unadjusted analyses were included in all four multivariate models. 
 
Ethics 
All questionnaires, consent forms and other study documents were translated into Swahili and 
piloted prior to use. Written informed consent was collected from dispensers prior to census, 
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patient registration, and interview and from patients or their caregivers prior to interview. The 
study protocol was approved by the ethical review boards of Ifakara Health Institute and London 
School of Hygiene and Tropical Medicine. CDC advisors provided technical assistance in design 
and analysis but were not engaged in data collection and did not have access to personal 
identifiers.  
 
 
Results 
 
Patient characteristics, care received, and status at interview 
Data were collected from patients obtaining AL at all 40 selected health facilities and 37 of 40 
selected ADDOs, with three ADDOs closed or refusing to participate. Of 604 registered health 
facility patients obtaining AL (median=16 patients per outlet, range two to 32), 572 patients 
(95%) were interviewed. From ADDOs, 537 patients obtaining AL were registered (median=17 
patients per outlet, range one to 29), and 450 patients (84%) were interviewed. The most 
common reasons in both sectors for non-completion of interviews were not locating the patient’s 
home (38% at public facilities and 43% at ADDOs), or the patient having travelled out of the 
study region (28 and 16%).  
 
Characteristics of patients differed between sectors (Table 1). ADDO patients were more likely 
to be male and older than those attending public health facilities. ADDO patients/caregivers were 
wealthier, with 32% in the least poor wealth quintile compared to 10% of public health facility 
patients, and were more likely to have finished primary school (72 vs 58%, p=0.007). Over a 
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third of patients in both sectors had previously sought care for their illness episode, many of 
whom had gone to a general store/kiosk or taken drugs stored at home or from a neighbour. 
Reported symptoms were similar across outlet type, except more patients from public health 
facilities had experienced respiratory symptoms (14 vs 7.5%, p=0.007) and more ADDO patients 
had experienced body pain (30 vs 15%, p<0.0001) or fatigue (18 vs 10%, p=0.003), with few 
patients in either sector reporting convulsions or other signs of severe disease. ADDOs were 
much more likely than public health facilities to be located in urban areas, but outlets in both 
sectors were attended mostly by patients living within 2.5 km (about half-an-hour walk) from the 
outlet. ADDO patients were also more likely to have obtained AL later in the day, reflecting the 
fact that most public health facilities in Mtwara close for outpatient services by mid-afternoon, 
while ADDOs often stay open through the evening. Because of this, the day-4 interview was 
more likely to occur earlier (between 60-67 hours from the time the drug was obtained) for 
ADDO patients than for public health facility patients (26 vs 6%). 
 
Table 2 compares care received at the outlet and patient status at interview for each sector. Half 
of the public health facility patients reported being tested for malaria, while 11% reported being 
tested in ADDOs, where diagnostic tests for malaria had not been officially introduced. Public 
health facility patients were slightly more likely to be told a diagnosis (64 vs 54%, p=0.051) and 
more likely to take the first dose of AL immediately at the outlet (41 vs 10%, p<0.0001), while 
ADDO patients were more likely to pay for AL (98 vs 29%, p<0.0001). Similar percentages of 
patients using outlets in both sectors reported receiving advice on how to take AL from the 
dispenser, with 60% able to recall correct instructions on the number of pills per dose, number of 
doses per day, and number of days to take AL. Approximately 60% of patients in both sectors 
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reported being told to take the second dose of AL after eight hours and to take each dose with 
food or milk. Public health facility patients were more likely to recall being told to finish all 
doses even if feeling better (78 vs 63%, p=0.0006). However, less than 5% of patients treated in 
either sector reported being advised on possible side effects or on what to do in case of vomiting 
within half-an-hour of taking a dose.  
 
At the time of interview, approximately 14% of both public health facility and ADDO patients 
reported a current fever and 92% could play or work. More patients who had attended public 
health facilities tested positive by the mRDT performed by study staff during the interview (50% 
compared to 28% of ADDO patients, p=0.001). However, by reference blood smear, indicating 
current infection status at the time of interview, only 2.9% of public health facility patients and 
1.4% of ADDO patients were positive (p=0.1).  
 
Comparison of adherence between sectors 
Among public health facility patients, 74.5% (95% CI: 69.8, 78.8) completed treatment, 
compared with 69.8% (95% CI: 64.6, 74.5) among ADDO patients (p=0.2). Timely completion 
was much lower and differed between sectors, with 46.0% (95% CI: 40.9, 51.2) of public health 
facility patients and 34.8% (95% CI: 30.1, 39.8) of ADDO patients taking the correct number of 
pills at the correct time of day for each dose (p=0.003). Variables that made important 
differences to the odds ratio for sector in the bivariate models were wealth quintile, distance from 
home to outlet, and time of day AL was obtained, and these were included along with age group, 
patient/caregiver education, and time between obtaining AL and interview in the models 
comparing adherence between sectors. Patients in the two least poor wealth quintiles had higher 
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adjusted odds of both measures of adherence compared to those in the poorest wealth quintile 
(Table 3). The adjusted odds of completed treatment for those who had finished primary school 
was 1.68 times that of patients who had not (95% CI: 1.20, 2.36; p=0.003), but there was no 
evidence of an association with timely completion (aOR=1.06, 95% CI: 0.77, 1.75; p=0.9). 
Compared to patients who obtained AL in the morning, patients who obtained AL in the evening 
were similarly likely to complete treatment (aOR=0.93, 95% CI: 0.50, 1.70; p=0.8), but had 
much lower adjusted odds of timely completion (aOR=0.35, 95% CI: 0.19, 0.64; p=0.001). 
Furthermore, patients interviewed a longer time after obtaining AL (68-72 hours, 73-84 hours, 
and 85 hours or more) had higher adjusted odds of completed treatment and timely completion 
than patients visited 60-67 hours after obtaining AL (Table 3). When controlling for these patient 
characteristics, the adjusted odds of completed treatment for ADDO patients was 0.65 times the 
odds of completed treatment for public health facility patients (95% CI: 0.43, 1.00; p=0.048), 
and the adjusted odds of timely completion for ADDO patients was 0.69 that of health facility 
patients (95% CI: 0.47, 1.01; p=0.056). 
 
Factors associated with adherence within sectors 
Unadjusted associations of patient characteristics and care received at the outlet with completed 
treatment and timely completion are presented for each sector in Additional files 1-2. Variables 
not associated with either adherence measure in either sector, such as patient sex, having sought 
previous treatment, report of specific symptoms, and paying for AL, were not included in the 
sector specific multivariate analyses shown in Table 4. In contrast with the analyses comparing 
the effect of sector on adherence, in these sector specific models there were no clear patterns of 
association between education and socioeconomic status and either measure of adherence. 
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Similar to the previous analysis for the effect of sector, patients obtaining AL in the afternoon or 
in the evening had lower adjusted odds of timely completion than those obtaining AL in the 
morning, although this was the case only in public health facilities. In both public health 
facilities and ADDOs, longer time between obtaining AL and interview were again strongly 
associated with completed treatment. However, there was no evidence of an association with 
timely completion in public health facilities, and in ADDOs only being interviewed 72-84 hours 
after obtaining AL (not 68-72 hours or 85 hours or more) compared to 60-67 hours was 
associated with timely completion. In addition, public health facility patients, but not ADDO 
patients, sleeping under a bed net the night before the interview, having experienced fever 
symptoms, and living within 2.5 km of the outlet was associated with completed treatment, while 
seeking care within two days of fever onset was associated with timely completion. 
 
Factors related to care received at the outlet varied by sector in their associations with both 
adherence measures (Table 4). In the public sector, reporting being tested for malaria at the 
outlet was not associated with completed treatment (aOR=1.30, 95% CI: 0.82, 2.04; p=0.3), but 
there was weak evidence of an association with timely completion (aOR=1.47, 95% CI: 0.96-
2.29; p=0.078). Among ADDO patients, however, the adjusted odds of completed treatment and 
timely completion were lower for those who reported being tested compared to those who did 
not report being tested (aOR=0.39, 95% CI: 0.17-0.85; p=0.018 and aOR=0.48, 95% CI: 0.24, 
0.97; p=0.041). There were no evident associations of taking the first dose of AL at the outlet 
with completed treatment in either sector or timely completion in ADDO patients, but the 
adjusted odds of timely completion were higher among health facility patients who took the first 
dose of AL at the outlet (aOR: 2.11, 95% CI: 1.46, 3.04; p<0.001). Recalling correct instructions 
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given by the dispenser on the AL regimen was strongly associated with both measures of 
adherence in public health facility and ADDO patients. In public health facilities, reporting that 
the dispenser used the packaging as a visual aid to explain how to take AL was also associated 
with timely completion (aOR=1.77, 95% CI: 1.12, 2.80; p=0.022). In addition, the adjusted odds 
of timely completion among ADDO patients who recalled being told to take the second dose 
after eight hours were 1.77 times that of their counterparts (95% CI: 1.12, 2.80; p=0.015), but 
recalling this advice was not associated with either measure of adherence in public health facility 
patients. Reporting being told to complete all doses of AL even if feeling better was also not 
associated with either adherence measure, except for a lower adjusted odds of timely completion 
in public health facility patients (aOR=0.44, 95% CI: 0.28, 0.70; p=0.001).  
 
 
Discussion 
 
This study indicates that patients seeking care for malaria at public health facilities and ADDOs 
in southern Tanzania have different characteristics, with those attending ADDOs more likely to 
be older, more educated, wealthier, and seeking treatment later in the day. Although similar 
proportions of patients from both sectors completed treatment, the proportion of patients taking 
each dose at the correct time (timely completion) was lower in ADDO patients. When 
controlling for patient characteristics, there was some evidence that the adjusted odds of 
completed treatment and timely completion were lower in ADDO patients compared to public 
health facility patients. 
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Completed treatment and timely completion among patients from public health facilities were 75 
and 46%, respectively, comparable to other studies under real-life conditions (i.e., not clinical 
trials) in the public sector, which had found completed treatment verified by pill count of 64-
77% and timely completion verified by pill count of 39-75% [10], including one study from 
Tanzania [32]. Another study from the public sector in Tanzania recently reported lower timely 
completion (14.9%) [35], while two other studies using different definitions and study designs 
found higher adherence (88.3 and 90%) [33, 34]. In ADDOs, completed treatment verified by 
pill count was 70%, comparable to the 66% adherent by the same definition in the study by 
Cohen et al. in the private retail sector in Uganda [18].  
 
Characteristics related to care received at the outlet differed between sectors, with health facility 
patients more likely to be tested for malaria at the outlet, be told their diagnosis, take the first 
dose of AL at the outlet, and receive advice on completing treatment even if feeling better. 
However, there was no difference between sectors in other advice patients reported receiving. It 
is possible that advice provision in Mtwara region may have been superior to that in other 
regions, as ADDOs in Mtwara and Lindi regions received a one-day training, including ACT 
treatment, in 2011. In the sector-specific models, some differences between sectors were 
observed in the association of these characteristics with completed treatment and timely 
completion, although caution in interpretation is needed given the number of comparisons made 
in the analyses. For example, in public health facilities, obtaining a malaria test at the outlet was 
not associated with completed treatment or timely completion. However, in ADDOs, patients 
who reported obtaining a malaria test appeared to be less adherent by both measures. One 
explanation for this contrast might be the status of mRDT roll out, which had occurred in public 
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health facilities in Mtwara several months prior to the study, whereas ADDOs were not officially 
permitted to use mRDTs, and only 50 patients (11%) reported being tested (compared to 275 
(54%) in public health facilities). The difference is not explained by reported test results, as 96% 
of patients reporting a malaria test in both sectors reported a positive result, though only 70% of 
tested health facility patients and 35% of tested ADD0 patients had a positive study mRDT at 
interview. 
 
At public health facilities, taking the first dose of AL at the outlet was associated with timely 
completion, but not completed treatment. In ADDOs, where less than 10% of patients took the 
first dose at the outlet, there was no evidence of an association with either measure of adherence. 
Taking the first dose at the outlet might improve adherence by providing a model for patients or 
caregivers on how to take treatment, generating more communication with patients, or improving 
their confidence to complete the remaining doses at home. In addition, patients in both sectors 
who recalled correct instructions on how to take AL had much higher odds of completing 
treatment and timely completion than patients who did not recall correct instructions. This 
highlights the importance of clear instructions for achieving adherence [36]. A review of the 
previous literature shows considerable variation in factors associated with adherence to anti-
malarials, but provision of better information on how to take drugs has been an important factor 
in more than one study [10]. Alternatively, patients who are more conscientious about their 
treatment may also be more likely to recall instructions. Another factor that might affect 
adherence but was not assessed reliably in this study is the attendance of the patient at the outlet, 
which is required to obtain treatment at public health facilities but not at ADDOs. Patients who 
received advice second-hand could be less likely to adhere. However, this should not affect the 
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comparison between sectors, as whether or not the patient attended the outlet might lie on the 
causal pathway between sector and adherence, similar to the other variables related to care 
received at the outlet. Other factors that were not assessed, related to patient understanding of 
treatment or respect for dispensers, might also be important in explaining adherence.  
 
Timely completion was 30-35 percentage points lower than completed treatment, even though 
timeliness of doses was based on times of day rather than exact times. While there is consensus 
that ACT will only be effective if taken correctly, the importance for treatment effectiveness of 
the recommended time intervals between doses is less clear. In this study, only 46% of public 
health facility patients and 35% of ADDO patients completed all doses at the recommended 
intervals, and there was no association between study mRDT positivity at interview (indicating 
malaria infection at care seeking) and adherence. While 50% of health facility patients and 28% 
of ADDO patients were positive by study mRDT at interview, only 22 patients overall 
(approximately 2%) were positive by reference blood smear, suggesting that most patients who 
had been malaria positive at the time of care seeking may have been treated effectively, even 
though only half of these had completed all doses at the correct time. However, blood smears 
may not capture all submicroscopic parasitaemia present at day 4, although these could lead to 
subsequent treatment failure [37].   
 
The dosing regimen for AL in national guidelines states that doses should be taken at 0, 8, 24, 
36, 48, and 60 hours, but for practical reasons a simpler regimen is recommended, illustrated by 
pictograms on packaging, which assume that patients obtain AL in the morning, take the second 
dose later the same day, followed by the remaining doses morning and evening for two more 
106
days [22]. More patients from ADDOs than public health facilities had obtained AL later in the 
day, as ADDOs had longer operating hours than public health facilities. Patients who obtained 
AL in the evening in the analysis for the effect of sector, and public health facility patients who 
obtained AL in the afternoon or evening, had lower adjusted odds of timely completion than 
patients obtaining AL in the morning. If eight hours after the first dose falls in the middle of the 
night, patients may not wake up to take the second dose, and they may be unsure when to take 
the remaining doses. Modified recommendations and pictograms for patients obtaining AL in the 
evening may be helpful in improving adherence, but this depends on establishing a clearer basis 
for the importance of the timing of dose intervals.  
 
This study has several limitations. Patients may have altered their behaviour if they became 
aware of a potential visit or study objectives. In an attempt to prevent this, information given to 
dispensers was limited, visits of study research assistants to the outlets were minimized, and the 
study was conducted in a large number of outlets, each for a short period of time. The data 
presented here are also based primarily on patient self-report, which is susceptible to recall bias 
and social desirability bias, if patients did not remember when each dose was taken or provided 
the expected responses in order to avoid being seen as negligent. In addition, patients’ 
consultations with dispensers were intentionally not observed to avoid influencing behaviour. 
Instead patients’ reports of care and advice received were analysed, though recall may not have 
been accurate or advice of good quality. While dispensers’ characteristics and knowledge of 
advice to provide to patients were reported as part of the intervention study in ADDOs [31], 
interviews of dispensers were not conducted in health facilities, and it was therefore not possible 
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to assess the impact of these factors across the sectors. Similarly, there may have been other 
important patient or care-related factors that were not assessed.  
 
This study was conducted in the context of AFMm-subsidized ACT, and the median cost of AL 
in ADDOs was low (approximately $0.04 per tablet, or $0.84 for an adult equivalent treatment 
dose). In a setting without AL subsidies, adherence could vary. One could argue that lower 
adherence in ADDO patients could be a reason not to continue a subsidy of ACT in these outlets. 
However, the differences in adherence levels were not very large and the reasons for the 
differences remain unclear. Moreover, even if subsidized ACTs were not available in ADDOs 
(as was previously the case) patients would likely continue to seek care at these outlets, but 
obtain less effective antimalarials. Thus, improving care for malaria at both ADDOs and public 
health facilities should be a priority.  
 
 
Conclusion 
 
Similar proportions of patients dispensed ACT from public health facilities and ADDOs 
completed treatment, but the proportion with timely completion was lower in ADDO patients. 
Characteristics of patients obtaining ACT differed between sectors. When controlling for patient 
characteristics, there was some evidence that the adjusted odds of completed treatment and 
timely completion for ADDO patients was lower than that for public health facility patients. 
Further studies are necessary to understand and improve the impact of patient care on adherence, 
including the role of effective provision of advice.  
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Table 1  Patient characteristics by sector (%, 95% CI) 
 Public health facilities 
(N=572 patients from 40 
outlets) 
Private ADDOs 
(N=450 patients from 37 
outlets) 
p-value 
Male  43.2 (39.9, 46.5) 53.1 (46.8, 59.4) 0.007 
Age1    
     Under 3 years  42.5 (37.4, 47.8) 18.2 (14.5, 22.6)  
     3 years to under 8 years 28.2 (23.5, 33.3) 23.1 (18.8, 28.0)  
     8 years to under 12 years 6.6 (4.3, 10.0) 9.1 (6.9, 12.0)  
     12 years and above 22.7 (18.7, 27.3) 49.6 (43.0, 56.2) <0.0001 
Patient (or caregiver if patient below age 12) 
completed primary school2 
58.2 (50.7, 65.4) 71.8 (65.2, 77.6) 0.007 
Socio-economic status3    
     1st quintile (most poor) 27.9 (23.1, 33.2) 10.2 (7.6, 13.5)  
     2nd quintile 24.5 (20.5, 29.1) 14.2 (10.1, 19.8)  
     3rd quintile 20.0 (16.5, 23.9) 20.2 (15.4, 26.1)  
     4th quintile 17.3 (13.1, 22.6) 23.3 (19.5, 27.6)  
     5th quintile (least poor) 10.3 (7.4, 14.4) 32.1 (23.3, 42.2) <0.0001 
Slept under net  the night before the 
interview 
73.6 (68.9, 77.8) 71.4 (65.3, 76.9) 0.6 
Sought care for this episode prior to 
attending outlet 
36.4 (31.9, 41.2) 37.8 (31.6, 44.4) 0.7 
Sought care at outlet within two days of 
fever onset4 
77.5 (73.5, 81.1) 72.0 (67.8, 75.9) 0.051 
Symptoms    
     Fever or headache 94.1 (91.3, 96.0) 91.1 (87.6, 93.7) 0.1 
     Respiratory 14.0 (10.5, 18.4) 7.5 (5.3, 10.7) 0.007 
     Stomach upset 53.5 (47.7, 59.2) 48.9 (42.3 55.6) 0.3 
     Body/joint pain 15.4 (12.2, 19.1) 30.4 (25.2, 36.2) <0.0001 
     Fatigue 10.1 (7.5, 13.6) 18.0 (14.2, 22.5) 0.003 
     Convulsions 2.5 (1.6, 3.9) 0.4 (0.1, 1.7) 0.007 
     Other5 12.4 (9.6, 15.9) 10.0 (7.5, 13.1) 0.2 
Attended an outlet in an urban ward 13.1 (5.1, 29.6) 68.4 (48.3, 83.4) <0.0001 
Distance of 2.5 km or less from home to 
outlet (by GPS coordinates6) 
69.4 (62.6, 75.4) 71.4 (58.5, 81.5) 0.8 
Time of day drug was obtained    
     Morning  77.1 (71.9, 81.6) 44.7 (38.2, 51.3)  
     Afternoon 18.7 (14.6, 23.6) 26.9 (22.2, 32.2)  
     Evening 4.2 (2.5, 7.0) 28.4 (21.6, 36.4) <0.0001 
Time between obtaining AL and interview 
(hours)7  
   
     60-67 5.8 (3.8, 8.6) 24.8 (20.7, 29.3)  
     68-72 47.0 (41.7, 52.4) 37.4 (33.1, 41.9)  
     73-84 32.5 (28.5, 36.7) 21.6 (16.9, 27.2)  
     85 or more 14.7 (11.4, 18.8) 16.2 (12.1, 21.4) <0.0001 
1Age categories based on recommended age breakdown for AL blister packs in Tanzania. 
2Caregiver education missing for five public health facility patients. 
3Wealth quintiles pooled for public health facilities and ADDOs using principal component analysis of sampled patients 
based on standard Demographic and Health Survey variables. Data missing for one public health facility patient. 
4Number of days since illness onset missing for 3 public health facility patients and 11 ADDO patients. 
5Includes dizziness, crying/fussiness, startling (kustukastuka), sleep-talking (kuweweseka), worms, fast heart rate, stays in 
sun, red/inflamed eyes, and sores/ulcers. 
6GPS data missing from 30 public health facility patients and 52 ADDO patients. 
7Rounded to nearest hour. Data missing for 15 public health facility patients and 6 ADDO patients. 
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Table 2  Care received at outlet and patient status at interview by sector (%, 95% CI) 
 Public health facilities 
(N=572 patients from 40 
outlets) 
Private ADDOs 
(N=450 patients from 37 
outlets) 
p-value 
Treatment received at outlet    
Tested for malaria 54.4 (40.3, 67.9) 11.1 (8.0, 15.4) <0.0001 
Told diagnosis  64.1 (56.3, 71.1) 53.5 (46.1, 60.8) 0.051 
Obtained correct blister pack for age
1
 78.9 (74.7, 82.5) 83.1 (78.7, 86.8) 0.1 
Paid for AL 28.7 (24.0, 34.0) 97.8 (96.1, 98.7) <0.0001 
Took first dose of AL at outlet 40.7 (29.8, 52.7) 9.6 (6.3, 14.2) <0.0001 
Recall of instructions received from 
dispenser 
   
Recalled correct instructions given by 
dispenser on the number of pills per 
dose, number of doses, and number of 
days to take AL 
60.8 (56.4, 65.2) 59.3 (53.7, 64.7) 0.7 
Recalled that dispenser used packaging 
as a visual aid to explain how to take 
AL 
85.6 (81.9, 88.6) 82.9 (77.9, 86.9) 0.3 
Reported being told to take the second 
dose of AL eight hours after the first 
dose 
58.0 (51.3, 64.5) 
 
63.3 (57.9, 68.4) 0.2 
Reported being told to take AL with 
food or milk 
63.8 (57.9, 69.3) 61.8 (54.6, 68.5) 0.7 
Reported being told to complete all 
doses of AL even if feeling better 
77.9 (73.5, 81.7) 63.3 (55.7, 70.4) 0.0006 
Reported being told to take a 
replacement dose in case of vomiting 
within half hour of taking a dose 
1.9 (1.1, 3.5) 2.4 (1.3, 4.6) 0.6 
Reported being told about possible side 
effects 
2.3 (1.3, 4.0) 3.0 (1.6, 5.6) 0.6 
Health status at interview    
Reported current fever at time of 
interview 
13.7 (10.5, 17.7) 14.7 (11.1, 19.1) 0.7 
Could play or work at time of interview 92.6 (89.2, 95.1) 92.4 (89.7, 94.5) 0.9 
Tested positive by mRDT at interview
2 
49.6 (39.7, 59.5) 27.9 (20.7, 36.6) 0.001 
Tested positive by blood smear 
collected at interview
3 
2.9 (1.7, 4.7) 1.4 (0.6, 3.0) 0.1 
Adherence to AL    
Adherent by ‘verified completed 
treatment’4 
74.6 (69.8, 78.8) 69.8 (64.6, 74.5) 0.2 
Adherent by ‘verified timely 
completion’5 
46.0 (40.9, 51.2) 34.8 (30.1, 39.8) 0.003 
1
Age categories based on recommended age breakdown for AL blister packs in Tanzania.
 
2
mRDT data missing for 7 public health facility patients and 17 ADDO patients. 
3
Blood smear data missing for 15 public health facility patients and 18 ADDO patients. 
4
Patient completed all doses, verified by pill count when available. Data missing for 2 public health facility 
patients and 3 ADDO patients. 
5
Patient completed each dose at correct time with the correct number of pills per dose, verified by pill count 
when available. Data missing for 13 public health facility patients and 10 ADDO patients. 
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Table 3  Effect of sector on adherence controlling for potential confounders
1  
 Verified completed 
treatment
2
 
Verified timely completion
3
 
 Adjusted odds 
ratio 
p-value Adjusted odds 
ratio 
p-value 
Attended ADDO vs. public 
health facility 
0.65  
(0.43, 1.00) 
0.048 0.69 
(0.47, 1.01) 
0.056 
Age
4 
    
     Under 3 years (ref) --- --- --- --- 
     3 years to under 8 years 1.01 
(0.67, 1.52) 
0.9 0.88 
(0.61, 1.28) 
0.5 
     8 years to under 12 years 1.07 
(0.57, 2.09) 
0.8 1.12 
(0.62, 2.01) 
0.7 
     12 years and above 1.02 
(0.56, 2.05) 
0.8 0.87 
(0.60, 1.27) 
0.5 
Patient (or caregiver if patient 
below age 12) completed 
primary school
 
1.68 
(1.20, 2.36) 
0.003 1.06 
(0.77, 1.45) 
0.9 
Socio-economic status
5 
    
     1
st
 quintile (most poor, ref) --- ---   
     2
nd
 quintile 0.98 
(0.62, 1.57) 
0.9 1.04 
(0.66, 1.64) 
0.9 
 
     3
rd
 quintile 1.17 
(0.73, 1.88) 
0.5 1.10 
(0.70, 1.75) 
0.7 
     4
th
 quintile 2.25 
(1.33, 3.81) 
0.003 1.64 
(1.03, 2.65) 
0.039 
     5
th
 quintile (least poor) 2.24 
(1.28, 3.81) 
0.005 2.34 
(1.40, 3.93) 
0.001 
Distance from home to outlet 
within 2.5 km by GPS
 
1.30 
(0.92, 1.85) 
0.2 1.20 
(0.87, 1.66) 
0.3 
Time of day drug was obtained     
     Morning (ref) --- --- --- --- 
     Afternoon 0.96 
(0.62, 1.47) 
0.8 0.70 
(0.48, 1.03) 
0.070 
     Evening 0.93 
(0.50, 1.70) 
0.8 0.35 
(0.19, 0.64) 
0.001 
Time between obtaining AL and 
interview (hours)  
    
     60-67 (ref) --- --- --- --- 
     68-72 2.43 
(1.39, 4.23) 
0.002 1.46 
(0.81, 2.63) 
0.2 
     73-84 2.83 
(1.49, 5.37) 
0.001 1.92 
(1.00, 3.66) 
0.049 
     85 or more 6.44 
(3.19, 13.01) 
<0.001 2.61 
(1.37, 4.95) 
0.003 
1
Number of observations=912 (110 patients excluded from model due to missing data) and 
number of outlets=77. Covariates are those presented in Table.
 
2
Patient completed all doses, verified by pill count when available. Data missing for 5 patients. 
3
For each dose, patients took the correct number of pills at the correct time of day, verified by pill 
count when available. Data missing for 23 patients.  
4
Age categories based on recommended age breakdown for AL blister packs in Tanzania. 
5
Wealth quintiles pooled for public health facilities and ADDOs using principal component 
analysis of sampled patients based on standard Demographic and Health Survey variables. 
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Table 4  Multivariate analyses of factors associated with adherence by sector
 
 Verified completed treatment
1
 Verified timely completion
2
 
 Public health facilities 
(N=572)
3
 
ADDOs 
(N=450)
4
 
Public health facilities 
(N=572)
3
 
ADDOs 
(N=450)
4
 
 Adjusted 
odds ratio 
(95% CI)
 
p-value Adjusted 
odds ratio 
(95% CI)
 
p value Adjusted 
odds ratio 
(95% CI) 
p-value Adjusted 
odds ratio 
(95% CI)
 
p-value 
Age
5 
        
     Under 3 years (ref) --- --- --- --- --- --- --- --- 
     3 years to under 8 years 1.32 
(0.76, 2.28) 
0.3 0.69 
(0.35, 1.36) 
0.3 1.03 
(0.60, 1.78) 
0.9 0.51 
(0.28, 0.93) 
0.029 
     8 years to under 12 years 1.33 
(0.49, 3.57) 
0.6 0.97 
(0.43, 2.16) 
0.9 2.25  
(0.74, 6.86) 
0.2 0.75 
(0.31, 1.82) 
0.5 
     12 years and above 1.19 
(0.62, 2.31) 
0.6 0.94 
(0.48, 1.84) 
0.9 1.06 
(0.59, 1.93) 
0.8 0.69 
(0.35, 1.38) 
0.3 
Patient (or caregiver if 
patient below age 12) 
completed primary school 
1.16 
(0.70, 1.91) 
0.6 1.56 
(1.00, 2.43) 
0.050 0.88 
(0.55, 1.40) 
0.6 0.94 
(0.54, 1.63) 
0.8 
Socio-economic status
6 
        
     1
st
 quintile (most poor, 
ref) 
--- --- --- --- --- --- --- --- 
     2
nd
 quintile 0.97 
(0.60, 1.57) 
0.9 0.82 
(0.38, 1.81) 
0.6 0.93 
(0.52, 1.64) 
0.8 1.19 
(0.62, 2.26) 
0.6 
     3
rd
 quintile 1.04 
(0.54, 1.98) 
0.9 1.48 
(0.72, 3.03) 
0.3 0.70 
(0.37, 1.34) 
0.3 2.84 
(1.15, 7.05) 
0.024 
     4
th
 quintile 2.20 
(1.09, 4.47) 
0.038 1.75 
(0.87, 3.51) 
0.1 1.25 
(0.64, 2.44) 
0.5 1.82 
(0.61, 5.45) 
0.3 
     5
th
 quintile (least poor) 2.19 
(0.81, 5.93) 
0.2 1.99 
(0.71, 5.54) 
0.2 2.21 
(1.01, 4.82) 
0.046 2.47 
(0.93, 6.55) 
0.070 
Slept under a bed net the 
night before the interview 
1.60 
(1.10, 2.34) 
0.015 0.98 
(0.59, 1.62) 
0.9 1.23 
(0.77, 1.96) 
0.4 0.79 
(0.50, 1.27) 
0.3 
Sought care within two days 
of fever onset 
1.01 
(0.60, 1.72) 
0.9 1.16 
(0.63, 2.13) 
0.6 1.61 
(0.99, 2.61) 
0.056 1.11 
(0.59, 2.09) 
0.8 
Fever symptoms 3.38 
(1.21, 9.47) 
0.020 1.18 
(0.56, 2.47) 
0.7 1.65 
(0.64, 4.25) 
0.3 0.86 
(0.47, 1.58) 
0.6 
Distance from home to outlet 
within 2.5 km
7 
1.67 
(1.05, 2.65) 
0.031 0.76 
(0.48, 1.20) 
0.2 1.14 
(0.68, 1.91) 
0.6 1.09 
(0.65, 1.82) 
0.8 
Time of day drug was 
obtained
 
        
     Morning (ref)
 
--- --- --- --- --- --- --- --- 
     Afternoon  1.11 
(0.62, 2.01) 
0.7 1.12 
(0.52, 2.38) 
0.8 0.55 
(0.31, 0.97) 
0.038 1.04 
(0.57, 1.88) 
0.9 
     Evening
 
0.81 
(0.22, 3.04) 
0.7 0.95 
(0.44, 2.05) 
0.9 0.10 
(0.02, 47.6) 
0.004 0.69 
(0.31, 1.53) 
0.4 
Time between obtaining AL 
and interview (hours) 
        
     60-67 (ref) --- --- --- --- --- --- --- --- 
     68-72 2.37 
(0.87, 6.51) 
0.093 2.80 
(1.35, 5.82) 
0.006 1.47 
(0.44, 4.95) 
0.5 1.55 
(0.71, 3.36) 
0.3 
     73-84 3.64 
(1.31, 
10.08) 
0.013 2.73 
(1.12, 6.63) 
0.027 2.03 
(0.56, 7.29) 
0.3 2.94 
(1.20, 7.20) 
0.018 
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     85 or more 5.59 
(1.66, 
18.79) 
0.005 5.94 
(2.70, 
13.06) 
<0.001 2.72 
(0.75, 9.84) 
0.1 2.09 
(0.85, 5.13) 
0.1 
Tested for malaria at outlet 1.30 
(0.82, 2.04) 
0.3 0.39 
(0.17, 0.85) 
0.018 1.47 
(0.96, 2.26) 
0.078 0.48 
(0.24, 0.97) 
0.041 
Took first dose of AL at 
outlet 
1.05 
(0.71, 1.55) 
0.8 1.34 
(0.60, 3.01) 
0.5 2.11 
(1.46, 3.04) 
<0.001 1.33 
(0.57, 3.13) 
0.5 
Recalled correct instructions 
given by dispenser on the 
number of pills per dose, 
number of doses, and number 
of days to take AL 
4.04 
(2.59, 6.31) 
<0.001 2.98 
(2.03, 4.37) 
<0.001 6.09 
(3.71, 
10.02) 
<0.001 2.51 
(1.41, 4.45) 
0.002 
Recalled that dispenser used 
packaging as a visual aid to 
explain how to take AL
 
1.33 
(0.75, 2.36) 
0.3 1.28 
(0.62, 2.66) 
0.5 1.85 
(1.09, 3.11) 
0.022 1.40 
(0.73, 2.67) 
0.3 
Reported being told to take 
the second dose of AL eight 
hours after the first dose 
1.15 
(0.74, 1.79) 
0.5 1.28 
(0.87, 1.89) 
0.2 0.85 
(0.52, 1.38) 
0.5 1.77  
(1.12, 2.80) 
0.015 
Reported being told to 
complete all doses of AL 
even if feeling better 
0.96 
(0.54, 1.71) 
0.9 1.02 
(0.61, 1.70) 
0.9 0.44 
(0.28, 0.70) 
0.001 1.05 
(0.73, 1.50) 
0.8 
1
Patient completed all doses, verified by pill count when available. Data missing for 2 public health facility patients and 3 ADDO 
patients. 
2
Patient completed each dose at correct time with the correct number of pills per dose, verified by pill count when available. Data 
missing for 13 public health facility patients and 10 ADDO patients. 
3
Standard errors adjusted for 37 clusters. 
4
Standard errors adjusted for 40 clusters. 
5
Age categories based on recommended age breakdown for AL blister packs in Tanzania. 
6
Wealth quintiles pooled for public health facilities and ADDOs using principal component analysis of sampled patients based on 
standard Demographic and Health Survey variables. 
7
Based on GPS coordinates. Data missing from 30 public health facility patients and 52 ADDO patients. 
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Additional file 1  Association of patient characteristics with adherence by sector
 
 Verified completed treatment1 Verified timely completion2 
 Public health facilities (N=572) Private ADDOs (N=450) Public health facilities (N=572) Private ADDOs (N=450) 
 Percent 
adherent 
Unadjusted 
odds ratio 
(95% CI) 
p-value Percent 
adherent 
Unadjusted 
odds ratio 
(95% CI) 
p value Percent 
adherent 
Unadjusted 
odds ratio 
(95% CI) 
p-value Percent 
adherent 
Unadjusted 
odds ratio 
(95% CI) 
p-value 
Sex             
     Female (ref) 73.5 --- --- 66.0 --- --- 46.7 --- --- 33.3 --- --- 
     Male 75.9 1.13 
(0.74, 1.74) 
0.5 73.1 1.40  
(0.88, 2.21) 
0.2 45.0 0.93 
(0.70, 1.25) 
0.7 36.0 1.13 
(0.81, 1.57) 
0.5 
Age3             
     Under 3 years 
(ref) 
72.8 --- --- 70.4 --- --- 46.5 --- --- 38.8 --- --- 
     3 years to under 
8 years 
76.3 1.20 
(0.78, 1.84) 
0.4 66.7 0.84  
(0.46, 1.54) 
0.6 45.9 0.98 
(0.63, 1.51) 
0.9 29.4 0.66  
(0.40, 1.08) 
0.095 
     8 years to under 
12 years 
75.7 1.16 
(0.54, 2.51) 
0.7 73.2 1.15  
(0.52, 2.56) 
0.7 48.7 1.09 
(0.63, 1.90) 
0.8 39.0 1.01  
(0.50, 2.04) 
0.9 
     12 years and 
above 
75.4 1.14 
(0.63, 2.06) 
0.7 70.4 1.00 
(0.58, 1.72) 
0.9 44.3 0.92 
(0.59, 1.43) 
0.7 35.0 0.85 
(0.53, 1.37) 
0.5 
Patient (or 
caregiver if patient 
below age 12) 
completed primary 
school4 
            
     No (ref) 70.8 --- --- 59.1 --- --- 45.9 --- --- 30.7 --- --- 
     Yes      77.8 1.45 
(1.03, 2.04) 
0.033 74.1 1.98 
(1.27, 3.11) 
0.003 46.4 1.02 
(0.75, 1.39) 
0.9 36.4 1.30 
(0.84, 1.99) 
0.2 
Socioeconomic 
status5 
            
     1st quintile (most 
poor, ref) 
69.2 --- --- 63.0 --- --- 42.0 --- --- 29.6 --- --- 
     2nd quintile 70.5 1.06 
(0.69, 1.64) 
0.8 57.1 0.78 
(0.40, 1.55) 
0.5 44.5 1.11  
(0.68, 1.81) 
0.7 25.8 0.83 
(0.45, 1.53) 
0.6 
     3rd quintile 71.7 1.13 
(0.67, 1.90) 
0.7 67.0 1.19 
(0.72, 1.99) 
0.5 38.2 0.85 
(0.51, 1.41) 
0.5 39.6 1.56 
(0.69, 3.53) 
0.3 
     4th quintile 85.9 2.70 
(1.54, 4.74) 
0.001 73.8 1.65 
(0.85, 3.20) 
0.1 53.1 1.56 
(0.91, 2.68) 
0.1 35.6 1.32 
(0.57, 3.07) 
0.5 
     5th quintile (least 
poor) 
86.4 2.84 
(1.21, 6.67)  
0.017 76.4 1.90 
(0.92, 3.93) 
0.085 64.3 2.48 
(1.36, 4.52) 
0.003 36.6 1.38 
(0.62, 3.05) 
0.4 
Slept under a bed 
net the night before 
the interview 
            
     No (ref) 68.2 --- --- 70.3 --- --- 42.6 --- --- 41.7 --- --- 
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     Yes      76.9 1.55 
(1.16, 2.07) 
0.003 69.5 0.96 
(0.63, 1.47) 
0.9 47.2 1.21 
(0.81, 1.80) 
0.4 31.7 0.65 
(0.45, 0.94) 
0.021 
Sought care prior to 
attending the study 
outlet 
            
     No (ref) 74.4 --- --- 68.8 --- --- 46.6 --- --- 32.6 --- --- 
     Yes      75.2 1.05 
0.73, 1.51) 
0.8 71.4 1.13  
(0.71, 1.81) 
0.6 45.1 0.94 
(0.66, 1.34) 
0.7 38.4 1.29 
(0.87, 1.91) 
0.2 
Sought care within 
two days of fever 
onset6 
            
     No (ref) 71.0 --- --- 66.9 --- --- 36.2 --- --- 32.3 --- --- 
     Yes      75.6 1.27 
(0.84, 1.91) 
0.3 71.0 1.21 
(0.75, 1.92) 
0.4 48.8 1.68 
(1.15, 2.46) 
0.008 35.8 1.17 
(0.76, 1.79) 
0.5 
Fever symptoms             
     No (ref) 58.8 --- --- 65.0 --- --- 39.4 --- --- 35.0 --- --- 
     Yes 75.6 2.16 
(1.09, 4.31) 
0.028 70.3 1.27  
(0.64, 2.55) 
0.5 46.4 1.33 
(0.65, 2.72) 
0.4 34.8 0.99 
(0.54, 1.80) 
0.9 
Respiratory 
symptoms 
            
     No (ref) 74.9 --- --- 69.7 --- --- 46.6 --- --- 34.2 --- --- 
     Yes 72.5 0.88 
(0.53, 1.47) 
0.6 70.6 1.04 
(0.47, 2.30) 
0.9 42.3 0.84 
(0.59, 1.21) 
0.4 41.2 1.35 
(0.65, 2.78) 
0.4 
Stomach ache             
     No (ref) 71.3 --- --- 69.0 --- --- 44.4 --- --- 33.3 --- --- 
     Yes 77.4 1.38 
(0.96, 1.97) 
0.082 70.6 1.08 
(0.78, 1.49) 
0.6 47.3 1.13 
(0.86, 1.48) 
0.4 36.2 1.14 
(0.79, 1.63) 
0.5 
Fatigue             
     No (ref) 75.2 --- --- 69.4 --- --- 46.3 --- --- 34.0 --- --- 
     Yes 69.0 0.73  
(0.45, 1.21) 
0.2 71.6 1.11  
(0.64, 1.93) 
0.7 42.9 0.87 
(0.46, 1.63) 
0.7 38.3 1.20 
(0.71, 2.05) 
0.5 
Joint / body pain             
     No (ref) 74.7 --- --- 70.0 --- --- 45.7 --- --- 33.1 --- --- 
     Yes 73.9 0.96 
(0.56, 1.65) 
0.9 69.3 0.97 
(0.65, 1.46) 
0.9 47.6 1.08 
(0.71, 1.66) 
0.7 38.5 1.27 
(0.80, 1.99) 
0.3 
Convulsions             
     No (ref) 74.3 --- --- 69.7 --- --- 46.4 --- --- 34.5 --- --- 
     Yes 85.7   2.08 
(0.44, 9.74) 
0.4 1007  --- --- 28.6 0.46 
(0.16, 1.34) 
--- 1007 --- --- 
Other symptoms8             
     No (ref) 74.4 --- --- 70.4 --- --- 45.1 --- --- 34.4   
     Yes 75.7 1.07 
(0.63, 1.83) 
0.8 64.4 0.76  
(0.41, 1.40) 
0.4 52.2 1.33 
(0.75, 2.35) 
0.3 38.6 1.20 
(0.57, 2.55) 
0.6 
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Outlet ward             
     Rural (ref) 76.2 --- --- 68.8 --- --- 46.1 --- --- 36.3 --- --- 
     Urban 64.0 0.56 
(0.26, 1.18) 
0.1 70.3 1.07  
(0.63, 1.81) 
0.8 45.3 0.97 
(0.51, 1.85) 
0.9 34.1 0.91  
(0.52, 1.59) 
0.7 
Distance from home 
to outlet by GPS 
coordinates9 
            
     More than 2.5 
km (ref) 
66.3  --- --- 71.9 --- --- 42.3 --- --- 33.3 --- --- 
     2.5 km or less 78.1 1.81 
(1.20, 2.75) 
0.005 65.8 0.75 
(0.54, 1.06) 
0.1 48.1 1.26 
(0.83, 1.92) 
0.3 33.8 1.02  
(0.70, 1.50) 
0.9 
Time of day drug 
was obtained 
            
     Morning (ref) 75.7 --- --- 75.5 --- --- 49.9 --- --- 43.1 --- --- 
     Afternoon 73.3 0.88 
(0.50, 1.54) 
0.7 67.5 0.67 
(0.40, 1.15) 
0.2 38.5 0.63 
(0.43, 0.92) 
0.017 34.2 0.69 
(0.41, 1.16) 
0.2 
     Evening 58.3 0.45 
(0.22, 0.93) 
0.031 63.0 0.55  
(0.35, 0.89) 
0.014 8.3  0.09 
(0.02, 0.37) 
0.001 22.4 0.38 
(0.18, 0.79) 
0.010 
Time between 
obtaining AL and 
interview (hours)10 
            
     60-67 53.1 ---  54.5 --- --- 18.9   19.3 --- --- 
     68-72 72.0 2.27 
(1.20, 4.00) 
0.004 72.1 2.16 
(1.25, 3.71) 
0.006 43.3 3.31 
(1.42, 7.70) 
0.005 35.6 2.31 
(1.19, 4.50) 
0.013 
     73-84 76.8 2.92 
(1.47, 5.82) 
0.002 70.5 1.99 
(1.08, 3.69) 
0.028 47.8 3.96 
(1.70, 9.20) 
0.001 43.5 3.22 
(1.62, 6.42) 
0.001 
     85 or more 84.0  4.62 
(2.00, 10.63) 
<0.001 87.3 5.74 
(3.14, 10.49) 
<0.001 56.3 5.57 
(2.26, 13.75) 
<0.001 44.3 3.33 
(1.66, 6.69) 
0001 
1Patient completed all doses, verified by pill count when available. Data missing for 2 public health facility patients and 3 ADDO patients. 
2Patient completed each dose at correct time with the correct number of pills per dose, verified by pill count when available. Data missing for 13 public health facility patients and 10 
ADDO patients. 
3Age categories based on recommended age breakdown for AL blister packs in Tanzania. 
4Caregiver education missing for five patients attending public health facilities. 
5Wealth quintiles pooled for public health facility and ADDO clients using principal component analysis of sampled patients based on standard Demographic and Health Survey variables. 
Data missing for public health facility patient. 
6Number of days since illness onset missing for 3 public health facility patients and 11 ADDO patients. 
7Analysis not possible as only 2 ADDO patients reported convulsions. 
8Includes dizziness, crying/fussiness, startling (kustukastuka), sleep-talking (kuweweseka), worms, fast heart rate, stays in sun, red/inflamed eyes, and sores/ulcers. 
9GPS data missing from 30 public health facility patients and 52 ADDO patients. 
10Rounded to nearest hour. Data missing for 15 public health facility patients and 6 ADDO patients. 
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Additional file 2  Association of factors related to care received at outlet and patient status at interview with adherence by sector 
 Verified completed treatment1 Verified timely completion2 
 Percent 
adherent,   
Public 
health 
facilities 
(N=572) 
Unadjusted 
odds ratio 
(95% CI) 
p-value Percent 
adherent, 
ADDOs 
(N=450) 
Unadjusted 
odds ratio 
(95% CI) 
p value Percent 
adherent,   
Public 
health 
facilities 
(N=572) 
Unadjusted 
odds ratio 
(95% CI) 
p-value Percent 
adherent, 
ADDOs 
(N=450) 
Unadjusted 
odds ratio 
(95% CI) 
p-value 
Tested for malaria 
at outlet 
            
     No (ref) 70.0 --- --- 70.7 --- --- 40.1 --- --- 35.5 --- --- 
     Yes 78.8 1.59 
(1.09, 2.33) 
0.016 62.0 0.68 
(0.31, 1.46) 
0.3 50.8 1.55 
(1.12, 2.13) 
0.008 30.0 0.78 
(0.41, 1.50) 
0.5 
Told diagnosis at 
outlet 
            
     No (ref) 71.3 --- --- 68.3 --- --- 45.7 --- --- 35.3 --- --- 
     Yes 77.4 1.38 
(0.83, 2.28) 
0.2 71.8 1.18 
(0.76, 1.84) 
0.5 46.3 1.02 
(0.68, 1.54) 
0.9 34.4 0.96 
(0.70, 1.30) 
0.8 
Took first dose of AL 
at outlet 
            
     No (ref) 73.8 --- --- 68.8 --- --- 40.2 --- --- 34.0 --- --- 
     Yes 75.8 1.11 
(0.73, 1.70) 
0.6 79.1 1.71 
(0.87, 3.39) 
0.1 54.4 1.78 
(1.29, 2.45) 
<0.001 41.9 1.40 
(0.67, 2.90) 
0.4 
Obtained correct 
blister pack for age3 
             
     No (ref) 78.3 --- --- 65.8 --- --- 47.8 --- --- 34.2 --- --- 
     Yes 73.6 0.77 
(0.45, 1.30) 
0.3 70.6 1.25 
(0.86, 1.83) 
0.3 45.5 0.91 
(0.61, 1.36) 
0.7 34.9 1.03 
(0.59, 1.79) 
0.9 
Paid for AL             
     No (ref) 75.1 --- --- 69.6 --- --- 47.8 --- --- 30.0 --- --- 
     Yes 73.6 0.92 
(0.59, 1.44) 
0.7 80.0 0.57 
(0.14, 2.35) 
0.4 41.8 0.79 
(0.55, 1.12) 
0.2 34.9 1.25 
(0.29, 5.42) 
0.8 
Recalled correct 
instructions given by 
dispenser on the 
number of pills per 
dose, number of 
doses, and number 
of days to take AL 
            
     No (ref) 58.3 --- --- 55.6 --- --- 22.8 --- --- 22.4 --- --- 
     Yes 85.0 4.06 
(2.71, 6.09) 
<0.001 79.4 3.08 
(2.16, 4.41) 
<0.001 60.9 5.26 
(3.59, 7.71) 
<0.001 43.3 2.65 
(1.68, 4.19) 
<0.001 
Recalled that             
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dispenser used 
packaging as a 
visual aid to explain 
how to take AL 
     No (ref) 65.4 --- --- 61.6 --- --- 32.1 --- --- 26.0 --- --- 
     Yes 76.3 1.70 
(1.04, 2.78) 
0.036 71.4 1.56 
(0.94, 2.59) 
0.090 48.3 1.98 
(1.29, 3.05) 
0.002 36.5 1.64 
(1.01, 2.65) 
0.046 
Reported being told 
to take the second 
dose of AL eight 
hours after the first 
dose 
            
     No (ref) 67.4 --- --- 59.8 --- --- 41.7 --- --- 24.8 --- --- 
     Yes 79.8 1.91 
(1.30, 2.80) 
0.001 75.6 2.09 
(1.56, 2.80) 
<0.001 49.1 1.35 
(0.94, 1.92) 
0.1 40.5  2.06 
(1.44, 2.94) 
<0.001 
Reported being told 
to take AL with food 
or milk 
            
     No (ref) 72.5 --- --- 66.1 --- --- 45.8 --- --- 33.7 --- --- 
     Yes 75.8 1.19 
(0.72, 1.96) 
0.5 72.1 1.33 
(0.91, 1.93) 
0.1 46.1 1.01 
(0.65, 1.56) 
0.9 35.4 1.08 
(0.69, 1.68) 
0.7 
Reported being told 
to complete all 
doses of AL even if 
feeling better 
            
     No (ref) 66.7 --- --- 63.2 --- --- 46.0 --- --- 28.1 --- --- 
     Yes 76.9 1.67 
(1.09, 2.56) 
0.019 73.6 1.62  
(1.13, 2.34) 
0.009 46.1 1.00 
(0.65, 1.55) 
0.9 38.6 1.61 
(1.25, 2.06) 
<0.001 
Reported being told 
to take a 
replacement dose in 
case of vomiting 
within half hour of 
taking a dose 
            
     No (ref) 74.4 --- --- 69.8 --- --- 46.1 --- --- 35.0 --- --- 
     Yes 81.8 1.55 
(0.37, 6.40) 
0.6 72.7 1.16 
(0.40, 3.36) 
0.8 40.0 0.78 
(0.19, 3.21) 
0.7 27.3 0.70 
(0.19, 2.59) 
0.6 
Reported being told 
about possible side 
effects 
            
     No (ref) 74.7 --- --- 70.1 --- --- 45.7 --- --- 35.1 --- --- 
     Yes 76.9  1.13 
(0.32, 4.03) 
0.9 76.9 1.42 
(0.37, 5.39) 
0.6 61.5 1.90 
(0.72, 5.06) 
0.2 30.8  0.82 
(0.25, 2.75) 
0.8 
Reported current             
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fever at time of 
interview 
     No (ref) 75.2 --- --- 72.1 --- --- 46.7 --- --- 35.7 --- --- 
     Yes 71.8 0.84 
(0.53, 1.34) 
0.5 56.3 0.50 
(0.27, 0.94) 
0.031 42.1 0.83 
(0.55, 1.26) 
0.4 29.2 0.74 
(0.40, 1.37) 
0.3 
Could play or work 
at time of interview 
            
     No (ref) 64.3 --- --- 39.4 --- --- 43.9 --- --- 23.5 --- --- 
     Yes 75.5 1.71 
(0.85, 3.44) 
0.1 72.4 4.04 
(1.88, 8.66) 
<0.001 46.1 1.09 
(0.58, 2.05) 
0.8 35.8 1.81 
(0.74, 4.42) 
0.2 
Tested positive by 
mRDT at interview4 
            
     No (ref) 76.1 --- --- 69.8 --- --- 47.5 --- --- 36.6 
 
--- --- 
     Yes 73.7 0.88 
(0.51, 1.51) 
0.6 69.8 1.00 
(0.69, 1.45) 
0.9 44.9 0.90 
(0.57, 1.41) 
0.6 33.3 0.87 
(0.60, 1.25) 
0.4 
Tested positive by 
blood smear 
collected at 
interview5 
            
     No (ref) 74.6 --- --- 69.8 --- --- 45.3 --- --- 35.6 --- --- 
     Yes 75.0  1.02 
(0.35, 2.98) 
0.9 66.7 0.87 
(0.15, 4.88) 
0.9 56.3 1.56 
(0.60, 4.04) 
0.4 33.3  0.91 
(0.15, 5.60) 
0.9 
1Patient completed all doses, verified by pill count when available. Data missing for 2 public health facility patients and 3 ADDO patients. 
2Patient completed each dose at correct time with the correct number of pills per dose, verified by pill count when available. Data missing for 13 public health facility patients and 10 
ADDO patients. 
3Age categories based on recommended age breakdown for AL blister packs in Tanzania. 
4RDT data missing for 7 public health facility patients and 17 ADDO patients. 
5Blood smear data missing for 15 public health facility patients and 18 ADDO patients. 
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6.3  Supplementary data 
 This section presents two additional analyses. First, Table 6.3.1 shows the percentage of 
patients taking AL with fatty food and the percentage vomiting within half an hour of taking a dose. 
Secondly, Tables 6.3.2 and 6.3.3 show the concordance of RDT and blood smear results in public health 
facility and ADDO patients, respectively. 
  Food intake and vomiting. Taking AL with fatty food is important for optimal lumefantrine 
absorption [1]. One study demonstrated a 16-fold variation in lumefantrine bioavailability among 
healthy Thai adults compared to volunteers that had not taken a fatty meal [2]. Another study showed 
that a small amount of fat was necessary for lumefantrine absorption, but only 1.2 g, the amount in 36 
ml of soya milk, was sufficient [3].  
In Tanzania, national guidelines state that each dose of AL should be taken with meals [4], but 
whether or not the meal must contain fat is less clear [5]. Foods commonly eaten in Tanzania that 
contain fat are cow milk or breast milk, oil used in cooking, coconuts, peanuts, cashews, avocados, eggs, 
fish, and meat, although people of lower socioeconomic status may not be able to afford some of these 
foods. Relatively inexpensive foods such as porridge (uji or ugali), cassava, maize, and fruits have little 
fat on their own. Guidelines also state that the first dose should be taken under observation of the 
dispenser, although many patients have not brought food to the outlet and cannot afford to purchase 
food from vendors [5]. Furthermore, if a dose is vomited, a replacement dose must be obtained, but 
guidelines do not specify how replacements should be obtained.  
 Table 6.3.1 shows that the majority of patients in the studies presented in the research paper in 
this chapter took at least one dose with a meal, although this was slightly higher for public health facility 
patients compared to ADDO patients (94% vs. 89%, p=0.023). Approximately 70% of patients attending 
both sectors took at least one dose with fatty food, and 10% of patients reported vomiting at least one 
dose. Very few of these patients (14/108) reported obtaining replacement doses. 
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 Among patients who completed treatment, 38% of public health facility patients and 37% of 
ADDO patients took all six doses with food, and very few patients took all six doses with fatty food (7% 
and 10%, respectively), with no difference between sector. 
Table 6.3.1 Patient report of taking AL with food and occurrence of vomiting (%, 95% CI)1 
 Public health facilities 
(N=572 patients from 
40 outlets) 
Private ADDOs  
(N=450 patients from 
37 outlets) 
p-value 
Took at least one dose 
with food or drink 
94.2 
(91.5, 96.0) 
89.0 
(83.7, 92.7) 
0.023 
Took at least one dose 
with fatty food or milk 
72.0 
(66.8, 76.6) 
69.7 
(63.2, 75.5) 
0.5 
Vomited within 30 
minutes after at least 
one dose2 
10.7 
(7.9, 14.3) 
10.5 
(8.0, 13.6) 
0.9 
Of those who completed 
treatment:  
   
     Took all six doses   
with food or drink 
37.9 
(31.8, 44.3) 
36.7 
(30.3, 43.6) 
0.7 
     Took all six doses 
with fatty food or milk 
6.9 
(4.6, 10.2) 
9.7 
(6.5, 14.3) 
0.2 
     Did not vomit after 
any dose 
90.1 
(85.7, 93.3) 
90.3 
(86.3, 93.2) 
0.9 
1
Data missing for 10 patients for taking at least one dose with food / fatty food; for 3 patients on vomiting after at least one 
dose; for 9 patients who completed treatment on taking all doses with food / fatty food; and for 3 patients who completed 
treatment on vomiting after any dose. 
2
Only 6 public health facility patients and 8 ADDO patients took a replacement dose after vomiting. 
 
 These results show that a low proportion of patients reported taking all six doses with any food 
or drink, and very few patients reported taking all six doses with fatty food. In contrast, 60% of patients 
reported being told to take AL with food or milk. No differences were observed between sector in taking 
all doses with food or fatty food, or in reported advice. Other studies in public health facilities in 
Tanzania have also found very low proportions of patients taking AL with food [5-7]. Possible reasons for 
this include a lack of understanding among patients that the drug should be taken with food, difficulty 
eating when ill, or not having food available. In the study presented in the research paper, several 
patients (n=10) reported not having food available as a reason for stopping treatment. While infrequent, 
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this resonates with anecdotal accounts from dispensers that telling patients to take AL with food, and 
particularly fatty food, could result in confusion that discourages adherence. There is also potential for 
confusion with instructions for DHA-piperaquine, which should not be taken within three hours before 
or after eating due to the risk for prolongation of the corrected electrocardiograph (QT) interval [8]. 
 Approximately 10% of patients vomited at least one dose, with very few patients obtaining a 
replacement dose. However, 72 of the 108 patients who reported vomiting were considered to have 
completed treatment, although only five of these had obtained a replacement dose. This may have 
resulted in slightly overestimated adherence in both sectors.  
In the data presented in the research paper, only about 2% of both public health facility and 
ADDO patients reported being told to obtain a replacement dose in case of vomiting within half an hour 
of taking a dose. Dispensers might be concerned that telling patients about vomiting or minor side 
effects would affect their adherence or, in ADDOs, discourage them from purchasing the drug. They 
might also be unsure of how patients who vomit should obtain a replacement dose, as AL is only 
available in blister packs that are not intended to be split. Another study in Tanzania reported that half 
of all caretakers thought a replacement dose could be taken from the existing blister pack [7]. There is 
thus a need to clarify guidelines and options for patients who require replacement doses. 
 
RDT and blood smear data concordance. As shown in the research paper in this chapter, 50% of 
public health facility patients and 28% of ADDO patients were positive by RDT at the interview on day 4, 
while only 3% and 1.4%, respectively, were positive by reference blood smear. Tables 6.3.2 and 6.3.3 
show the matrices of RDT and blood smear concordance in public health facilities and ADDOs. Among 
patients testing positive by RDT, 5.4% of public health facility and 3.3% of ADDO patients had a positive 
blood smear. Due to small numbers, it was not possible to look at the effect of adherence on RDT and 
blood smear concordance in each sector. However, among patients testing positive by RDT in both 
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sectors combined, there was no difference in the proportion of patients who did or did not complete 
treatment with a positive blood smear (4.6% and 5.5%, respectively, p=0.6). 
Table 6.3.2 Matrix of RDT and blood smear results for public health facility patients1 
 Blood smear positive Blood smear negative Total 
RDT positive 15 
(5.4%) 
261 
(94.6%) 
276 
(100%) 
RDT negative 1 
(0.4%) 
279 
(99.6%) 
280 
(100%) 
Total 16 
(2.9%) 
540 
(97.1%) 
556 
(100%) 
1
Data missing for 15 patients. 
 
Table 6.3.3 Matrix of RDT and blood smear results for ADDO patients1 
 Blood smear positive Blood smear negative Total 
RDT positive 4 
(3.3%) 
117 
(96.7%) 
121 
(100%) 
RDT negative 2 
(0.6%) 
309 
(99.4%) 
311 
(100%) 
Total 6 
(1.4%) 
426 
(98.6%) 
432 
(100%) 
1
Data missing for 18 patients. 
 
 In order to measure effectiveness of AL, a longer follow up period (e.g. 28 or optimally 42 days) 
would be required. Although the artemether component of AL is rapidly absorbed and effectively clears 
parasites, the lumefantrine component has a longer elimination half-life and acts to prevent 
recrudescence [9, 10]. Thus, sub-microscopic parasites not exposed to sufficient lumefantrine, due to 
metabolic factors or not taking all doses, could survive and ultimately cause treatment failure. In the 
studies presented in this chapter, the small number of patients with positive blood smears might have 
made it difficult to detect any differences in patient adherence. However, even studies with 28 or 42-
day follow up periods have seen very high effectiveness and have thus been unable to tease out the 
effects of adherence [11-13]. These challenges are discussed further in Chapter 8. 
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7  Methods of measuring adherence 
7.1  Introduction 
 Chapters 5 and 6 have reported adherence measures based on self-report and pill count, as is 
common in the literature. However, there are concerns that self-reported data are not accurate due to 
patient recall and social desirability biases. In this chapter, we describe an assessment of the validity of 
self-report verified by pill count, using the novel approach of smart blister packs. 
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Abstract 
 Self-report is the most common and feasible method for assessing patient adherence to 
medication, but can be prone to recall bias and social desirability bias. Most studies assessing adherence 
to artemisinin-based combination therapies (ACTs) have relied on self-report. In this study, we use a 
novel customised electronic monitoring device — termed smart blister packs — to examine the validity 
of self-reported adherence to artemether-lumefantrine (AL) in southern Tanzania. 
 Smart blister packs were designed to look identical to locally available AL blister packs and to 
record the date and time each tablet was removed from packaging. Patients obtaining AL at randomly 
selected health facilities and drug stores were followed up at home three days later and interviewed 
about each dose of AL taken. Blister packs were requested for pill count and extraction of smart blister 
pack data.  
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 Data on adherence from both self-report verified by pill count and smart blister packs were 
available for 696 of 1,204 patients. There was no difference between methods in the proportion of 
patients assessed to have completed treatment (64% and 67%, respectively). However, the percentage 
taking the correct number of pills for each dose at the correct times (timely completion) was higher by 
self-report than smart blister packs (37% vs. 24%; p<0.0001). By smart blister packs, 64% of patients 
completing treatment did not take the correct number of pills per dose or did not take each dose at the 
correct time interval. 
 Smart blister packs resulted in lower estimates of timely completion of AL and may be less 
prone to recall and social desirability bias. They may be useful when data on patterns of adherence are 
desirable to evaluate treatment outcomes. Improved methods of collecting self-reported data are 
needed to minimise bias and maximise comparability between studies. 
   
Keywords: Patient adherence, measuring adherence, self-report, electronic monitoring, ACTs 
 
Introduction 
Self-reported adherence, based on detailed questionnaires, is considered the most feasible 
method for assessing adherence in resource-poor settings [1,2]. Self-reported data are relatively low 
cost to collect and do not involve complicated field logistics or invasive procedures such as blood 
sampling. However, despite its many advantages, self-reported adherence is prone to several sources of 
bias [2-4]. Data may be subject to recall bias if patients do not accurately recall their treatment history, 
including the number of pills taken, day and time of each dose, and when the full course was completed. 
Social desirability bias may also occur if patients provide perceived expected responses in order to avoid 
being seen as negligent.  
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Several other methods have been used to complement or even replace patient recall. Many 
studies verify self-reported adherence by counting the number of pills remaining in packaging, although 
this is not always accurate as patients may remove pills without taking them, or packaging may not be 
available for inspection [5,6]. Electronic methods of assessing adherence have been used extensively in 
chronic diseases, mostly in the form of pill containers with caps that record the day and time the 
container is opened, such as MEMS™  [4,7]. While not feasible for routine clinical practice in many parts 
of the world, MEMS™  have been used to validate other adherence measures in studies of adherence to 
antimalarial drugs [8,9], tuberculosis treatment [10], and antiretroviral therapy [11].  
Artemisinin-based combination therapies (ACTs) are first line treatment for malaria in most 
endemic countries and are increasingly obtained by patients seeking treatment in both public and 
private health sectors. Good patient adherence is required to maximise their clinical impact and 
minimise the rate of development of drug-resistance [12-14]. A number of studies assessing adherence 
to ACTs have been conducted in recent years, with results showing that anywhere between 39% and 
100% of patients can be considered adherent [5,6], reflecting both genuine differences in adherence as 
well as variation in study design and measurement methods. The majority of these studies relied on self-
report with or without pill count. One study in Malawi used MEMS™ containers and found 100% 
adherence to artemether-lumefantrine (AL) by self-report and lower adherence (92%) by MEMS™ [8]. 
However, ACTs are now typically dispensed in blister packs designed to improve adherence [15] and 
look considerably different than MEMS™ containers. This may result in over-estimated adherence, as 
patients using MEMS™ are likely to be aware that their adherence is being monitored and their 
experience is no longer comparable to that of patients receiving unit doses in their customary 
packaging. 
In this study, set in southern Tanzania, the validity of self-reported patient adherence to AL was 
assessed using a novel customised electronic monitoring device — termed smart blister packs — that 
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looked identical to regular AL packs, but contained a device that registered the date and time each pill 
was removed from the pack. This is the first study to our knowledge to employ this technology under 
routine conditions to investigate adherence to antimalarial treatment. 
 
Methods 
Study setting. The study was conducted in Mtwara, a rural region in southeastern Tanzania with 
more than a third of the population in the lowest national wealth quintile [16]. Community prevalence 
of falciparum malaria parasitaemia among children 6-59 months of age in Mtwara was 17.4% in the 
2011-2012 HIV/AIDS and Malaria Indicator Survey [17]. 
  In Tanzania, AL was introduced in public health facilities for treatment of uncomplicated malaria 
in 2006. The recommended treatment regimen is six doses over 3 days, with 1-4 tablets (each containing 
20 mg artemether / 120 mg lumefantrine) per dose depending on the patient's weight / age band. 
National guidelines state that the second dose should be taken eight hours after the first dose, followed 
by the remaining doses each morning and evening of the second and third days [18].  
In Tanzania’s private sector, more than two thirds of antimalarial drug sales occur in small drug 
stores [19], many of which have been upgraded to Accredited Drug Dispensing Outlets (ADDOs) through 
a process of training and accreditation. ADDOs are allowed to sell a limited number of prescription-only 
drugs, including some antibiotics and ACTs [20,21]. By 2011, all drug shops in Mtwara were officially 
required to have upgraded to ADDO status, but in practice some shops had not yet paid fees or received 
training and were tolerated as “prospective ADDOs” (in this paper the term ADDOs is used to include 
both accredited outlets and “prospective ADDOs”). 
This study was embedded in two parallel and contemporaneous studies of adherence to AL: a 
cluster randomised trial of a text message intervention targeted at ADDO dispensers to improve 
knowledge of advice to provide when dispensing AL, and an observational adherence study in public 
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health facilities. Details and results of these studies are presented separately [22,23]. Smart blister pack 
data were collected from a subset of patients in both studies for the analyses reported here.  
Smart blister packs. Smart blister packs were prepared using Med-ic® blister package technology 
(Information Mediary Corporation, Ottawa, Canada). This comprises a fine wire, connected to a 
microchip, across each blister. When a tablet is pushed through the foil, the wire is disrupted, and the 
precise time this occurs is recorded on the chip. Wallet cards were designed for all four weight / age 
bands of AL (Coartem®) and looked identical to AL locally available in Tanzania, but with a slight 
thickness near the top centre illustrations due to the electronic tag and cell battery (Figure 1). Smart 
blister packs were assembled by research assistants at the Ifakara Health Institute by folding the wallet 
cards around blister packs of Coartem® purchased in Tanzania and sealing adhesively. At the beginning 
of the study, the blister packs were activated by scanning with a portable device developed by 
Information Mediary Corporation. Following treatment, collected blister packs were scanned to retrieve 
data.  
Sample size and selection of study outlets. We aimed to provide smart blister packs to all 936 
patients required for the cluster randomised trial in ADDOs [23] and all 448 patients required for the 
observational adherence study in public health facilities [22]. However, sample size calculations 
indicated that 600 patients receiving smart blister packs were sufficient, assuming conservatively that 
sensitivity and specificity of self-report was 50%, with a true adherence of 60%, a design effect due to 
correlation of responses within outlets of 2.5, and a precision of 10 percentage points [24]. A small 
number of patients per outlet was desired in order to reduce any potential bias caused by increasing 
community awareness of the study's objectives. Thus, 40 public health facilities (but not hospitals) were 
randomly selected from a list of all dispensaries and health centres in Mtwara, and 82 ADDOs meeting 
study inclusion criteria [23] were randomly selected from a census register of all ADDOs in Mtwara.   
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Study procedures. From September through November 2012, dispensers at selected public 
health facilities and ADDOs were visited by study supervisors and given a standard introduction about 
the study's objectives. Dispensers were provided with smart blister packs of AL to be dispensed in public 
health facilities to patients prescribed ACTs, and in ADDOs to patients indicating an intention to 
purchase treatment for malaria. In order to limit patients’ awareness of our primary interest in assessing 
adherence, which could have led to a biased assessment, dispensers were not told that the blister packs 
provided were any different than the regular AL packs used locally. Dispensers were told we would visit 
at home some, but not all, patients obtaining treatment for fever and were asked to fill out a 
registration form for all fever patients, including a description of where patients lived. Study staff visited 
outlets every day to check and collect registration forms. The intention was to register 12 patients 
obtaining ACTs in one week per outlet, but it took 2-3 weeks to recruit this number in some outlets.  
Eligible patients who obtained AL were identified from the registration forms and followed up 
three days later (day 4). Where written informed consent was given, patients / caregivers were asked 
about demographic and socioeconomic characteristics, treatment-seeking history, symptoms, detailed 
information about each dose of AL taken, and advice provided by the dispenser. The blister packs were 
requested for a pill count and extraction of timestamp data, following a brief explanation of the nature 
and purpose of the smart blister packs. Blood smears were collected to detect infection at the time of 
interview, and histidine-rich protein II (HRP-2)-based malaria rapid diagnostic tests (RDTs) (Pf-specific 
from ICT Diagnostics, Cape Town, South Africa) were conducted to indicate infection prior to treatment. 
Blood smears were stained in the field and transported to the Ifakara Health Institute laboratory where 
they were double-read by two microscopists blinded to results from each other and the RDT. Discrepant 
readings were resolved by a third microscopist.  
 Adherence definitions. Adherence was defined by both self-report and smart blister packs in two 
ways: verified completed treatment and verified timely completion [5]. Patients were considered to 
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have verified completed treatment (hereafter termed completed treatment) by self-report if they 
reported taking all pills by the time of the follow up visit, verified by counting zero pills remaining in 
packaging. Patients who reported completing treatment but had pills remaining were considered non-
adherent, as were patients who reported not completing treatment but presented an empty blister 
pack. Where blister packs were not available, self-report alone determined if patients completed 
treatment. By smart blister pack, patients were considered to have completed treatment if a timestamp 
was recorded for each pill by the time of the follow up visit.  
Verified timely completion (hereafter termed timely completion) was a more stringent 
definition and included a time component. For self-report, Swahili times of day were used: “alfajiri” 
(early morning, defined here as 4:00 am – 6:59 am), “asubuhi” (morning, 7:00 am – 11:59 am), 
“mchana” (afternoon, 12:00 pm – 3:59 pm), “jioni” (evening, 4:00 pm – 6:59 pm), “usiku” (night, 7:00 
pm – 9:59 pm), and “usiku sana” (late night, 10:00 pm – 3:59 am). Patients were considered to have self-
reported timely completion if they took the correct number of pills for each dose and took each dose at 
the correct Swahili time of day. The second dose was considered correct if taken at the Swahili times of 
day corresponding with 8 hours after the beginning or end of the time interval for the Swahili time of 
day when the first dose was taken. For example, if the first dose was taken in the morning (“asubuhi”), 
then the second dose could be taken in the afternoon (“mchana”), evening (“jioni”), or night (“usiku”) of 
the same day (i.e. between 3:00 pm and 7:59 pm). Remaining doses were considered correct if taken at 
the Swahili times of day corresponding with 12 hours after the beginning or end of the time interval for 
the Swahili time of day when the previous dose was taken. As with completed treatment, examination 
of packaging when available was used to verify adherence.  
By smart blister pack, patients were considered to have timely completion if they took the 
correct number of pills for each dose, and took the second dose eight hours plus or minus four hours 
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after the first dose, followed by taking each of the remaining doses 12 hours plus or minus four hours 
after the previous dose. 
For describing non-adherence, we distinguish between “intended doses” and “actual doses.” 
“Intended dose” refers to the pills that are intended by the manufacturer to be taken together at one of 
six specified times and, in the AL used in this study, grouped together in the blister packaging. “Actual 
dose” refers to pills that were actually taken together. An actual dose might have included pills that 
were not grouped together, or a different number than specified for the intended dose. Pills that were 
administered at least 30 minutes apart from each other were considered different actual doses. 
Data entry and analysis. All patient and dispenser interview data were collected using personal 
digital assistants, and data extracted from study forms (census, registration, and follow-up forms) were 
double entered into a Microsoft Access databases. Data were analysed in Stata 11.0 (Stata Corporation, 
College Station, USA). McNemar’s analysis for paired data and conditional logistic regression were used 
to test the difference in completed treatment and timely completion between self-report and smart 
blister packs. 
Ethics. All questionnaires, consent forms, and other study documents were translated into 
Swahili and piloted prior to use. Written informed consent was collected from dispensers prior to 
census, patient registration, and interview and from patients or their caregivers prior to interview. The 
study protocol was approved by the ethical review boards of Ifakara Health Institute and London School 
of Hygiene and Tropical Medicine. CDC advisors provided technical assistance in design and analysis but 
were not engaged in data collection and did not have access to personal identifiers.  
 
Results 
Interviews were conducted with 1,204 patients from 117 outlets (five ADDOs were closed or 
refused to participate). Blister packs were not available for collection from 257 patients (21%). Smart 
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blister packs that had been damaged or from which data were not extractable were collected from 251 
patients (21%). In total, data were extracted from the blister packs of 696 patients (58%) (Figure 2). Due 
to infeasible dosing patterns or errors in smart blister pack technology, 55 patients were excluded from 
the analysis of timely completion, but not the analysis of completed treatment, since pills remained in 
their blister packs. For self-report, this applied to 18 patients who reported taking a subsequent dose 
before an earlier dose. For smart blister pack data, this applied to 10 patients with timestamps recorded 
before the treatment was dispensed or after the pack was collected, and 27 patients with a different 
number of pills observed by the study team at scanning than the number read by the software.  
Table 1 shows characteristics of patients with and without availability of smart blister pack data 
(results comparing patient characteristics and adherence to AL across outlet types are presented 
elsewhere [21]). Based on the recommended age groups for AL blister packs in Tanzania, 27% of the 696 
patients with smart blister pack data available were in the youngest age group (under three years), 24% 
were three years to under eight years, 6% were eight years to under 12 years, and 43% were 12 years 
and above. Fewer patients without smart blister pack data available were under three years (21%) and 
more were 12 years and older (50%). Taking the first dose at the outlet was reported by 23% of patients 
with smart blister pack data available and 17% without (p=0.0281), but all other characteristics were 
similar for patients with and without availability of smart blister pack data. 
 
Comparison of adherence by self-report and smart blister pack data 
Completed treatment. For patients with both types of data available, estimates of completed 
treatment were similar by smart blister packs (67%) and self-report (64%), with little difference in 
adherence by weight / age band of AL (Table 2). Considering smart blister packs as a gold standard, 
sensitivity and specificity of self-reported adherence were 96% and 100% respectively (Supporting 
Information Table 1). It was not possible to calculate an odds ratio because there were no instances 
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where patients who reported completing treatment did not complete treatment by smart blister pack 
data. 
Among patients who did not present blister packs for collection, self-reported completed 
treatment was higher (87%) compared to both all patients who presented blister packs (66%; p<0.0001) 
and patients for whom smart blister pack data were available (64%; p<0.0001). Self-reported completed 
treatment was slightly lower among patients with smart blister pack data available (64%) than among 
patients presenting damaged smart blister packs from which data were not extractable (72%; p=0.050).  
Timely completion. Timely completion was 37% by self-report and 24% by smart blister pack 
data (Table 3), much lower than completed treatment. The odds of timely completion by smart blister 
pack data were 0.36 times that of self-report (95% CI: 0.29, 0.43, p <0.0001). Sensitivity and specificity of 
self-reported timely completion were 74% and 74% respectively (Supporting Information Table 2). 
Although the number of patients ages eight to 12 years with a 3x6 pack was relatively small, this group 
appeared to have slightly higher timely completion, especially by smart blister pack data (Table 3), than 
patients taking other packs. Adult patients (with 4x6 packs) also appeared to have slightly higher timely 
completion than the two youngest age groups according to smart blister pack data, but not self-report. 
Timely completion consisted of two aspects, taking the correct number of pills for each dose and 
taking all six doses at the correct time intervals. Of the 418 patients with data on timely completion 
available who reported having completed treatment (Table 3), 97% reported taking the correct number 
of pills for each of six actual doses. In contrast, according to smart blister pack data, only 67% of the 436 
patients completing treatment appeared to have taken the correct number of pills for each of six actual 
doses, a finding more pronounced for younger children than older children and adults. Of patients who 
reported completing treatment, 58% reported taking all six doses at the correct time intervals, 
compared with 40% of those completing treatment based on smart blister pack data. Thus, by self-
report, correct time intervals were the primary obstacle for timely completion among patients who had 
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completed treatment, but the smart blister pack data revealed problems both with the correct number 
of pills for each dose and the correct time intervals between doses. 
 
Patterns of non-adherence  
Figure 3 shows the number of actual doses taken, ranging from 0-6 by self-report and from 0-8 
by smart blister pack data. Overall, the proportions reporting completion of each dose were similar, 
except that by self-report more people reported taking six doses. This may be because patients were 
asked only about each of the six intended doses. Only about 5% of patients took more than six actual 
doses according to smart blister pack data, including both patients who completed treatment and those 
who did not (Figure 3 and Table 4). For both self-report and smart blister pack data, the median 
numbers of actual doses taken by patients who did not complete treatment were 4 for the 1x6 and 2x6 
packs and 5 for the 3x6 and 4x6 packs. By self-report and smart blister pack data, respectively, the 
median total numbers of pills taken for patients who did not complete treatment were 4 and 4.5 for the 
1x6 pack, 8 (by both methods) for the 2x6 pack, 15 and 13.5 for the 3x6 pack, and 20 (by both methods) 
for the 4x6 pack (Table 4).  
For the first actual dose, timely completion (based only on taking the correct number of pills for 
each dose, as timeliness of the first dose was not assessed) was 98% by self-report and 87% by smart 
blister pack data. Timely completion for the second actual dose decreased to 71% by both self-report 
and smart blister pack data (Figure 4). For the third dose onward, timely completion by self-report was 
clearly higher than for the second dose (above 80%), but this increase was not evident in the smart 
blister pack data. Cumulatively, timely completion after two actual doses was similar for self-report and 
smart blister pack data, reflecting a slightly larger drop in timely completion by self-report. From dose 
three onwards, timely completion declined more rapidly by smart blister pack data.  
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Discussion 
This paper examines the validity of self-reported adherence in comparison with smart blister 
packs that recorded the day and time pills were removed from packaging. Timely completion (37% by 
self-report and 24% by smart blister packs) was much lower than completed treatment (64% by self-
report and 67% by smart blister packs). No difference was observed between self-report and smart 
blister pack data for the percentage of patients completing treatment, but timely completion was lower 
when assessed using smart blister pack data (OR=0.36, 95% CI: 0.29, 0.42, p<0.0001). Smart blister pack 
data showed that, even among patients who completed treatment, 33% did not take the correct 
number of pills for all doses, and 60% did not take each dose at the correct time interval.  
This study has several limitations. First, recovery of blister packs might have been higher had 
dispensers and patients been more aware of the aims of the study. However, to avoid artificially 
increasing adherence, we intentionally did not tell dispensers or patients that the objective of the study 
was to assess adherence. Secondly, dispensers did not always accurately record the time that drugs 
were dispensed, despite daily visits by the study team and attempts to clarify times that were unclear. 
We therefore concluded that the data were not sufficiently robust to assess the timeliness of the first 
dose.  
For both self-report and smart blister pack data, we allowed a margin of error around the 
correct time intervals when assessing timely completion. Clocks are not commonly used in rural Mtwara, 
and Swahili times of day which each cover several hours were therefore used for self-reported timely 
completion. Recorded timestamps plus or minus four hours were used to define acceptable limits for 
smart blister pack data. Among patients with timely completion by both methods, Swahili times of day 
corresponded well with timestamps, so it is unlikely that the definitions of timely completion affected 
the difference between methods. However, more stringent definitions for both methods might have 
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resulted in lower levels of timely completion. Variability in adherence definitions has been frequently 
noted as a challenge for comparing adherence results across studies [5,6,25].  
Self-report and smart blister pack data have various advantages and disadvantages for assessing 
patient adherence to ACTs. Self-reported adherence is collected through interviews, which are relatively 
inexpensive and are a widely accepted method of collecting data in many populations, including in 
southern Tanzania. Nonetheless, collecting accurate self-reported data can be challenging. Patients may 
have provided expected answers on the number of pills taken for each dose, or not remembered, and 
interviewers reported that patients often seemed confused about when and how each dose was taken. 
Some patients reporting taking more pills in total than the number in the blister pack, and some 
reported taking a subsequent dose before a previous dose. In this study, specific questions were asked 
about each of the six intended doses. However, patients may have taken pills grouped in a way that 
differed from the intended doses in the blister packs, and may therefore have taken more than six 
actual doses, as smart blister pack data indicated was the case. If any actual doses beyond the six 
intended are not captured by self-report interviews, this could underestimate the percentage 
completing treatment. In order to avoid some of these challenges, data collection tools need to be 
improved and evaluated, for example, including both open and closed-ended questions to identify 
actual doses taken [6]. 
As part of both the completed treatment and timely completion definitions, self-report was 
verified by counting pills remaining in packaging for the 83% of patients that presented blister packs. 
Very few patients (9/696) reported completing treatment but had pills remaining, similar to the high 
concordance between self-report alone and pill count described in a review of adherence to medication 
across diseases [3]. While this suggests that definitions incorporating pill counts may not differ from self-
report alone, the patients who did not present blister packs reported higher completed treatment than 
those who did present blister packs (85% vs. 68%). This suggests that requesting blister packs may 
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reduce over-reporting of adherence, unless patients for whom blister packs were not available were 
more likely to have finished packs and disposed of them. Blister packs were requested at the end of the 
questionnaire, which means patients could have removed pills from the pack after completing the 
interview but prior to presenting the pack.  
Compared to smart blister packs, self-report generally over-reported timely completion, 
consistent with most other studies of electronic monitoring of adherence across diseases [4]. However, 
27% (42 /155) of patients who did not report timely completion were found to have timely completion 
by smart blister pack data (Supporting Information Table 1). This is likely due to patient confusion when 
reporting dose history, which was noted frequently by study staff, or possibly removing pills for later 
consumption. Studies of adherence to tuberculosis treatment and antiretroviral therapy have also 
documented that some patients non-adherent by self-report were adherent by electronic pill containers 
[10,11]. Our smart blister pack data revealed how some patients took pills in more than six actual doses, 
or removed a large number of pills at once, including removal of all pills remaining in the packaging on 
the date of the interview - possibly at the time of the interview.  
The smart blister packs were easy to assemble, the software and portable scanner were 
straightforward to use, and the packs were designed to look identical to regular AL packs commonly 
available in Tanzania. However, they had a slight bulge at the top of the package for a small chip that 
stored data. Some patients noticed this and opened up the packaging to investigate, damaging the 
capacity to record and extract timestamps. Several patients were alarmed when the chip was 
discovered, requiring the study team to provide full explanations to participants and village leaders. 
Other blister packs were destroyed when children were allowed to play with them after completion of 
treatment, or when dropped in water or fires before, during, or after taking pills. 
Although smart blister packs accurately recorded when pills were removed from the packaging, 
it was also possible for a timestamp to be recorded for a pill if pressure had been applied and a pill was 
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partially removed, even if the seal was not obviously broken. While it was evident when timestamps 
were recorded before the treatment was dispensed to the patient or after the pack was collected, this 
could also have occurred in the middle of treatment, which could have altered timely completion 
estimates, though this is not thought to have occurred frequently. In addition, for some patients, the 
number of pills observed by the study team at scanning did not correspond with the number read by the 
software. Future smart blister pack designs should be improved to reduce the chances that timestamps 
would be recorded when pills weren’t completely removed and to reduce the bulge in the packaging so 
that patients are less likely to notice and tamper with the packaging.  
Another approach to getting insights into adherence is through the measurement of drug levels 
in patients’ blood during follow-up. In the case of ACTs, this has been approached by measuring the 
concentration of the non-artemisinin partner drug since the artemisinin component is absorbed and 
eliminated rapidly [26]. We collected blood spots on filter paper for the assessment of lumefantrine 
concentrations. However, analysis 19-24 months after collection found lumefantrine concentrations 
below the lower limit of quantification, reflecting the need for filter papers to be stored at appropriate 
temperatures and ideally analysed within 4-6 weeks post-collection [27].   
Moreover, studies of adherence to AL have not found significant differences in blood 
lumefantrine concentrations between patients considered adherent and non-adherent by self-report 
[8,28-30]. Some studies have reported significant differences in lumefantrine concentrations (usually 
measured 7 days after initiation of treatment) between supervised versus non-supervised patients [31-
33]. These and other studies have not reported differences in treatment failure based on cut-offs of 280 
ng / ml [29,31-33] or 175 ng / ml [8], which have been previously found to predict recrudescence 
[12,26]. In addition, lumefantrine is known to have high inter-individual metabolic variation, with factors 
such as weight, age, pregnancy, and fat intake affecting absorption [34-36]. As a result, while biological 
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measures of lumefantrine concentration might provide some additional objective information about 
adherence, they can be difficult to obtain, process and interpret in follow-up studies.  
Finally, methods for measuring adherence should be based on levels and components of 
adherence that are important for effectiveness. The recommended regimen for AL was developed in 
early trials showing that a six-dose regimen of AL taken twice per day, with the second dose taken after 
eight hours, resulted in higher cure rates than a four-dose regimen [34,37,38]. However, it is unclear 
how strictly dose intervals must be adhered to in order for treatment to be effective. For example, 
patients who obtain ACTs in the evening may be less likely to adhere to correct dose timing than 
patients who obtain ACTs in the morning, and it is unclear to what extent this matters.  As adherence 
needs to be defined and measured depending on what is required for drug effectiveness, the 
importance of exact dose timing must be clarified.  
 
Conclusion 
 Accurate measurements of patient adherence are important for developing strategies to assure 
the effectiveness of ACTs. While self-reported data along with examination of packaging might be 
sufficient to assess completion of treatment, patient reports of timely completion appear to be affected 
by both recall and/or social desirability bias. Smart blister packs provided slightly lower, and potentially 
more accurate, estimates of the number of pills taken for each dose and the time intervals between 
doses. In settings where data on dose timing are considered important for clinical outcomes, smart 
blister packs may be a useful tool, though innovations to make them more robust and discreet would be 
useful. Improved methods for collecting self-reported data are also likely to enhance the accuracy of 
measured patient adherence to treatment. Finally, a clearer rationale for what is considered adequate 
adherence is required. 
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Table 1: Characteristics of patients with and without self-report and smart blister pack data available 
(percent (number))1,2 
 Patients with 
smart blister 
pack data 
available 
(N=696) 
Patients 
without smart 
blister pack 
data available 
(N=508) 
p-value 
Male 45.3 (315)  48.0 (244) 0.3 
Age3   0.0249 
     Under 3 years  26.9 (187) 21.1 (107)  
     3 years to under 8 years 23.8 (166) 21.3 (108)  
     8 years to under 12 years 5.8 (40) 8.1 (41)  
     12 years and above 43.5 (303) 49.6 (252)  
Patient (or caregiver if patient below age 12 
years) completed primary school 
70.9 (490)  71.0 (360) 0.9 
Slept under net  the night before the interview 72.2 (502) 76.7 (388) 0.1 
Attended an outlet in an urban ward 47.6 (331)  50.8 (258) 0.4 
Attended ADDO (vs. public health facility) 64.2 (447)  66.9 (340) 0.2 
Distance of 2.5 km or less from home to outlet 
(by GPS coordinates) 
73.9 (468) 75.2 (340) 0.6 
Reported being tested for malaria at outlet 26.4 (183) 24.2 (122) 0.5 
Reported taking first dose of AL at the outlet 22.8 (158) 17.4 (88) 0.0281 
Reported receiving correct instructions on AL 
regimen4 
59.6 (281) 57.3 (291) 0.4 
1
 For patients with self-reported data and smart blister pack data available, data were missing for education for 5 patients, net 
use for 1 patient, GPS data for 63 patients, being tested for malaria for 2 patients, and taking the first dose of AL at the outlet 
for 4 patients.
 
2 
For patients without self-reported data and smart blister pack data available, data were missing for education for 3 patients, 
net use for 2 patients, GPS data for 73 patients, being tested for malaria for 5 patients, and taking the first dose of AL at the 
outlet for 2 patients. 
3
Age categories based on recommended age breakdown for AL blister packs in Tanzania. 
4
Reported the correct number of pills per dose, the correct number of doses per day, and the correct number of days per 
dispenser instructions.
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Table 2: Completed treatment by self-report and smart blister packs  
 Self-report Smart blister packs 
Number with self-reported data and 
electronic blister pack data available 
(N) 
696 696 
 Percent completed treatment  
(numerator / denominator) 
(95% CI) 
  
     Total1 64.1 (446/696) 
(59.8, 68.1) 
66.7 (464/696) 
(62.3, 70.7) 
     1x6 (6 tablets) 65.1 (162/249) 
(58.2, 71.4) 
65.5 (163/249) 
(58.8, 71.6) 
     2x6 (12 tablets) 64.5 (80/124) 
(55.9, 72.3) 
66.9 (83/124) 
(58.2, 74.6) 
     3x6 (18 tablets) 53.7 (22/41) 
(39.8, 67.0) 
61.0 (25/41) 
(46.0, 74.1) 
     4x6 (24 tablets) 64.5 (182/282) 
(58.6, 70.1) 
68.4 (193/282) 
(62.2, 74.1) 
1
An odds ratio for the effect of measurement method on completed treatment could not be calculated because 
there were zero patients who reported completing treatment but did not complete treatment by smart blister 
pack data. 
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Table 3: Timely completion by self-report and smart blister packs1 (percent (number)) 
 Self-report Smart blister packs 
 Patients 
completing 
treatment  
All patients Patients 
completing 
treatment 
All patients 
     Total 418 641 436 641 
     1x6 (6 tablets) 154 239 155 239 
     2x6 (12 tablets) 77 121 80 121 
     3x6 (18 tablets) 21 36 24 36 
     4x6 (24 tablets) 166 245 177 245 
     
 
Percent taking the correct number of pills for each of six actual doses2,3 
     Total 96.9 (405) 63.5 (407) 67.2 (293) 45.7 (293) 
     1x6 (6 tablets) 96.1 (148)  62.3 (149) 75.5 (117) 49.0 (117) 
     2x6 (12 tablets) 98.7 (76) 62.8 (76)
  
71.3 (57) 47.1 (57) 
     3x6 (18 tablets) 100 (21) 58.3 (21) 62.5 (15) 41.7 (15) 
     4x6 (24 tablets) 96.4 (160) 65.7 (161) 58.8 (104) 42.5 (104) 
 
Percent taking six actual doses at the correct time intervals: 4,5 
     Total 58.4 (244) 39.6 (254) 40.4 (176) 27.6 (177) 
     1x6 (6 tablets) 57.8 (89) 38.1 (91) 32.9 (51) 21.3 (51) 
     2x6 (12 tablets) 58.4 (45) 38.0 (46) 36.3 (29) 24.8 (30) 
     3x6 (18 tablets) 71.4 (15) 44.4 (16) 54.2 (13) 36.1 (13) 
     4x6 (24 tablets) 57.2 (95) 41.2 (101) 46.9 (83 ) 33.9 (83) 
 
 Timely completion (Percent taking the correct number of pills at the correct time intervals for each of 
six actual doses): 
     Total6 57.4 (240) 37.4 (240) 35.6 (155) 24.2 (155) 
     1x6 (6 tablets) 56.5 (87) 36.4 (87) 32.9 (51) 21.3 (51)  
     2x6 (12 tablets) 58.4 (45) 37.2 (45) 32.5 (26) 21.5 (26) 
     3x6 (18 tablets) 71.4 (15) 41.7 (15) 50.0 (12) 33.3 (12) 
     4x6 (24 tablets) 56.0 (93) 38.0 (93) 37.3 (66) 26.9 (66) 
1
55 patients were excluded from this analysis because data on timing of each actual dose were not possible to assess for self-
report for 18 patients and for smart blister pack data for 37 patients. 
2
“Actual doses” refers to pills actually taken together, including pills that were not grouped together, or a different number 
than specified for the intended dose. Pills administered at least 30 minutes apart from each other were considered different 
actual doses. 
3 
By self-report, number of pills taken missing for one dose for 2 patients for the 1x6 pack, 1 patient for the 2x6 pack, and 8 
patients for the 4x6 pack. 
4
 By self-report, time of taking one or more doses missing for 24 patients for the 1x6 pack, 12 patients for the 2x6 pack, 2 
patients for the 3x6 pack, and 20 patients for the 4x6 pack.  
5
By smart blister pack data, no patients who completed treatment and took more than six actual doses took the first six at the 
correct intervals. 
6
 For all patients (total columns) the odds ratio for timely completion by smart blister pack vs. self-report was 0.36, 95% CI: 
0.29, 0.42; p<0.0001. 
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Table 4: Median number of actual doses and pills taken by self-report and smart blister packs 1 
 Self-report Smart blister packs 
 Patients 
completing 
treatment  
Patients not 
completing 
treatment 
All patients Patients 
completing 
treatment  
Patients not 
completing 
treatment 
All patients 
     Total 418 223 641 436 205 641 
     1x6 (6 tablets) 154  85 239 155 84 239 
     2x6 (12 tablets) 77  44 121 80 41 121 
     3x6 (18 tablets) 21 15 36 24 12 36 
     4x6 (24 tablets) 166 79 245 177 68 245 
       
 
Median (range) number of actual doses taken2  
     Total 6 (6-6) 5 (0-6) 6 (0-6) 6 (1-8) 4 (0-7) 6 (0-8) 
     1x6 (6 tablets) 6 (6-6) 4 (1-5) 6 (1-6) 6 (1-6) 4 (1-5) 5 (1-6) 
     2x6 (12 tablets) 6 (6-6) 4 (0-5) 6 (0-6) 6 (1-7) 4 (1-7) 6 (1-7) 
     3x6 (18 tablets) 6 (6-6) 5 (2-6) 6 (2-6) 6 (1-8) 5 (2-6) 6 (1-8) 
     4x6 (24 tablets) 6 (6-6) 5 (0-6) 6 (0-6) 6 (1-8) 5 (0-7) 6 (0-8) 
       
Median (range) number of pills taken3,4  
     1x6 (6 tablets) 6 (6-7) 4 (1-6) 6 (1-7) 6 (6-6) 4.5 (1-5) 6 (1-6) 
     2x6 (12 tablets) 12 (12-13) 8 (0-12) 12 (0-13) 12 (12-12) 8 (1-11) 12 (1-12) 
     3x6 (18 tablets) 18 (18-18) 15 (6-15) 18 (6-18) 18 (18-18) 13.5 (6-15) 18 (6-18) 
     4x6 (24 tablets) 24 (24-24) 20 (0-24) 24 (0-24) 24 (24-24) 20 (0-22) 24 (0-24) 
1
55 patients were excluded from this analysis because data on timing of each actual dose were not possible to assess for self-report for 18 
patients and for smart blister pack data for 37 patients. 
2
“Actual doses” refers to pills actually taken together, including pills that were not grouped together, or a different number than specified 
for the intended dose. Pills administered at least 30 minutes apart from each other were considered different actual doses. 
3
By self-report, number of pills taken was missing for one dose for 2 patients for the 1x6 blister pack, 1 patient for the 2x6 blister pack, and 
8 patients for the 4x6 blister pack. 
4
6 patients reported taking all pills, but since pills remained in the blister pack, they were not considered to have completed treatment (4 
patients taking the 1x6 pack, 1 patient for the 2x6 pack, and 1 patient for the 4x6 pack). 1 patient for the 2x6 pack and 2 patients for the 
4x6 blister reported taking no actual doses. 
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Figure 1: Picture of a smart blister pack showing resemblance to regular blister packs 
 
 
Figure 2: Flow chart of patients included in analysis 
 
Patients interviewed 
(n=1204) 
Smart blister pack data not available 
 Blister pack not available for 
collection (n=256; 21%) 
 Smart blister pack damaged or data 
could not be extracted (n=252; 21%) 
Patients with self-report and 
smart blister pack data 
available (n=696; 58%) 
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Figure 3: Number of actual doses taken by self-report and smart blister packs1-3 
 
1
55 patients were excluded from this analysis because data on timing of each actual dose were not possible to assess for self-
report for 18 patients and for smart blister pack data for 37 patients. 
2
“Actual doses” refers to pills actually taken together, including pills that were not grouped together, or a different number 
than specified for the intended dose. Pills administered at least 30 minutes apart from each other were considered different 
actual doses. 
3
By self-report, patients were asked only about each of the six intended doses. 
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Figure 4: Timely completion for each actual dose and cumulatively1 
 
 
1
55 patients were excluded from this analysis because data on timing of each actual dose were not possible to assess for self-
report for 18 patients and for smart blister pack data for 37 patients. 
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Supporting Information Table 1: Matrix of completing treatment showing sensitivity and specificity of 
self-report compared to smart blister pack data  
Percent (number) 
(95% CI) 
  Smart blister packs 
  
Completed 
treatment 
Did not complete 
treatment 
Total 
Self-report 
Completed 
treatment 
96.1 (446) 
(93.6, 97.7) 
0 
64.1 (446) 
(59.8, 68.1) 
Did not complete 
treatment 
3.9 (18) 
(2.32, 6.42) 
100 (232) 
35.9 (250) 
(31.9, 40.2) 
Total 100 (464) 100 (232) 100 (696) 
 
 
Supporting Information Table 2: Matrix of timely completion showing sensitivity and specificity of 
self-report and smart blister pack data  
Percent (number) 
(95% CI)  
  Smart blister packs 
  Timely completion 
No timely 
completion 
Total 
Self-report 
Timely completion 
73.5 (114) 
(66.1, 79.8) 
25.9 (126) 
(21.7, 30.6) 
37.4 (240) 
(32.8, 42.3) 
No timely 
completion 
36.5 (41) 
(20.2, 33.9) 
74.1 (360) 
(69.4, 78.3) 
72.6 (401) 
Total 100 (155) 100 (486) 100 (641) 
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8  Discussion 
 The final chapter of this thesis summarises the main findings of the research, discusses strengths 
and limitations, and considers the implications of this work for policy and future studies.  
Table 1 Synthesis of key thesis results  
Key results Interpretation & implications 
Adherence in public health facilities and ADDOs 
 
Levels of adherence
1
 in public health facilities and ADDOs, 
respectively: 
Completed treatment: 75% & 70% (p=0.2) 
Timely completion: 46% & 35% (p=0.003) 
 
Adjusted odds ratios
2
 for ADDO patients vs. public health 
facility patients: 
Completed treatment: 0.65 (95% CI: 0.43, 1.00)  
Timely completion: 0.69 (95% CI: 0.47, 1.01)  
 
There was limited evidence of lower adherence among 
patients attending ADDOs vs. public health facilities, 
although the reasons for this were not clear. 
Interventions to improve care for malaria patients are 
needed in both sectors.  
 
Text message intervention targeted at ADDO dispensers to 
improve patient adherence to AL 
 
Levels of adherence
1
 in intervention and control arms, 
respectively: 
Completed treatment: 68.3% & 69.8%, (p[adjusted]=0.6) 
Timely completion: 33.1% & 32.6% (p[adjusted]=0.9) 
 
A text message intervention targeted at ADDO 
dispensers was not successful in improving patient 
adherence. The potential of other interventions 
depends on the true reasons for non-adherence, 
which are still poorly understood. 
 
Comparison of patient adherence measured by self-report and 
smart blister packs  
 
Levels of adherence
1
 by self-report and smart blister pack data, 
respectively: 
Completed treatment: 64% & 67%
3 
Timely completion: 37% & 24% (p<0.0001) 
 
Self-reported data may overestimate verified timely 
adherence compared to smart blister pack data. 
Improved smart blister pack designs may be useful for 
future studies where precise data on dose timing are 
needed.  
 
Existing concepts of adherence Caution should be used when comparing adherence 
levels across studies, as differences in study design 
and approach to assessing adherence can influence 
results. 
 
Better understanding is needed of how adherent 
patients must be for treatment to be effective, 
particularly in terms of dosing schedule and fatty food 
intake. 
 
Guidance on dosing schedules for patients who obtain 
AL in late afternoon or evening needs to be 
determined and should be clearly communicated to 
providers and patients. 
 
1
Verified by pill count when available 
2
Adjusted for patient characteristics 
3
A p-value for the effect of measurement method on completed treatment could not be calculated because there were 
zero patients who reported completing treatment but did not complete treatment by smart blister pack data. 
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8.1 Summary of findings 
 In addition to undertaking an updated systematic review on adherence to antimalarial drugs, 
the objectives of this thesis were to (1) determine differences in patient characteristics and levels of 
adherence between patients obtaining AL in public health facilities and ADDOs, and to examine factors 
associated with adherence in both of these settings; (2) evaluate the effect on dispenser knowledge and 
patient adherence of text message reminders targeted at ADDO dispensers concerning advice to provide 
when dispensing AL; and (3) compare the validity of assessing patient adherence with self-reported data 
compared to smart blister packs. A summary of key results and their interpretation and implications is 
shown in Table 1 and referred to throughout this chapter. 
 In Chapter 2, a published literature review and addendum in Chapter 2.3 described all studies of 
adherence to antimalarial drugs through September 2014. Extensive variation was observed in levels of 
adherence, with some studies reporting high adherence above 90%, and others reporting extremely 
suboptimal adherence of less than 50%. Among studies of adherence to ACTs, results ranged from 7%-
100%. 
 Because results may vary depending on the relative lenience of the definition of adherence, five 
approaches for assessing adherence were identified: Completed treatment, verified completed 
treatment, timely completion, verified timely completion, and biological assays. All but 6 of the 67 
studies (including those added in Chapter 2.3) used one or more of these approaches, with the 
remaining six using only unique approaches. While the diversity of study drugs, settings, and factors 
related to study design made it difficult to identify systematic differences in adherence between 
approaches, among studies of AL there was a weak indication that studies using pill counts had lower 
adherence. 
 The review also demonstrated that patient interaction with research staff may increase social 
desirability bias. Studies where patients had given informed consent prior to taking treatment and those 
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where consultations had been observed by research staff tended to report higher adherence. In 
addition, studies where there was a larger research presence (e.g. effectiveness trials with multiple 
follow-up visits) often reported higher adherence. Studies where patients had been tested for malaria 
prior to obtaining AL and those where the first dose was taken under observation also reported higher 
adherence. However, these practices were often part of the research protocol, so it is unclear if the 
same effects would be seen under routine conditions.  
 As the majority of studies reporting adherence to ACTs were conducted in the public sector, 
even though ACTs are now also available in the private for-profit sector, we conducted two parallel and 
contemporaneous studies in public health facilities and ADDOs to compare adherence to AL between 
these outlet types (the first research objective, reported in Chapter 6). As summarised in Table 1, 
adherence in both sectors was suboptimal, with verified completed treatment of 75% among health 
facility patients and 70% among ADDO patients (p=0.2) and verified timely completion of 46% among 
health facility patients and 35% among ADDO patients (p=0.003). In comparison to other studies of AL in 
public health facilities in Tanzania, verified completed treatment in our study was similar to two other 
studies (with and without pill counts) (77%-80%) [1, 2], but verified timely completion was lower than in 
three other studies (75%-90%) [3-5] and higher than in another study (7%) [2]. Adherence has not been 
previously assessed from drug stores in Tanzania, though verified completed treatment in our study was 
similar to levels of completed treatment (without pill count) in a household survey in Tanzania (69%) 
and a study from drug stores in Uganda (66%) [6]. 
Characteristics of patients varied substantially between sectors, with those attending ADDOs 
wealthier, more educated, older, visiting the outlet later in the day, and less likely to have malaria than 
health facility patients. When controlling for patient characteristics, there was some evidence that 
adherence by both measures was lower among ADDO patients than health facility patients. In both 
sectors, recalling correct advice on how to take AL was associated with both verified completed 
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treatment and verified timely completion. In health facilities, taking the first dose of AL at the outlet was 
associated with verified timely completion (but not verified completed treatment). 
 In order to address concerns about lower adherence to ACTs obtained in the private retail 
sector, we conducted a cluster-randomised trial of a text message intervention to improve dispenser 
knowledge and patient adherence (second research objective, Chapter 5). While the intervention was 
delivered effectively, the text messages only had some effect on dispenser knowledge (e.g. taking with 
fatty food and continuing treatment if minor side-effects occurred) and had no effect on advice patients 
reported receiving or on patient adherence. Verified completed treatment was 68.3% and 69.8% in the 
intervention and control arms, respectively (p [adjusted] = 0.6), and verified timely completion was 
33.1% and 32.6%, respectively (p [adjusted] = 0.9) (Table 1).   
One possible reason for the lack of observed effect could be the recent training on treatment of 
malaria with ACTs in the study site, and therefore relatively high knowledge among dispensers in both 
arms. It is also possible that gaps in dispenser knowledge were not addressed by the content of the 
messages, and that dispensers did not increase the advice they provided to patients, as they were 
deliberately not told that the reason for the messages was to increase adherence. Alternatively, patients 
may have had poor recall of the advice or were otherwise unreceptive to extra advice received. Patients 
in both arms did report receiving some advice, but the relative roles and impact of advice and other 
determinants of adherence remain unclear.  
 In Chapter 7, the third research objective of comparing methods to assess adherence, was 
examined. There was no difference between self-reported adherence and smart blister pack data for 
verified completed treatment, but verified timely completion was lower by smart blister pack data 
(Table 1). While self-reported data are cheaper and easier to collect, their results for timely completion 
were prone to patient confusion, poor recall, and social desirability bias. Smart blister packs provided 
more accurate information on how each actual dose was taken, though a large number of smart blister 
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packs were damaged and did not allow for extraction of data. Because of these missing data, self-report 
was used to report adherence for the CRT and observational study in public health facilities. The results 
of the smart blister pack data in Chapter 7 suggest that the estimates of self-reported completed 
treatment presented in these research papers (Chapters 5 and 6) were likely accurate, but that timely 
completion may have been over-estimated. A third method of assessing adherence, quantification of 
lumefantrine concentrations from filter paper dried blood spots, was not successful, most likely due to 
the lengthy time of storage prior to analysis.  
 
8.2  Thesis strengths and limitations 
 This section reviews key strengths and limitations of the research papers in Chapters 2, 5, 6, & 7 
and focuses on strengths and limitations of the thesis as a whole. The first part of the section (8.2.1) 
highlights the work on definitions of adherence and methods of data collection, while the second part 
(8.2.2) addresses the private for-profit sector, and the third section (8.2.3) draws these together to 
consider the evaluation of the text message intervention in ADDOs. 
 
8.2.1 Adherence definitions and methods 
 Throughout the thesis a key theme has been the methodological challenges of assessing 
adherence. These relate to both defining adherence itself and to the techniques for recording it. 
Challenges of comparability of definitions with other studies and limiting sources of bias are also 
important considerations. 
Definitions of adherence. The literature review in Chapter 2 identified five approaches to 
assessing adherence to antimalarials that encompassed the approaches used in 61/67 of studies (see 
Table 4 in Chapter 2.2). This categorization scheme is useful for identifying patterns in results and 
facilitating further discussions on comparing adherence across settings. However, within these general 
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approaches, there is variation in how completion and timeliness are defined, and how pill counts are 
incorporated. For example, for AL, completion could mean completing the course of treatment obtained 
or completing the correct course of treatment based on patient weight, or completing all doses within 4 
days, or completing all doses by the time of the follow-up visit. Similarly, timeliness could include, for 
example, taking two doses per day morning and evening for three days or taking the correct number of 
pills at the correct times for each of six doses. Furthermore, timeliness could involve taking the second 
dose after 8 hours (as opposed to 12 hours), allowing several hours more or less for each correct 
interval. As noted in Table 1, these variations affect comparability between studies, as within a single 
study, each variation could yield a different result.  
In the studies presented in the research papers in Chapters 5 and 6, we opted to evaluate 
adherence to the AL pack obtained, rather than to the pack that corresponded to the patient’s age, 
which would have combined both dispenser and patient behaviour and been more difficult to interpret. 
However, some patients did obtain incorrect doses; 15% of the 249 patients with self-report and smart 
blister pack data that obtained a 1x6 pack were older than three years, although some of these may 
have been small for their age. Patients were followed up on day 4, as this is most consistent with 
treatment recommendations and with follow up periods used in other studies. A further strength is the 
use of Swahili times of day to assess timeliness, which were thought to be more accurate than asking for 
exact times, as patients are unlikely to recall exact times and do not typically use clocks or watches. The 
validity of this approach was confirmed by matching reported times of day with exact times from smart 
blister pack data for patients with verified timely completion by both self-report and smart blister pack 
data. However, it is unclear if and how this approach could be applied to other countries. 
Limiting sources of bias. An important emphasis in this thesis was the careful use of strategies in 
study design and data collection to limit sources of bias. For example, in selecting ADDOs for the CRT, a 
buffer zone was required between control and intervention outlets, although the limited number of 
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shops restricted this distance to only 400 meters (Appendix 3a). A large number of outlets (77 ADDOs 
and 40 public health facilities) were enrolled so that a small number of patients from each shop could be 
registered over a short period of time (1-3 weeks); this was done to lessen community awareness of the 
study that might have impacted behaviour. Since the literature review indicated that requesting 
informed consent at the outlet and observation of the dispenser-interaction could result in increased 
Hawthorne bias, study staff had no interaction with patients and limited their presence at the outlet to a 
short visit once per day to collect forms. Similarly, dispensers were not told that the purpose of the 
messages or the intent of the evaluation was to assess adherence. They were asked to register all 
patients obtaining a drug for fever or malaria, not just ACTs, and to provide minimum details about the 
possibility of a home visit from study staff (Appendix 1a-b). Informed consent was not requested of 
patients until they were visited on day 4. 
We attempted to limit recall bias by visiting patients as soon as possible three days after 
treatment should have been completed (day 4). We estimated the time of the visit to be 68-72 hours 
after the drug was obtained, but there was a large degree of uncertainty due to challenges with 
dispensers recording the time the drug was obtained and field logistics. In order to improve our chances 
of blister pack recovery, we erred on visiting earlier rather than later on day 4, but this meant more 
patients obtaining AL at ADDOs compared to health facilities were visited between 60-67 hours (this was 
controlled for in the analyses in Chapter 6). The data collection tool was designed to talk patients 
through each dose, and Swahili times rather than exact hours likely improved recall, but accounts of 
some patients were still inconsistent. An alternative strategy would be to visit patients daily, but this 
would result in a much greater Hawthorne effect. Other studies have randomised patients to different 
follow up times during the course of the treatment [3, 5]. While this approach might provide more 
accurate information about early doses, results become difficult to compare with studies that visit 
patients after treatment is expected to be complete.  
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Patients may have responded to questions about adherence dishonestly in order to appear less 
negligent, or may have answered other questions according to their perception of the “expected” or 
“correct” response (e.g. results of an RDT conducted at the outlet). To limit this social desirability bias, 
patients were told when explaining the consent form prior to interview that the purpose of the visit was 
to understand how people in the region prefer to take medicines in order to improve malaria services. 
Patients were also asked for blister packs at the end of the interview so that they would not attempt to 
make their accounts match with the blister packs (however, pills could still have been removed prior to 
presenting the packs).  
Use of smart blister packs. This thesis reports the first time that smart blister pack technology 
has been applied to antimalarials. It is also the first time that smart blister packs have been designed 
and used with the intent of patients being unaware of adherence monitoring until the follow up 
interview, which was important for avoiding a Hawthorne effect and assessing the validity of self-report. 
The smart blister packs enabled collection of accurate and specific data on when each pill was removed 
from the blister pack. These data are useful in understanding patterns of non-adherence, including 
errors in the number of pills taken for each dose, the number of actual doses taken, and the number of 
hours between each dose. The research paper in Chapter 7 constitutes the most detailed report in the 
literature to date of how ACTs are taken.  
Despite the novel advantages of the smart blister packs, there were several notable issues. First, 
while the packs were easy to assemble and graphically looked identical to the Coartem® available in 
Tanzania, the slight bulge of the data chip was more prominent than in the samples provided by the 
company as examples. Due to the expense of the smart blister packs and time constraints, we were not 
able to pilot the final smart blister pack product prior to the study. The majority of dispensers and 
patients did not notice or were not concerned with the slight bulge in the packaging. However, some 
patients did become suspicious and open the packs to investigate. In several villages in one district 
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(Tandahimba), the positive sign on the small battery component of the chip was interpreted to be a 
symbol of the highly distrusted free masons group, angering some community members and causing 
suspicion of the research teams. However, village leaders, dispensers, and affected community 
members were receptive to meetings held with study leaders explaining the design of the blister packs 
and research objectives as a whole, and the study was able to continue.  
Although approximately 20% of patients had damaged blister packs, this appeared to have only 
a minimal impact on results. Self-reported completed treatment was actually slightly higher for patients 
with damaged packs compared to those with smart blister pack data available, and was not different 
from self-reported completed treatment among a similar number of patients that had obtained regular 
packs (dispensed from outlets’ own stock or provided by the study team when supplies of smart blister 
packs ran low). One of the main reasons given for damaged packs was that children had been allowed to 
play with them following treatment. The majority of patients with intact smart blister packs had not 
noticed the special nature of the pack, and very few patients (less than five) gave concern over the pack 
as a reason for not completing treatment. 
Following completion of our research, meetings were held with leaders in each administrative 
division of Tandahimba district by IHI to discuss community concerns and perceptions about research 
conducted by IHI projects. A newsletter about IHI and details of our studies was distributed, including 
information on the smart blister packs. The majority of concerns raised at the meetings were about 
clashes with the government regarding cashew crop payments and various general questions about 
malaria, maternal health, and HIV. The association of IHI with free masons was mentioned only briefly in 
one division and appeared to have not caused widespread concern.  
A second challenge with the smart blister packs was realised during the analysis phase, when 
data were laborious to work with. According to our design, a separate timestamp was recorded for each 
tablet. However, these timestamps had to be grouped manually into doses, which may have 
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inadvertently introduced error. Had we been able to pilot the smart blister packs, it is possible that we 
could have worked with the company to design a relatively simple programming solution that would 
have made the data easier and quicker to work with. This should be considered by any future projects 
that use smart blister packs for ACTs.   
Measuring blood levels of lumefantrine. In addition to the use of smart blister packs, we also 
collected dried blood spot filter papers for analysis of lumefantrine concentrations. These data could 
have been a great asset to the research paper comparing methods of assessing adherence (Chapter 7). 
Following data collection, filter papers were stored for 19-24 months, mostly in Switzerland, while 
waiting for equipment and funding for the analysis to become available. When finally analysed, most 
filter papers had lumefantrine concentrations below the lower limit of quantification. As the methods 
used in the lab had been previously validated, either the storage conditions or the lengthy period prior 
to analysis are the most likely reasons for the poor lumefantrine recovery [7]. 
 
8.2.2 Studying the private for-profit sector 
The research paper in Chapter 6 represents one of the first studies to report adherence to 
antimalarial drugs obtained in the private for-profit sector and to follow-up and compare patients 
attending outlets in both public and private sectors, which is important given the role of the private for-
profit sector in provision of antimalarials [8]. This was also the first study to examine adherence to 
antimalarial drugs in ADDOs. In Tanzania, ADDOs are a major source of antimalarial drugs [9], and the 
ADDO model has been cited as an example for regulation of drug stores in other countries [10]. In 
addition, this was one of the first studies to assess adherence to AMFm co-paid ACTs, helping to address 
a gap in evidence that was not considered in the AMFm Independent Evaluation [11]. Another recent 
study including both public and private for-profit outlets was conducted in Ghana, where AMFm-
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subsidised drugs were also available [12]1. This study reported a slightly lower percentage of patients 
completing treatment compared to our study (62%, compared to 70% in ADDOs).  
One limitation of our study comparing adherence to AL obtained in public health facilities and 
ADDOs is that dispenser interviews were not conducted at health facilities. A frequently raised concern 
regarding treatment of malaria in the private retail sector is that dispensers may be less qualified than 
health facility dispensers and have less training and lower knowledge on treatment of malaria with ACTs 
[13]. In the analysis examining the effect of sector on patient adherence, we controlled for patient 
characteristics. It would have been interesting to also examine the effect of outlet-level and dispenser 
characteristics in sector-specific models, as done for patient report of factors related to care and advice 
received. In addition, this thesis did not address adherence to ACTs obtained at other less common 
sources of antimalarials, such as mission facilities, pharmacies, general shops, and community health 
workers. 
 
8.2.3 Evaluation of the text message intervention in ADDOs 
Chapter 5 reports one of the first intervention studies to improve patient adherence to ACTs 
obtained in the private for-profit sector. (Two other similar randomised controlled trials have recently 
been conducted and will be discussed in Section 8.3 below.)  
Text message intervention. The strengths and limitations of the text message intervention are 
considered in detail in the research paper in Chapter 5. As discussed in Section 8.1, one important 
finding was that dispenser knowledge in the control arm was higher than expected, which might have 
been partly due to the recent refresher training in Mtwara that had covered ACTs. While knowledge of 
the message content was evaluated at the dispenser level, several of the messages (e.g. taking the first 
dose under observation at the outlet, taking with fatty food, and obtaining a replacement dose in case 
                                                          
1
 This study was not included in the literature review in Chapter 2, including the update in Chapter 2.3, as it was 
not published by the end of September 2014. 
169
 
 
of vomiting) were not part of the verified completed treatment and verified timely completion outcome 
measures (although these characteristics are described for both ADDO and public health facility patients 
in Chapter 6).  
Strengths and limitations of study and evaluation design. The study was designed as a CRT, with 
the text message intervention randomly allocated at the cluster level (ADDOs). The advantages of this 
study design include reducing selection bias and confounding through the random allocation of the 
intervention and minimizing contamination between control and intervention arms. However, this 
design and additional efforts to limit potential Hawthorne effects and recall bias likely caused the 
evaluation setting to be different than if the intervention was applied in a programmatic setting, as the 
latter might involve being more explicit about raising awareness about adherence in both the shops and 
the community.  
Secondly, the intervention was evaluated by patient interviews, followed by dispenser 
interviews. These methods were chosen to assess the effect of the intervention on both dispensers and 
patients, while limiting potential sources of bias. However, the evaluation might have been 
strengthened by the inclusion of additional types of data collection. For example, exit interviews might 
have provided insight into where the intervention broke down- either at the point of dispenser 
communication with patients, or with patients’ subsequent recall and behaviour. Mystery clients might 
have allowed us to more accurately assess dispenser communication. Qualitative data collection could 
also have been useful for understanding perceptions of dispensers and patients, why some advice was 
not communicated, and why some patients were non-adherent.  
 
8.3  Thesis implications 
 This section begins by examining the importance of adherence for treatment effectiveness. 
Implications related to comparing adherence studies and measuring adherence are then discussed, 
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followed by possible reasons for differences in adherence between sectors and generalizability of these 
results. Finally, potential interventions to improve adherence are considered.  
Does adherence matter? “Drugs don’t work in patients who don’t take them.” This quote from 
C. Everett Koop, cited in a review of adherence to medication across diseases [14], reflects a concept 
mentioned ubiquitously in studies on adherence to antimalarials. This thesis also states that patient 
adherence to ACTs is important in order to avoid treatment failure and limit resistance to ACTs. 
However, as mentioned in Chapter 1, there is very little data on how adherent patients must be in order 
to avoid treatment failure.  
Early trials indicated that a four-dose regimen of AL was less effective than a six-dose regimen 
[15, 16]. One trial compared the four-dose regimen to a 3 day six-dose regimen and a 5 day six-dose 
regimen and found day 28 cure rates of 83.3%, 96.9%, and 99.1% [17]. While there was a significant 
difference between the four-dose regimen and the six-dose regimens, there was no difference between 
the two six-dose regimens, as also reported by a second study comparing these three regimens, over a 
42-day follow-up period [18]. Interestingly, most studies of adherence to AL, including those reported in 
this thesis, interview patients on day 4 (Chapter 2), categorising patients that would have finished AL 
within 5 days as non-adherent. Although patients taking the six-dose regimens were shown to have 
higher day 7 lumefantrine levels than those taking the four-day regimen [18], sufficient therapeutic 
levels of drug can still be achieved in many patients in less than six doses. 
Studies examining differences in treatment effectiveness between adherent and non-adherent 
patients have not reported significant differences [19-21]. While one study reported slightly higher 
treatment failure rates to artesunate-mefloquine in an unsupervised group compared to a supervised 
group (3.9% vs. 0.0%, p=0.015) [22], studies of AL have not [21, 23, 24]. This may be due to very high 
adherence (>90%) and / or very high cure rates (>95%) in both supervised and non-supervised groups. 
Additional studies are required in which adherence and effectiveness are assessed but with minimal or 
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no interaction with study staff prior to taking the treatment course. This is challenging, as malaria must 
be confirmed in these patients at the time of obtaining treatment, and consent must be requested from 
patients prior to collecting blood samples. Patients must also be monitored for treatment failure for 42 
days. As demonstrated in Chapter 2, greater interaction with study staff and awareness of the research 
are likely to inflate adherence. 
This study did not assess the effectiveness of treatment obtained. The study aimed to assess 
adherence to AL obtained routinely from ADDOs and health facilities, and thus two-thirds of the patients 
who obtained AL tested negative by RDT performed by the study team on day 4 and probably did not 
have malaria at the time of seeking care. Of 1,422 patients from both sectors combined, 35.5% were 
RDT positive and 2% were positive by reference blood smear collected on day 4. There was no 
difference between adherent and non-adherent patients in the percentage of patients testing positive 
by RDT that had a positive blood smear (Chapter 6.3). While this indicates good parasite clearance for 
both adherent and non-adherent patients, a much longer follow-up period (e.g. to 42 days) would have 
been required formally to assess treatment failure. 
While completing six doses may not be essential for all patients, it is likely necessary on a 
population level, as the recrudescence rates in the four-dose regimen were unacceptably high in some 
settings [18, 25]. It is also important to limit the proportion of patients that are exposed to sub-
therapeutic levels of treatment, which can select for resistant parasites [26, 27]. However, the rationale 
behind exact timing of doses is less clear. The recommended schedule for each dose is 0, 8, 24, 36, 48, 
and 60 hours, also described as “at the time of diagnosis, 8 hours later, and then twice daily (morning 
and evening) on each of the following two days” [28]. The schedule is presumably derived from the 
concentration profiles of the partner drugs, although likely selected to a degree to conveniently fit six 
doses within three days. In this thesis, verified timely completion was much lower than completed 
treatment. Depending on the importance of timely completion for effectiveness, this may or may not be 
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of major concern. As national guidelines and interventions are implemented to improve timely 
completion, the basis behind the recommended regimen must be clarified (Table 1).  
Similarly, intake of a small amount of fat with AL has been shown to affect lumefantrine 
absorption. According to the WHO Guidelines for the Treatment of Malaria, it is essential for patients 
and caretakers to be informed that they should take AL immediately after a meal or drink containing at 
least 1.2 g of fat [29]. However, in Tanzania the national guidelines specify taking AL with food and are 
ambiguous as to whether or not the food must contain fat [30, 31]. In the studies reported in this thesis, 
dispenser knowledge of the need to take AL with fatty food was significantly lower in the control arm 
(20%) than in the intervention arm (60%), and less than 10% of both public health facility and ADDO 
patients took all six doses with fatty food or milk. If taking each dose with fat is essential to 
effectiveness, as stressed by the WHO guidelines, then this message must be communicated more 
clearly across health sectors. The relative importance for effectiveness of AL should also determine if fat 
intake should be incorporated into adherence definitions, similar to the inclusion of dose timing 
discussed above. On the other hand, there could be potential confusion with instructions for DHA-
piperaquine, the second-line treatment in Tanzania, which according to national guidelines should be 
taken with water only and no food to minimise the risk of adverse cardiac events [31, 32].  
Comparing adherence studies. The literature review in Chapter 2 showed wide variation in 
adherence studies and makes clear that adherence studies are not all equal. Studies conducted under 
routine conditions cannot be compared to clinical trials or other studies where patients are subject to 
more interaction with study staff, testing, and careful monitoring. Comparing studies using different 
definitions or approaches to assessing adherence is also problematic. Even among similar studies, for 
example those assessing completed treatment or timely completion, the number of days of follow up 
allowed or the stringency of time intervals considered correct can alter adherence levels, which must be 
taken into account when interpreting results. Future studies reporting adherence need to be very 
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specific about the objectives, methods, and generalizability of results, and caution should be used when 
comparing results across studies (Table 1).  
How to measure adherence. Self-reported data on adherence is the most feasible and least-
expensive method of data collection. Compared to smart blister packs, we found good sensitivity and 
specificity of self-reported completed treatment. However, both sensitivity and specificity of self-
reported timely completion were suboptimal (both 74%). Smart blister pack data provided more 
accurate data on when each pill was taken, which would be useful for studies where this type of data is 
needed. It also showed that both taking an incorrect number of pills and taking them at incorrect times 
contributed to non-adherence. However, the expense and some of the challenges encountered in the 
field may not make smart blister packs ideal for routine measurement of adherence.  
Collection of self-reported adherence data needs to be improved in order to yield less biased 
and more accurate results. Limiting interaction with study staff and requesting informed consent at the 
time of the follow up interview when possible may reduce patient awareness of their adherence being 
monitored. Shorter time periods for running the study at each outlet might limit awareness in the 
community of study objectives and thus also help avoid a Hawthorne effect. Pill counts conducted at the 
time of interview are probably beneficial to avoid over-report of adherence, though evidence of this is 
limited (Chapter 2.3). Finally, further work is needed to assess the most appropriate way of asking dose-
specific questions so as to avoid leading questions and patient confusion. Standard adherence 
definitions and approaches that minimise potential Hawthorne effects should also be agreed upon. This 
could possibly involve the development of a standardised questionnaire, although cultural factors such 
as different concepts of time could make this challenging. 
Adherence in the public and private for-profit sectors. As mentioned above, this was one of the 
first studies to assess adherence to ACTs from the private for-profit sector. Although adherence was low 
in both sectors, our study found some evidence that adherence was lower in ADDOs (Table 1). There are 
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several possible explanations for this. First, dispenser characteristics, such as training on ACTs, might 
have been lower among ADDO dispensers, resulting in provision of less or poorer quality advice to 
patients. However, both public health facility and ADDO patients reported receiving similar levels and 
types of advice on how to take AL. Lower training or other factors could have affected the dispenser 
rapport with patients, and advice might not have been expected or followed [33].  
Secondly, public health facility patients were more likely to actually have malaria and may have 
been more ill and therefore more likely to take treatment. However, it is difficult to discern which 
patients were most ill from patients’ report of symptoms, none of which were associated with 
adherence. More than 90% of patients reported having had fever, while more public health facility 
patients reported respiratory symptoms (14% vs. 7.5%, p=0.007), and more ADDO patients reported  
body pain (30% vs. 15%, p<0.0001) and fatigue (18% vs. 10%, p=0.003). Very few patients reported 
convulsions, though this was significantly higher in public health facility patients (2.5% vs. 0.4%, 
p=0.007). At interview on day 4, more than 90% in both sectors reported they could work or play. As an 
alternative to asking about the presence or absence of specific symptoms, a recent study of adherence 
to AL from drug shops in Uganda used ladder scales from 1-10 to help patients gauge symptom severity 
(Cohen et al., in draft)2. The study found that patients reporting having had more severe symptoms 
halfway through the treatment course were more likely to complete treatment.  
A third potential reason for the difference in adherence between sectors is that more patients 
took the first dose of AL at health facilities compared to ADDOs (41% vs. 10%, p<0.0001), which might 
have started patients out on the right track. Although more patients were tested at health facilities (54% 
vs. 11%, p<0.0001), there was no clear association of the effect of testing on adherence in either sector. 
Further attention should be given to understanding these dynamics and differences between sectors in 
order to best target interventions to optimise care. 
                                                          
2
 This study was not included in the literature review in Chapter 2, including the update in Chapter 2.3, as it has not 
yet been published (December 2014). 
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One could argue that lower adherence in ADDO patients could be a reason not to continue a 
subsidy of ACTs in these outlets. However, the differences in adherence levels were not so large and, as 
noted above, the reasons for the differences remain unclear. Moreover, even if subsidised ACTs were 
not available in ADDOs (as was previously the case) patients would likely continue to seek care at these 
outlets, but obtain less effective antimalarials. 
The findings described are likely generalizable to much of rural and peri-urban Tanzania, 
although generalizability to ADDOs in urban areas, which were not evaluated in our studies, is less clear. 
Although ADDOs have been scaled up nationwide, ADDOs in some areas received less training on ACTs, 
which could negatively impact advice dispensed and patient adherence in the absence of an 
intervention. ACTs might also not be as available or as affordable now compared to 2012, and the 
effects of training and community sensitization conducted around AMFm could be weakened. It is also 
unclear how generalizable these results are to other countries with similar drug stores, as other 
contextual factors could affect adherence. However, the two other studies of adherence to ACTs in drug 
stores mentioned above have reported only slightly lower completed treatment (66% in Uganda and 
62% in Ghana, compared to 70% in our study) [6, 12]. 
Interventions to improve adherence. The private retail sector is a major source of treatment for 
malaria in Tanzania and in many malaria-endemic countries [34-38], and this is likely to continue. In both 
sectors, but particularly the private retail sector, interventions are needed to improve patient adherence 
to ACTs (Table 1). Although the text message intervention evaluated in this thesis did not have an 
impact on adherence, a similar intervention may still have potential for improving dispenser knowledge 
and encouraging provision of information to patients. Text messages to dispensers might be more 
effective with additional piloting, and in a setting where dispensers have not received recent training. 
The potential of utilising text messages should continue to be explored, given the low cost and relative 
ease of implementing this type of intervention, and the positive effects observed with health workers in 
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Kenya [39]. In this study by Zurovac et al. (discussed in Chapter 5.2), estimated costs under trial 
conditions were $0.50 per additional child correctly managed, with $98,000 needed for national scale up 
(only 1% of Kenya’s Global Fund award to strengthen malaria case-management) [40].  
Other studies are examining the effect of text messages targeted directly at patients. The study 
by Raifman (Goldberg) et al. in Ghana in public and private outlets demonstrated that a short text 
message reminding patients to “Please take your malaria drugs” increased the odds of completing 
treatment (adjusted OR=1.45, 95% CI [1.03 to 2.04]; p= 0.028), but there was no effect on adherence of 
a longer text message compared to the control group [12]. The full course of treatment was completed 
by 61% of AL patients and 62.5% of artesunate-amodiaquine patients (61.5% overall) in the control 
group. Adherence was 66.4% among patients receiving the short text message and higher in patients 
who obtained treatment in the public sector versus the private sector. Although the impact of the text 
messages was not large in this study, the authors suggested that different message content might have 
a greater effect and should be evaluated. In Kenya, a study is currently testing the effect on adherence 
to AL of text messages targeted at public health facility patients (D Zurovac and A Talisuna, personal 
communication). 
Other interventions that have been shown to increase patient adherence to antimalarials 
include improved packaging and a combination of community education and visual or verbal 
information provided to patients [41]. ACTs are already available in co-formulated blister packs, often 
with pictorial instructions. Package instructions for AL (e.g. Coartem®) assume that patients begin 
treatment in the morning, as depicted by pictures of the sun and moon for three days. Packaging could 
be modified to include instructions for patients who begin care later in the day, common in the private 
retail sector. This might depend on the importance of timely completion. On the other hand, a study in 
Uganda comparing the effect of different packaging found that a sticker affixed to a box of AL with the 
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message, “Malaria is not gone until ALL the tablets are finished” was more effective than colourful 
blister packs in raising the proportion of patients that completed treatment (Cohen et al., in draft). 
A combination of approaches is likely necessary to improve patient adherence. A study in Kenya 
showed that the provision of subsidised ACTs to drug shops, training of retail staff, and community 
awareness activities improved patient completion of treatment from 49% to 67% in household surveys 
[42]. Dispensers need to be appropriately trained and supervised on provision of advice on how to take 
ACTs, but community education or other interventions to enhance patient responsiveness to advice may 
also be required. Although our study did not find evidence that patients who were tested for malaria at 
the outlet were more likely to be adherent, a high proportion of ADDO patients did not have malaria by 
study RDT. Recent studies have shown that the use of RDTs in drug shops can reduce over-treatment of 
malaria (Visser et al., under review). In Tanzania, efforts are currently underway to evaluate the use of 
RDTs in ADDOs (K Maloney, personal communication).  
Finally, patient adherence is only one step in the pathway to treatment effectiveness and must 
not be considered in isolation to other health systems and individual factors [43]. Prompt access to 
ACTs, targeting ACTs to patients that have positive diagnostic tests, and provider compliance to test 
results and guidelines must also be addressed.  
8.4  Conclusion 
This thesis describes one of the first studies to assess patient adherence to ACTs in the private 
for-profit sector, where access to malaria treatment and appropriate use of ACTs must be ensured in 
order to reduce the burden of malaria. While adherence was suboptimal in both public and private 
sectors, there was some evidence of lower adherence among ADDOs, which calls for the need to better 
understand and support malaria treatment at drug shops. Future research priorities include developing 
a better understanding of the impact of care provided at outlets in both sectors on patient adherence to 
AL and characterising the reasons for non-adherence. These data should then support the design and 
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evaluation of additional interventions targeted at both dispensers and patients to improve patient 
adherence. Data collection tools based on self-report should be optimised and evaluated, and smart 
blister packs could be improved for studies that require collection of precise data on dose timing. There 
is also a need to clarify which components of adherence are necessary for treatment effectiveness in 
order to provide clear guidance to providers and patients, as well as to inform investigators assessing 
adherence levels and interpreting results. 
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Appendices 
Introduction 
 Appendix 1 provides examples of useful forms and tools. These include an outlet agreement 
form translated from Swahili (Appendix 1a), which demonstrates how dispensers were asked to 
participate in the studies; the registration form dispensers were asked to fill (adapted from a version 
on larger sized paper) (Appendix 1b); and an excerpt from the patient questionnaire showing how 
self-reported data on each dose were collected (Appendix 1c). 
 Appendix 2 contains three letters documenting ethical clearance. The first is the approval 
from LSHTM for the original protocol, followed by a letter approving an amendment to the protocol 
to allow for testing of patients with RDTs. The third letter is the approval of the revised protocol 
(including the amendment) from IHI. 
 Appendix 3 contains two components related to the text message intervention study in 
ADDOs. In Appendix 3a, details of the ADDO census, selection, and randomisation are presented. 
This is followed by the full schedule of text messages in Appendix 3b. 
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Appendix 1a: Outlet agreement form (English version) 
 
If, at any time, you have any questions about this study, please ask the project manager (Dr. Admirabilis Kalolella, PO Box 78373, 
Dar es Salaam or 022-277-4714).  
 
Evaluation of patients treated at health facilities or drug stores in Mtwara: 
Invitation to participate 
 
The Ministry of Health, Ifakara Health Institute, London School of Hygiene and Tropical Medicine and the 
U.S. Centers for Disease Control (CDC) are working with each other to improve malaria programs and 
appropriate treatment for malaria.  To do this, we are conducting a research study to improve what we 
know about malaria treatment and how people in this region prefer to take medicine for malaria.  
 
We would like to invite you to participate in our study without interrupting your regular treatment 
practices.  If you agree, we would like you to record brief information about every patient whom you treat 
for malaria or fever in our study log for one week only.  This information includes the drugs that are 
dispensed to the patient and details about how to find their homes, in case we want to visit them for our 
study.   
 
If you do agree to participate, we will provide you with 13 packs of AL to give to patients (health facilities) 
or to sell yourself at the subsidized price recommended by the government (drug shops).  We ask that you 
dispense the AL that we provide to no more than five patients per day.  Our study team will be the area and 
will ensure that you have enough AL for each age group, but if we give you more than 13 packs, we ask that 
you return the extra packs at the end of the week so that we can continue our work at other outlets. 
 
You are free to participate or not without any punishment or complaints, though we will be very happy if 
you do agree to participate in this study. 
 
We will be happy to answer any questions you might have. 
 
Do you agree to participate? 
 
 
Signature: _____________________________________________             ___________________ 
  
               Date 
Printed name: __________________________________________ 
 
 
Signature of study team member: _______________________ ___       ___________________  
           
                         Date 
Printed name: ____________________________ 
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Appendix 1b              Outlet ID: 
              Outlet Name:  
              District: 
              Date: 
 
 
              Date Collected: 
              Collected By: 
Registration Form 
For patients treated for fever or malaria 
Patient Name  
(If attending outlet on behalf of 
another person, ask the name of the 
person who is ill) 
Time 
(Please use 
Swahili time)  
Patient 
age 
Name of antimalarial 
drugs dispensed 
If ALu dispensed, 
which pack? 
If ALu dispensed, 
how many pills? 
Name of head of 
patient’s household 
Village and sub-
village where 
patient stays 
Location of house 
where patient stays 
Mobile number of 
patient or relative 
Staff 
initials 
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Appendix 1c 
 
Excerpt from patient questionnaire  
Note: Interview data was collected using personal digital assistants. 
Questions about taking the ALu obtained at the study outlet 
  
Number   
The next questions will refer to the 
ALu that was obtained at (name of 
study outlet). 
Maswali yafuatayo yatahusu ALu 
iliyopatikana katika (jina la kituo 
kinachofanyiwa utafiti).     
 
  
  
158 ALuPack 
Which blister pack of ALu was 
obtained at (name of study outlet)?  
Ni aina ipi ya kifungashio cha ALu 
kilichopatikana (jina la kituo 
kinachofanyiwa utafiti)? 
integer If AluPack=5 go to Q158, otherwise go to 
Q159 
  1= 1x6 (yellow) 1= 1x6 (njano) 
  2= 2x6 (blue) 2= 2x6 (bluu) 
  3= 3x6 (orange) 3= 3x6 (machungwa) 
  4= 4x6 (green) 4= 4x6 (kijani) 
  5=loose pills or incomplete pack 5=vidonge visivyofungashwa au 
kifungashio kisicho kamili 
  9=don't know 9=sijui 
  
159 PillNum1 
Number of pills dispensed Idadi ya vidonge vilivyotolewa numeric   
  |__|__| . |__| 99.9=don't know |__|__| . |__| 99.9=don't know 
  
160 ALuCost 
How much money was paid to 
obtain ALu? 
Ni kiasi gani cha pesa kilichotolewa 
kupata ALu? 
numeric   
  TSH |__|__|__|__|__|   TSH |__|__|__|__|__|   
  0=none, free 0=hakuna,bure 
  9=don't know 9=sijui 
  
161 DoseNum 
How many doses of ALu have been 
taken so far? 
Umemeza/Mgonjwa amemeza 
dawa mara ngapi hadi muda huu? 
integer  If DoseNum=0 go to Q161, otherwise skip 
to Q163 
  0=none  0=hakuna 
  1=1 1=1 
  2=2 2=2 
  3=3 3=3 
  4=4 4=4 
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5=5 5=5 
  6=6 6=6 
  7=more than 6 doses 7=zaidi ya dozi 6 
  9=don't know 9=sijui 
  
162 DoseNoneR 
Why did the patient not take any 
ALu? 
Kwa nini mgonjwa hakutumia ALu? Integer If DoseNoneR=18 go to Q162, otherwise 
skip to Q260 
  1=forgot 1=alisahau 
  2=felt better 2=alijisikia vizuri 
  3=gave to another person 3=alimpa mtu mwingine 
  4=saved for later use 4=alitunza kwa matumizi ya 
baadae 
  5=was lost or stolen 5=zilipotea au kuibiwa 
  6=did not understand instructions 6=hakuelewa maelekezo 
  7=patient has had adverse reaction 
to this medication before 
7=mgonjwa alipatwa na madhara 
ya dawa hii awali. 
  8=bad taste 8=ladha mbaya 
  9=didn't know it was needed 9=hakujua zinahitajika 
  10=took another medication 10=alimeza dawa zingine 
  11=plan to take later 11=anategemea kumeza baadae 
  18=other  18=ingine 
  
163 DoseNoneRSp 
Specify another reason the patient 
did not take any ALu. 
Taja sababu nyingine za mgonjwa 
kutotumia ALu. 
text Skip to Q260 
  
164 GaveDose 
Who usually gave the patient 
his/her medication at home? 
Je, kwa kawaida ni nani anayempa 
mgonjwa dawa nyumbani? 
integer   
  1=patient 1=mgonjwa 
  2=mother 2=mama 
  3=father 3=baba 
  4=grandmother 4=bibi 
  5=grandfather 5=babu 
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6=aunt 6=shangazi, mama mdogo, mama 
mkubwa 
  7=uncle 7=mjomba, baba mdogo, baba 
mkubwa 
  8=sister 8=dada 
  9=brother 9=kaka 
  10=other relative 10=ndugu mwingine 
  11=other non-relative 11=mwingine ambaye si ndugu 
  
165 Dose1Taken 
Was the first dose of ALu taken? Je, dozi ya kwanza ya ALu 
ilitumiwa?  
integer If Dose1Taken=1 go to Q166 , otherwise go 
to Q165 
    (Kila mgonjwa alimezapo dawa 
inahesabika kama ni dozi.) 
  1=yes; 2=no; 9=don't know 1=ndiyo; 2=hapana; 9=sijui 
  
166 Dose1TakenR 
Why was the first dose of ALu not 
taken? 
Je, kwanini dozi ya kwanza ya ALu 
haikutumiwa? 
integer If Dose1TakenR=18 go to Q167, otherwise 
If Dose1TakenR= 7 go to Q168, otherwise 
go to Q169  
If dose1takenR=11 then pop up msg ni 
kweli anategemea kumeza baadae?  
  1=forgot 1=alisahau 
  2=felt better 2=alijisikia vizuri 
  3=gave to another person 3=alimpa mtu mwingine 
  4=saved for later use 4=alitunza kwa matumizi ya 
baadae 
  5=was lost or stolen 5=zilipotea au kuibiwa 
  6=did not understand instructions 6=hakuelewa maelekezo 
  7=adverse reaction to the 
medication 
7=mgonjwa alipatwa na madhara 
ya dawa hii awali 
  8=bad taste 8=ladha mbaya 
  9=didn't know it was needed 9=hakujua zinahitajika 
  10=took another medication 10=alimeza dawa zingine 
  11=plan to take later 11=anategemea kumeza baadae 
  18=other  18=ingine 
  
 
Dose1IntendTime 
What time do you intend to take 
the first dose? 
Je, unategemea kumeza dozi ya 
kwanza saa ngapi? 
integer  
  
 
1=early morning (4am-6am) 1=alfajiri (Saa 10-12:59) 
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167 2=morning (7am-11:59am) 2=asubuhi (Saa 1-5:59) 
  
 
3=afternoon (12noon-3:59pm) 3=mchana (Saa 6-9:59) 
  
 
4=evening (4pm-6:59pm) 4=jioni (Saa 10-12:59) 
  
 
5=night (7pm-9:59pm) 
6=late night (10pm-3:59am) 
5=usiku (Saa 1-3:59) 
6=usiku sana (Saa 4-9:59) 
  
168 Dose1RSp 
Specify another reason the patient 
did not take the first dose of Alu. 
Taja sababu nyingine, kwanini 
mgonjwa hakutumia dozi ya 
kwanza ya ALu. 
text   
  
169 
Dose1Adverse1...Dose1Adve
rse3 
Specify the adverse reaction to the 
medication. 
Taja madhara ya dawa.   text Repeat several times for multiple adverse 
reactions 
  
170 Dose1Where 
Where was the first dose taken? Je, dozi ya kwanza ilitumiwa wapi?  integer   
  1=at (name of study outlet) 1=katika (jina la kituo 
kinachofanyiwa utafiti) 
  2=at home 2=nyumbani 
  3=other 3=ingine 
  
171 Dose1Day 
How many days ago was the first 
dose taken? (Identify the EXACT 
day) 
Je, dozi ya kwanza ilitumiwa siku 
ngapi zilizopita (Onyesha siku 
HUSIKA) 
numeric   
  |__|__| 00=today; 99=don't know |__|__| 00=leo; 99=sijui 
  
172 Dose1Time 
What time was the first dose 
taken? 
Je, dozi ya kwanza ilitumiwa saa 
ngani? 
integer   
  1=early morning (4am-6:59am) 1=alfajiri (Saa 10-12:59) 
  2=morning (7am-11:59am) 2=asubuhi (Saa 1-5:59) 
  3=afternoon (12noon-3:59pm) 3=mchana (Saa 6-9:59) 
  4=evening (4pm-6:59pm) 4=jioni (Saa 10-12:59) 
  5=night (7pm-9:59pm) 
6=late night (10pm-3:59am) 
5=usiku (Saa 1-3:59) 
6=usiku sana (Saa 4-9:59) 
  
173 
Dose1Pills 
How many pills were taken for the 
first dose? 
Je, vidonge vingapi vilitumiwa 
katika dozi ya kwanza? 
numeric double entry required 
  |__|__|.|__| |__|__|.|__| 
  
 
99.9=don't know 99.9=sijui 
  
174 Dose1Meal 
Did the patient have any food or 
drink in the hour before taking the 
first dose? 
Je, mgonjwa alikula au kunywa 
chochote saa moja kabla ya 
kutumia dozi ya kwanza? 
integer   
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1=yes; 2=no; 9=don't know 1=ndiyo; 2=hapana; 9=sijui 
  
175 Dose1MealType 
Which type of food or drink did the 
patient have? 
Ni aina gani ya chakula au kinywaji 
mgojwa amepata? 
check box If Dose1MealType=8 go to Q175, otherwise 
continue with Q176 
  
  
  
  
  
  
  
  1=food without oil (fruits, ugali or 
rice cooked without oil) 
1=chakula kisicho na mafuta 
(matunda, ugali au wali uliopikwa 
bila mafuta) 
  2=food with oil (peanuts, cashews, 
avocado, foods cooked with oil, 
meat, fish, etc.) 
2=chakula chenye mafuta 
(karanga, korosho, parachichi, 
chakula kilichopikwa na mafuta, 
nyama, samaki, n.k.) 
  3=milk 3=maziwa 
  4=water 4=maji 
  5=soda  5=soda 
  6=chai 6=chai 
  8=other 8=ingine 
  9=don't know 9=sijui 
  
176 Dose1MealSp 
Specify other food or drink that 
was taken with the first dose. 
Taja chakula au kinywaji kingine 
ambacho kilitumiwa pamoja na dozi 
ya kwanza. 
text   
  
177 Dose1Vomit 
Did the patient vomit within 30 
minutes of taking the first dose of 
the medication? 
Je, mgonjwa alitapika ndani ya 
dakika 30 baada ya kutumia dozi ya 
kwanza ya dawa?  
integer If Dose1Vomit=1 go to Q178, otherwise go 
to Q177 
  1=yes; 2=no; 9=don't know 1=ndio; 2=hapana; 9=sijui 
  
178 Dose1VRedose 
Did the patient take a replacement 
dose of the medication after 
vomiting the first dose? 
Je, mgonjwa alirudia dozi ya dawa 
baada ya kutapika dozi ya kwanza? 
integer   
  1=yes; 2=no; 9=don't know 1=ndio; 2=hapana; 9=sijui 
   
Questionnaire continues with Doses 2-6, as in Q165-178. 
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Appendix 2: Ethical clearances  
(Approval letters on next page) 
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Observational / Interventions Research Ethics Committee 
 
Katia Bruxvoort 
Research Degree Student 
DCd/ITD 
LSHTM 
 
15 June 2012  
 
Dear Ms Bruxvoort, 
 
Study Title: Evaluation of patient adherence to Artemether lumefantrine obtained 
from public and private drug outlets in Tanzania 
LSHTM ethics ref: 6205 
 
Thank you for your application of 15 May 2012 for the above research, which has now been considered by the 
Interventions Committee.  
 
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis 
described in the application form, protocol and supporting documentation as revised, subject to the conditions 
specified below. 
 
Conditions of the favourable opinion 
Approval is dependent on local ethical approval having been received, where relevant.   
 
Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document Version Date 
LSHTM ethics application  n/a 14/05/2012 
Protocol V001  14/05/2012 
Information Sheet  14/05/2012 
Consent form   14/05/2012 
 
After ethical review 
Any subsequent changes to the application must be submitted to the Committee via an E2 amendment form.   All 
studies are also required to notify the ethics committee of any serious adverse events which occur during the project 
via form E4.  An annual report form (form E3) is required on the anniversary of the approval of the study and should 
be submitted during the lifetime of the study.  At the end of the study, please notify the committee via form E5.   
 
Yours sincerely, 
 
 
 
 
 
 
Professor Andrew J Hall 
Chair 
ethics@lshtm.ac.uk  
http://intra.lshtm.ac.uk/management/committees/ethics/  
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After ethical review 
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anniversary of the approval of the study and should be submitted during the lifetime of the study.  At the end of the 
study, please notify the committee via form E5.   
 
Yours sincerely, 
 
 
Professor Andrew J Hall 
Chair 
ethics@lshtm.ac.uk  
http://intra.lshtm.ac.uk/management/committees/ethics/  
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Appendix 3a: ADDO sampling and randomisation methods 
ADDO census. A census of all ADDOs in Mtwara Region was conducted to identify location (GPS 
coordinates and time to reach by car from the district headquarters), antimalarials in stock and the 
number of each antimalarial sold in the previous seven days, and mobile phone use of each dispenser.  
In addition, information was collected on ADDO ownership (name of owner and other ADDOs owned), 
whether dispensers work at any other ADDOs and names of these ADDOs , whether any close relatives 
(“ndugu wa karibu”) work at any other ADDOs and names of these ADDOs, and dispenser age, 
education, health-related qualifications, and malaria-containing trainings received in previous five years. 
Dispensers were also asked about the number of people working in other ADDOs with whom they 
communicate, location of these ADDOs, and frequency of communication. Finally, dates of registration 
and accreditation were recorded.1 
Preparation of sampling frame. Of the 156 ADDOs censused, two were removed from the sampling 
frame due to location on the Mozambique border (with potential for customers to live on either side), 
one was in a prison area, one refused to complete the census, and one ADDO was censused twice. The 
remaining 151 ADDOs were then checked against the following exclusion criteria.  
i. More than 60 minutes by study car required to arrive at ADDO from district headquarters- This 
was very subjective, as study teams conducting the census did not always come from the district 
headquarters. Comparison with other sources of data (e.g. Google Earth and the IHI Mtwara 
team) was necessary to determine the time required to reach each ADDO. Since only one of the 
151 ADDOs was located more than 60 minutes away (at 75 minutes), the maximum time for 
reaching each ADDO was increased to 75 minutes. Thus, no ADDOs were excluded based on this 
criterion. 
                                                          
1
 Data on outlet and dispenser characteristics presented in Chapter 5 are based on the later dispenser interviews 
and not on the ADDO census. 
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ii. Sold less than five ACTs in the previous week- 14 ADDOs. Half of these shops had ACTs in stock 
and half did not. These 14 ADDOs were removed from the sampling frame. 
iii. At least one dispenser working at the ADDO did not use a mobile phone number- six ADDOs 
were removed from the sampling frame. 
The final sampling frame contained 131 ADDOs. 
Sampling procedure. The following steps were followed to conduct the sampling: 
i. Assign a random number in Stata to each ADDO.  
ii. Sort ADDOs by random number, and copy list to Excel. 
iii. Select the ADDO at the top of the list, beginning with the first random number.  
iv. See if dispensers working at the ADDO work at any other ADDOs or if any other ADDOs have the 
same owner.  If so, remove these other ADDOs from the sampling frame by deleting on Excel list 
and dropping from Stata.   
v. Use Stata geonear command to calculate the distance between each ADDO.   
vi. Check if the selected ADDO has any other ADDOs within 500 meters.  If so, remove these other 
ADDOs from the sampling frame by deleting on Excel list and dropping from the original Stata 
data file (not with all the distance matrix variables generated by geonear).  
vii. Save the Stata data file with a new name. 
viii. Go back to step iii, selecting the next ADDO on the list.  Repeat steps iii-viii, each time 
recalculating the distance matrix and saving with a new name. 
ix. Continue until 78-80 ADDOs are selected. 
Sampling results. Conducting this manual sampling process was very time consuming, with the first 
round taking nearly six hours. Upon completion, exactly 72 ADDOs had been selected. This was not 
sufficient, as 6-10 alternates were desired in case of ADDO closings or refusal to participate. Thus, the 
sampling was repeated by relaxing the criteria as follows:   
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i. ADDOs were excluded if they sold less than five antimalarial drugs instead of less than five ACTs. 
This added seven more shops to the sampling frame. 
ii. The minimum distance between shops was reduced to 400 meters. 
The second round of sampling resulted in 83 ADDOs. Of these, 57 were in peri-urban wards, 25 were 
in rural wards, and one did not have rural or urban defined and was inadvertently dropped, leaving 82 
selected ADDOs.  Had this second round or subsequent rounds not resulted in 72-80 ADDOs, I would 
have relaxed several criteria each time prior to repeating the sampling. 
Randomisation. While ADDOs were stratified by location in peri-urban or rural wards, restricted 
randomisation was not used.  The main reason for this decision was that the number of randomisation 
units was large, increasing the chances of a reasonably balanced sample.  Secondly, perfect balance on 
other variables, such as dispenser education and health-related qualifications or number of customers 
purchasing antimalarial drugs per day, was not thought to be essential, as the effect of these 
characteristics on dispenser advice is unclear. Thus, from the 82 selected ADDOs, the intervention was 
randomly allocated to 29 of the 57 urban ADDOs and 13 of the 25 rural ADDOs. The last three urban and 
rural intervention ADDOs and the last two urban and rural control ADDOs were designated as alternates, 
for a final count of 36 intervention, 36 control, and 10 alternate ADOOs. In practice, alternates were 
enrolled in the study to boost sample sizes, as overall patient registration was lower than expected.  
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Appendix 3b: Schedule of text messages 
 
Week 1 
Day 1 
Introduction message (send separately) (179 characters):  
Aksante kwa kusoma ujumbe huu, kuanzia sasa tutakutumia ujumbe mfupi wa maandishi kila siku kwa 
muda wa miezi miwili. Jishindie muda wa maongezi kwa kujibu maswali yatakayoulizwa. 
Content message (1): Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa. 
Complementary component: “Kauli njema haikusaidii wewe kupata faida pekee bali inakusaidia 
kujifunza vitu vipya kila siku.” 
MSG (147 characters):  
Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa. “Kauli njema haikusaidii 
kupata faida tu bali kujifunza vitu vipya kila siku.” 
 
Day 2 
Content message (2): Mshauri mgonjwa kumeza dozi ya 2 baada ya masaa 8 kamili halafu ameze dawa 
kila baada ya masaa 12  kwa siku 2. 
Complementary component: Siri pekee yakufanya kazi vizuri nikua na mudi yakufanya kazi.  
MSG (177 characters):  
Mshauri mgonjwa kumeza dozi ya 2 baada ya masaa 8 kamili halafu ameze dawa kila baada ya 
masaa 12 kwa siku 2. “Siri pekee ya kufanya kazi vizuri ni kuwa na mudi yakufanya kazi.” 
 
Day 3 
Content message (3): Mueleze mgonjwa kuwa ALu imezwe pamoja na chakula chenye mafuta. 
Complementary component: Si kila kinachohesabika kinafaa. 
MSG (99 characters) :  
Mueleze mgonjwa kuwa ALu imezwe pamoja na chakula chenye mafuta. “Si kila 
kinachohesabika kinafaa.” 
 
Day 4 
Content message (4): Mwambie mgonjwa kama akitapika kabla ya nusu saa kupita, arudie kumeza 
dozi nyingine. 
Complementary component: “Daima huonekana haiwezekani hadi itakapofanyika!” 
                 MSG (135 characters): 
Mwambie mgonjwa kama akitapika kabla ya nusu saa kupita, arudie kumeza dozinyingine. 
“Daima huonekana haiwezekani hadi itakapofanyika!” 
 
Day 5 
Content message (5): Mshauri mgonjwa kumaliza vidonge VYOTE kwa siku 3 kama ulivyomuelekeza 
ndiko kutamaliza malaria yote. 
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Complementary component: “Kama huwezi kufanya mambo makubwa fanya madogo kwa ufanisi 
zaidi.” 
MSG (169 characters): 
Mshauri mgonjwa kumaliza vidonge VYOTE kwa siku 3 kama ulivyomuelekeza ndiko kutamaliza 
malaria yote. “Kama huwezi kufanya mambo makubwa fanya madogo kwa ufanisi zaidi.” 
 
Week 2 
Day 1 
Content message (6): Mshauri mgonjwa kumaliza matibabu hata kama atajisikia nafuu ilikumaliza 
kabisa vimelea vyote vya malaria. 
Complementary component: “Afya sio tu kukosekana kwa maradhi.” 
MSG (144 characters) :  
Mshauri mgonjwa kumaliza matibabu hata kama atajisikia nafuu ilikumaliza kabisa vimelea 
vyote vya malaria.” Afya sio tu kukosekana kwa maradhi.” 
 
Day 2 
Content message (7): Mwambie mgonjwa madhara madogo madogo yatokanayo na matibabu ya Alu, 
yakitokea aendelee na matibabu. 
Complementary component: “Afya ndiyo mali halisi sio vipande vya dhahabu na shaba.”  
MSG (158 characters):  
Mwambie mgonjwa madhara madogo madogo yatokanayo na matibabu ya Alu yakitokea 
aendelee na matibabu. “Afya ndiyo mali halisi sio vipande vya dhahabu na shaba.” 
MSG (133 characters) (send separately):  
Madhara madogo madogo yatokanayo na Alu ni kama kizunguzungu, kichefuchefu, kikohozi, 
kuumwa kichwa, kuumwa tumbo na uchovu wa mwili. 
 
Day 3 
Content message (3): Mueleze mgonjwa kuwa ALu imezwe pamoja na chakula chenye  mafuta. 
Complementary component: “Dozi ya 2 ya dawa mseto ya malaria inatakiwa imezwe baada ya masaa 
mangapi? Jibu kwenda 0784666714” 
MSG (165 characters):  
Mueleze mgonjwa kuwa ALu imezwe pamoja na chakula chenye mafuta. “Dozi ya 2 ya dawa 
mseto ya malaria inatakiwa imezwe baada ya masaa mangapi? Jibu kwenda 0784666714” 
 
Day 4 
Content message (2): Mshauri mgonjwa kumeza dozi ya 2 baada ya masaa 8 kamili halafu ameze dawa 
kila baada ya masaa 12 kwa siku 2. 
Complementary component: “Kawaida ni kama sheria.” 
MSG (135 characters):  
Mshauri mgonjwa kumeza dozi ya 2 baada ya masaa 8 kamili halafu ameze dawa kila baada ya 
masaa 12 kwa siku 2. “Kawaida ni kama sheria.” 
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Day 5 
Content message (1): Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa.  
Complementary component: “Ugumu wa maisha usikukwaze,kwani hakuna awezaye kuzuia matatizo.” 
MSG (136 characters):  
Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa. “Ugumu wa maisha 
usikukwaze, kwani hakuna awezaye kuzuia matatizo.” 
 
Week 3 
Day 1 
Content message (4): Mwambie mgonjwa kama akitapika kabla ya nusu saa kupita, arudie kumeza 
dozi nyingine. 
Complementary component: “Kujiwekea malengo ni hatua ya kwanza ya mafanikio.” 
MSG (138 characters):   
Mwambie mgonjwa kama akitapika kabla ya nusu saa kupita, arudie kumeza dozi nyingine. 
“Kujiwekea malengo ni hatua ya kwanza ya mafanikio.” 
 
Day 2 
Content message (5): Mshauri mgonjwa kumaliza vidonge VYOTE kwa siku 3 kama ulivyomuelekeza 
ndiko kutamaliza malaria yote. 
Complementary component: “Jina jema hungara gizani.” 
MSG(128 characters):  
Mshauri mgonjwa kumaliza vidonge VYOTE kwa siku 3 kama ulivyomuelekeza ndiko kutamaliza 
malaria yote. “Jina jema hungara gizani.” 
 
Day 3 
Content message (6): Mshauri mgonjwa kumaliza matibabu hata kama atajisikia nafuu ilikumaliza 
kabisa vimelea vyote vya malaria. 
Complementary component: “Je, mgonjwa akitapika dakika tano baada ya kumeza dawa ila vidonge 
havionekani anatakiwa afanyeje? Jibu kwenda 0784666714” 
MSG (230 characters):  
Mshauri mgonjwa kumaliza matibabu hata kama atajisikia nafuu ilikumaliza kabisa vimelea 
vyote vya malaria. “Je, mgonjwa akitapika dakika tano baada ya kumeza dawa ila vidonge 
havionekani anatakiwa afanyeje? Jibu kwenda 0784666714” 
 
Day 4 
Content message (1): Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa. 
Complementary component: “Je, kama mgonjwa atameza dozi ya kwanza ya dawa mseto saa nne usiku, 
dozi ya pili itamezwa saa ngapi? Jibu kwenda 0784666714” 
MSG (195 characters):  
Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa. “Je, kama mgonjwa 
atameza dozi ya kwanza ya dawa mseto saa nne usiku, dozi ya pili itamezwa saa ngapi? Jibu 
kwenda 0784666714” 
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Day 5 
Content message (7): Mwambie mgonjwa madhara madogo madogo yatokanayo na matibabu ya Alu 
yakitokea aendelee na matibabu. 
Complementary component: “Huwezi kuvuka bahari isipokuwa kama unauwezo wa kutokuona 
mwambao.” 
MSG (168 characters):  
Mwambie mgonjwa madhara madogo madogo yatokanayo na matibabu ya Alu yakitokea 
aendelee na matibabu. “Huwezi kuvuka bahari isipokuwa kama unauwezo wa kutokuona 
mwambao.” 
 
Week 4 
Day 1 
Content message (2): Mshauri mgonjwa kumeza dozi ya 2 baada ya masaa 8 kamili halafu ameze dawa 
kila baada ya masaa 12 kwa siku 2. 
Complementary component: “Ukiamini jambo lolote, amini hivyo pasipo kusita hata kidogo.” 
MSG (173characters):  
Mshauri mgonjwa kumeza dozi ya 2 baada ya masaa 8 kamili halafu ameze dawa kila baada ya 
masaa 12 kwa siku 2. “Ukiamini jambo lolote, amini hivyo pasipo kusita hata kidogo.” 
 
Day 2 
Content message (4): Mwambie mgonjwa kama akitapika kabla ya nusu saa kupita, arudie kumeza 
dozi nyingine. 
Complementary component:  “Kabla yakuongea jiulize, ni muhimu? Ni kweli? Ni  zaidi ya kukaa kimya?” 
MSG (157 characters):  
Mwambie mgonjwa kama akitapika kabla ya nusu saa kupita arudie kumeza dozi nyingine. 
“Kabla yakuongea jiulize  ni muhimu? Ni kweli? Ni zaidi ya kukaa kimya?” 
 
Day 3 
Content message (3): Mueleze mgonjwa kuwa ALu imezwe pamoja na chakula chenye mafuta. 
Complementary component: “Alu inapaswa kumezwa na chakula cha aina gani? Jibu kwenda 
0784666714” 
MSG (136 characters):  
Mueleze mgonjwa kuwa ALu imezwe pamoja na chakula chenye mafuta. “Alu inapaswa 
kumezwa na chakula cha aina gani? Jibu kwenda 0784666714” 
 
Day 4 
Content message (5): Mshauri mgonjwa kumaliza vidonge VYOTE kwa siku 3 kama ulivyomuelekeza 
ndiko kutamaliza malaria yote. 
Complementary component: “Je, mgonjwa akitapika dakika ishirini na tano baada ya kumeza dawa 
anatakiwa afanyeje? Jibu kwenda 0784666714” 
MSG (212 characters): 
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Mshauri mgonjwa kumaliza vidonge VYOTE kwa siku 3 kama ulivyomuelekeza ndiko kutamaliza 
malaria yote. “Je, mgonjwa akitapika dakika ishirini na tano baada ya kumeza dawa anatakiwa 
afanyeje? Jibu kwenda 0784666714” 
 
Day 5 
Content message (7): Mwambie mgonjwa madhara madogo madogo yatokanayo na matibabu ya Alu 
yakitokea aendelee na matibabu. 
Complementary component: “Daima tunafikili jinsi ya kuwabadilisha wenzetu lakini hatufikilii jinsi ya 
kubadilika mienendo yetu wenyewe.”  
MSG (211 characters):  
Mwambie mgonjwa madhara madogo madogo yatokanayo na matibabu ya Alu yakitokea 
aendelee na matibabu. “Daima tunafikili jinsi ya kuwabadilisha wenzetu lakini hatufikilii jinsi ya 
kubadilika mienendo yetu wenyewe.” 
 
Week 5 
Day 1 
Content message (6): Mshauri mgonjwa kumaliza matibabu hata kama atajisikia nafuu ilikumaliza 
kabisa vimelea vyote vya malaria. 
Complementary component: “Mlango mmoja ukifungwa, mwingine hufunguka iwapo 
umejishughulisha.” 
MSG (175 characters):  
Mshauri mgonjwa kumaliza matibabu hata kama atajisikia nafuu ilikumaliza kabisa vimelea 
vyote vya malaria. “Mlango mmoja ukifungwa, mwingine hufunguka iwapo umejishughulisha.” 
 
Day 2 
Content message (1): Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa. 
Complementary component: “Ni sahihi mgonjwa kumeza dawa mseto akiwa hajala chakula? Jibu 
kwenda 0784666714” 
MSG (151 characters):  
Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa. “Ni sahihi mgonjwa 
kumeza dawa mseto akiwa hajala chakula? Jibu kwenda 0784666714” 
 
Day 3 
Content message (5): Mshauri mgonjwa kumaliza vidonge VYOTE kwa siku 3 kama ulivyomuelekeza 
ndiko kutamaliza malaria yote. 
Complementary component: “Vitu havibadiliki, watu ndio wanobadilika.” 
MSG (146 characters):  
Mshauri mgonjwa kumaliza vidonge VYOTE kwa siku 3 kama ulivyomuelekeza ndiko kutamaliza 
malaria yote. “Vitu havibadiliki, watu ndio wanobadilika.” 
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Week 6 
Day 1 
Content message (2): Mshauri mgonjwa kumeza dozi ya 2 baada ya masaa 8 kamili; halafu ameze 
dawa kila baada ya masaa 12  kwa siku 2. 
Complementary component: “Dozi ya kwanza ya dawa mseto inatakiwa imezwe chini ya uangalizi wa 
nani? Jibu kwenda 0784666714” 
MSG (210 characters): 
Mshauri mgonjwa kumeza dozi ya 2 baada ya masaa 8 kamili; halafu ameze dawa kila baada ya masaa 
12  kwa siku 2. “Dozi ya kwanza ya dawa mseto inatakiwa imezwe chini ya uangalizi wa nani? Jibu 
kwenda 0784666714” 
 
Day 2 
Content message (4): Mwambie mgonjwa kama akitapika kabla ya nusu saa kupita, arudie kumeza 
dozi nyingine. 
Complementary component: “Utajiri sio kipimo cha afya.”  
MSG (116 characters):  
Mwambie mgonjwa kama akitapika kabla ya nusu saa kupita, arudie kumeza dozi  
nyingine. “Utajiri sio kipimo cha afya.” 
 
Day 3 
Content message (6): Mshauri mgonjwa kumaliza matibabu hata kama atajisikia nafuu ilikumaliza 
kabisa vimelea vyote vya malaria. 
Complementary component: “Mafanikio mazuri huja baada ya mahangaiko.” 
MSG (151 characters):  
Mshauri mgonjwa kumaliza matibabu hata kama atajisikia nafuu ilikumaliza kabisa vimelea 
vyote vya malaria. “Mafanikio mazuri huja baada ya mahangaiko.” 
 
Week 7 
Day 1 
Content message (3): Mueleze mgonjwa kuwa ALu imezwe pamoja na chakula chenye mafuta. 
Complementary component: “Kila mlango na ufunguo wake.” 
MSG (95 characters): 
Mueleze mgonjwa kuwa ALu imezwe pamoja na chakula chenye mafuta. “Kila mlango na 
ufunguo wake.” 
 
Day 2 
Content message (1): Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa. 
Complementary component: “Mwenye kusita hupoteza.” 
MSG (94 characters): 
Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa. “Mwenye kusita 
hupoteza.” 
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Day 3 
Content message (7): Mwambie mgonjwa madhara madogo madogo yatokanayo na matibabu ya Alu, 
yakitokea aendelee na matibabu. 
Complementary component: “Watoto wenye kilo5 hadi 15 wanameza vidonge vingapi vya dawa mseto 
ya malaria? Jibu kwenda 0784666714” 
MSG (204 characters):  
Mwambie mgonjwa madhara madogo madogo yatokanayo na matibabu ya Alu, yakitokea 
aendelee na matibabu. “Watoto wenye kilo5 hadi 15 wanameza vidonge vingapi vya dawa mseto 
ya malaria? Jibu kwenda 0784666714” 
 
Week 8 
Day 1 
Content message (6): Mshauri mgonjwa kumaliza matibabu hata kama atajisikia nafuu ilikumaliza 
kabisa vimelea vyote vya malaria. 
Complementary component: “Amini kwa moyo wako utakifanya ulichopaswa kufanya.” 
MSG (160 characters): 
Mshauri mgonjwa kumaliza matibabu hata kama atajisikia nafuu ilikumaliza kabisa vimelea 
vyote vya malaria. “Amini kwa moyo wako utakifanya ulichopaswa kufanya.” 
 
Day 2 
Content message (5): Mshauri mgonjwa kumaliza vidonge VYOTE kwa siku 3 kama ulivyomuelekeza 
ndiko kutamaliza malaria yote. 
Complementary component: “Baada ya dozi ya pili, dozi zingine za dawa mseto humezwa kila baada ya 
masaa mangapi? Jibu kwenda 0784666714” 
MSG (213 characters): 
Mshauri mgonjwa kumaliza vidonge VYOTE kwa siku 3 kama ulivyomuelekeza ndiko kutamaliza 
malaria yote. “Baada ya dozi ya pili, dozi zingine za dawa mseto humezwa kila baada ya masaa 
mangapi? Jibu kwenda 0784666714” 
 
Day 3 
Content message (4): Mwambie mgonjwa kama akitapika kabla ya nusu saa kupita, arudie kumeza 
dozi nyingine. 
Complementary component: “Dozi ya kwanza ya dawa mseto inatakiwa imezwe chini ya uangalizi wa 
nani? Jibu kwenda 0784666714” 
MSG (183 characters): 
Mwambie mgonjwa kama akitapika kabla ya nusu saa kupita, arudie kumeza dozi nyingine “Dozi ya 
kwanza ya dawa mseto inatakiwa imezwe chini ya uangalizi wa nani? Jibu kwenda 0784666714” 
 
Week 9 
Day 1 
Content message (7): Mwambie mgonjwa madhara madogo madogo yatokanayo na matibabu ya Alu 
yakitokea aendelee na matibabu. 
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Complementary component: “Kujua haitoshi; ni lazima kufanya. Nia haitoshi; ni lazima kutenda.” 
MSG (169 characters): 
Mwambie mgonjwa madhara madogo madogo yatokanayo na matibabu ya Alu yakitokea 
aendelee na matibabu. “Kujua haitoshi; ni lazima kufanya. Nia haitoshi; ni lazima kutenda.” 
 
Day 2 
Content message (1): Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa. 
Complementary component: “Mafanikio katika maisha, au kitu, yanategemeana na idadi ya watu 
unashirikiana nao.” 
 MSG (154 characters): 
Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa. “Mafanikio katika 
maisha, au kitu, yanategemeana na idadi ya watu unashirikiana nao.” 
 
Day 3 
Content message (2): Mshauri mgonjwa kumeza dozi ya 2 baada ya masaa 8 kamili halafu ameze dawa 
kila baada ya masaa 12 kwa siku 2. 
Complementary component: “Mgonjwa afanye nini ili kumaliza vimelea vyote vya malaria? Jibu kwenda 
0784666714” 
MSG (194 characters):  
Mshauri mgonjwa kumeza dozi ya 2 baada ya masaa 8 kamili halafu ameze dawa kila baada ya 
masaa 12 kwa siku 2. “Mgonjwa afanye nini ili kumaliza vimelea vyote vya malaria? Jibu kwenda 
0784666714” 
 
Week 10 
Day 1 
Content message (4): Mwambie mgonjwa kama akitapika kabla ya nusu saa kupita, arudie kumeza 
dozi nyingine. 
Complementary component: “Furaha katika maisha yako inategemea na ubora wa mawazo yako; 
kwahiyo waza ipasavyo”. 
MSG (172 characters): 
Mwambie mgonjwa kama akitapika kabla ya nusu saa kupita, arudie kumeza dozi nyingine. 
“Furaha katika maisha yako inategemea na ubora wa mawazo yako; kwahiyo waza ipasavyo.” 
 
Day 2 
Content message (3): Mueleze mgonjwa kuwa ALu imezwe pamoja na chakula chenye mafuta. 
Complementary component: “Watu wenye kutaka kujua mengi, huishi sio muda mrefu tu bali kwa 
furaha pia.” 
MSG (143 characters): 
Mueleze mgonjwa kuwa ALu imezwe pamoja na chakula chenye mafuta. “Watu wenye kutaka 
kujua mengi, huishi sio muda mrefu tu bali kwa furaha pia.” 
 
Day 3 
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Content message (5): Mshauri mgonjwa kumaliza vidonge VYOTE kwa siku 3 kama ulivyomuelekeza 
ndiko kutamaliza malaria yote. 
Complementary component: “Dawa mseto ya malaria humezwa kwa siku ngapi? Jibu kwenda 
0784666714” 
MSG (172 characters): 
Mshauri mgonjwa kumaliza vidonge VYOTE kwa siku 3 kama ulivyomuelekeza ndiko kutamaliza 
malaria yote. “Dawa mseto ya malaria humezwa kwa siku ngapi? Jibu kwenda 0784666714” 
 
Week 11 
Day 1 
Content message (1): Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa. 
Complementary component: “Furaha haikai katika vitu tunavyomiliki au katika dhahabu, bali hukaa 
moyoni.” 
MSG (148 characters): 
Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa. “Furaha haikai katika 
vitu tunavyomiliki au katika dhahabu, bali hukaa moyoni.” 
 
Day 2 
Content message (6): Mshauri mgonjwa kumaliza matibabu hata kama atajisikia nafuu ilikumaliza 
kabisa vimelea vyote vya malaria. 
Complementary component: Watoto wenye kilo5 hadi 15 wanameza vidonge vingapi vya dawa mseto 
ya malaria? Jibu kwenda 0784666714 
MSG (209 characters): 
Mshauri mgonjwa kumaliza matibabuhata kama atajisikia nafuu ilikumaliza kabisa vimelea 
vyote vya malaria. “Watoto wenye kilo5 hadi 15 wanameza vidonge vingapi vya dawa mseto ya 
malaria? Jibu kwenda 0784666714” 
 
Day 3 
Content message (7): Mwambie mgonjwa madhara madogo madogo yatokanayo na matibabu ya Alu 
yakitokea aendelee na matibabu. 
Complementary component: Ni vema uwe mtu wa thamani sio mtu wa mafanikio. 
MSG (150 characters): 
Mwambie mgonjwa madhara madogo madogo yatokanayo na matibabu ya Alu yakitokea 
aendelee na matibabu. “Ni vema uwe mtu wa thamani sio mtu wa mafanikio.” 
 
Week 12 
Day 1 
Content message (3): Mueleze mgonjwa kuwa ALu imezwe pamoja na chakula chenye mafuta. 
Complementary component: “Mafanikio katika maisha ni kuweza kuishi upendavyo.” 
MSG (118 characters):  
Mueleze mgonjwa kuwa ALu imezwe pamoja na chakula chenye mafuta. “Mafanikio katika 
maisha ni kuweza kuishi upendavyo.” 
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Day 2 
Content message (4): Mwambie mgonjwa kama akitapika kabla ya nusu saa kupita, arudie kumeza 
dozi nyingine. 
Complementary component: “Siri ya mafanikio ni kufahamu kitu ambacho hamna mtu anayejua.” 
MSG (150 characters): 
Mwambie mgonjwa kama akitapika kabla ya nusu saa kupita, arudie kumeza dozi nyingine. “Siri 
ya mafanikio ni kufahamu kitu ambacho hamna mtu anayejua.” 
 
Day 3 
Content message (2): Mshauri mgonjwa kumeza dozi ya 2 baada ya masaa 8 kamili halafu ameze dawa 
kila baada ya masaa 12 kwa siku 2. 
Complementary component: “Taja mojawapo ya madhara madogo madogo yatokanayo na dawa mseto 
ya malaria. Jibu kwenda 0784666714” 
MSG (211 characters): 
Mshauri mgonjwa kumeza dozi ya 2 baada ya masaa 8 kamili halafu ameze dawa kila baada ya 
masaa 12 kwa siku 2. “Taja mojawapo ya madhara madogo madogo yatokanayo na dawa mseto 
ya malaria. Jibu kwenda 0784666714.” 
 
Week 13 
Day 1 
Content message (5): Mshauri mgonjwa kumaliza vidonge VYOTE kwa siku 3 kama ulivyomuelekeza 
ndiko kutamaliza malaria yote. 
Complementary component: “Ni ujinga kuogopa kitu ambacho uwezi kukizuia.” 
MSG (150 characters): 
Mshauri mgonjwa kumaliza vidonge VYOTE kwa siku 3 kama ulivyomuelekeza ndiko kutamaliza 
malaria yote. “Ni ujinga kuogopa kitu ambacho uwezi kukizuia.” 
 
Day 2 
Content message (6): Mshauri mgonjwa kumaliza matibabu hata kama atajisikia nafuu ilikumaliza 
kabisa vimelea vyote vya malaria. 
Complementary component: “Je, mtoto wa chini ya kilo tano atameza vidonge vingapi vya dawa mseto 
ya malaria? Jibu kwenda 0784666714”  
MSG (214 characters): 
Mshauri mgonjwa kumaliza matibabu hata kama atajisikia nafuu ilikumaliza kabisa vimelea 
vyote vya malaria. “Je, mtoto wa chini ya kilo tano atameza vidonge vingapi vya dawa mseto ya 
malaria? Jibu kwenda 0784666714” 
 
Day 3 
Content message (7): Mwambie mgonjwa madhara madogo madogo yatokanayo na matibabu ya Alu, 
yakitokea aendelee na matibabu. 
Complementary component: “Hakuna kushindwa isipokuwa katika kutokujaribu tena.” 
MSG (155 characters): 
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Mwambie mgonjwa madhara madogo madogo yatokanayo na matibabu ya Alu, yakitokea 
aendelee na matibabu. “Hakuna kushindwa isipokuwa katika kutokujaribu tena.” 
 
Week 14 
Day 1 
Content message (3): Mueleze mgonjwa kuwa ALu imezwe pamoja na chakula chenye mafuta. 
Complementary component: “Njia ya pekee ya kuandaa maisha ni kuanza kuishi.” 
MSG (116 characters): 
Mueleze mgonjwa kuwa ALu imezwe pamoja na chakula chenye mafuta. “Njia ya pekee ya 
kuandaa maisha ni kuanza kuishi.” 
 
Day 2 
Content message (2): Mshauri mgonjwa kumeza dozi ya 2 baada ya masaa 8 kamili halafu ameze dawa 
kila baada ya masaa 12 kwa siku 2. 
Complementary component: “Napenda ndoto za maisha ya jayo kuliko simuliza ya yaliyopita.” 
MSG (175 characters): 
Mshauri mgonjwa kumeza dozi ya 2 baada ya masaa 8 kamili; halafu ameze dawa kila baada ya 
masaa 12 kwa siku 2. “Napenda ndoto za maisha ya jayo kuliko simuliza ya yaliyopita.” 
 
Day 3 
Content message (1): Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa. 
Complementary component: “Je, mgonjwa akitapika dakika arobaini baada ya kumeza dawa mseto 
atapaswa kurudia dozi hiyo? Jibu kwenda 0784666714?” 
MSG (185 characters):  
Hakikisha dozi ya 1 ya ALu imemezwa chini ya uangalizi wa Mtoa Dawa “Je, mgonjwa akitapika 
dakika arobaini baada ya kumeza dawa mseto atapaswa kurudia dozi hiyo? Jibu kwenda 
0784666714” 
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